TWI593396B - Absorbent article - Google Patents

Absorbent article Download PDF

Info

Publication number
TWI593396B
TWI593396B TW102106979A TW102106979A TWI593396B TW I593396 B TWI593396 B TW I593396B TW 102106979 A TW102106979 A TW 102106979A TW 102106979 A TW102106979 A TW 102106979A TW I593396 B TWI593396 B TW I593396B
Authority
TW
Taiwan
Prior art keywords
acid
chain hydrocarbon
ester
fatty acid
group
Prior art date
Application number
TW102106979A
Other languages
Chinese (zh)
Other versions
TW201400098A (en
Inventor
野田祐樹
田村竜也
野本貴志
小野塚卓
Original Assignee
優你 嬌美股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2012082503A external-priority patent/JP5709789B2/en
Application filed by 優你 嬌美股份有限公司 filed Critical 優你 嬌美股份有限公司
Publication of TW201400098A publication Critical patent/TW201400098A/en
Application granted granted Critical
Publication of TWI593396B publication Critical patent/TWI593396B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/51104—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections
    • A61F13/51108—Topsheet, i.e. the permeable cover or layer facing the skin the top sheet having a three-dimensional cross-section, e.g. corrugations, embossments, recesses or projections the top sheet having corrugations or embossments having one axis relatively longer than the other axis, e.g. forming channels or grooves in a longitudinal direction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/45—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the shape
    • A61F13/47—Sanitary towels, incontinence pads or napkins
    • A61F13/472—Sanitary towels, incontinence pads or napkins specially adapted for female use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/51—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the outer layers
    • A61F13/511—Topsheet, i.e. the permeable cover or layer facing the skin
    • A61F13/512—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations
    • A61F13/5126—Topsheet, i.e. the permeable cover or layer facing the skin characterised by its apertures, e.g. perforations characterised by the planar distribution of the apertures, e.g. in a predefined pattern

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Absorbent Articles And Supports Therefor (AREA)

Description

吸收性物品 Absorbent article

本發明，係有關於生理用衛生棉、衛生護墊、拋棄式尿布、失禁墊、失禁護墊等之吸收性物品。 The present invention relates to absorbent articles for sanitary napkins, sanitary pads, disposable diapers, incontinence pads, incontinence pads and the like.

一般的吸收性物品，具備液體透過性的頂部薄片、液體不透過性的背部薄片、在頂部薄片及背部薄片間所設置的吸收體，從頂部薄片透過的液體經吸收體吸收．保留。而追求防止在吸收性物品的變形時吸收體過度被壓縮，吸收體所吸收．保留的液體逆流、由頂部薄片滲漏出(回滲)的工夫。 A general absorbent article comprising a liquid permeable top sheet, a liquid impervious back sheet, an absorbent body disposed between the top sheet and the back sheet, and the liquid permeated from the top sheet is absorbed by the absorbent body. Reserved. And the pursuit of preventing the absorption body from being excessively compressed when the absorbent article is deformed, the absorbent body absorbs. The retained liquid is countercurrent, and the leakage of the top sheet (leakage) takes time.

作為該工夫之一，提案有使液體不透過性的塑膠薄膜以設計有多數的孔的面與沿著孔形成側壁的面構成，作成3次元構造(專利文獻1)。 As one of the efforts, a plastic film having a liquid impermeability is proposed to have a surface in which a plurality of holes are designed and a surface on which a side wall is formed along the hole, and a three-dimensional structure is created (Patent Document 1).

[先前技術文獻] [Previous Technical Literature]

[專利文獻] [Patent Literature]

[專利文獻1]日本特表平7-502444號公報 [Patent Document 1] Japanese Patent Publication No. 7-502444

然而，專利文獻1記載之頂部薄片因於其全面具有規則配置的孔，故吸收性物品扭轉變形時，產生不規則折皺。如此不規則折皺不僅帶給著用者不適，在與著用者的肌膚間產生間隙，誘使應吸收液體滲漏至外部。 However, since the top sheet described in Patent Document 1 has a hole having a regular arrangement in its entirety, irregular wrinkles are generated when the absorbent article is torsionally deformed. Such irregular wrinkles not only bring discomfort to the user, but also create a gap between the skin of the user and the leakage of the absorbed liquid to the outside.

因此，本發明以提供可規則的扭轉變形之新穎的吸收性物品為目的。 Accordingly, the present invention is directed to a novel absorbent article that provides regular torsional deformation.

為了解決上述課題，本發明為提供具備液體透過性薄片、液體不透過性薄片、在前述液體透過性薄片及前述液體不透過性薄片間所設置的吸收體之吸收性物品，且前述液體透過性薄片中，在接受液體的供給之液體被供給領域形成有高剛性領域與低剛性領域，前述高剛性領域具有在與前述吸收性物品的長度方向交叉方向延伸設置、略平行並列設置的略直線狀的第1領域，且前述低剛性領域具有其剛性以比前述高剛性領域的剛性低之方式所形成的液體透過孔。 In order to solve the above problems, the present invention provides an absorbent article comprising a liquid permeable sheet, a liquid-impermeable sheet, and an absorbent body provided between the liquid-permeable sheet and the liquid-impermeable sheet, and the liquid permeability. In the sheet, a high rigidity region and a low rigidity region are formed in the liquid supply region in which the supply of the liquid is supplied, and the high rigidity region has a substantially linear shape which is arranged in the direction intersecting the longitudinal direction of the absorbent article and is arranged in parallel and arranged in parallel. In the first field, the low rigidity region has a liquid permeation hole formed such that its rigidity is lower than that of the high rigidity region.

本發明之吸收性物品扭轉變形時，可以相較 於低剛性領域剛性高的高剛性領域的第1領域為起點規則的扭轉變形。又，因高剛性領域的彈性復原力，扭轉變形的吸收性物品易復原成原本之形狀。 When the absorbent article of the present invention is twisted and deformed, it can be compared The first field of high rigidity in the low rigidity region is a torsional deformation of the starting point. Moreover, due to the elastic restoring force in the high rigidity region, the torsionally deformed absorbent article is easily restored to its original shape.

根據本發明，提供可規則的扭轉變形之新穎的吸收性物品。 According to the present invention, a novel absorbent article that provides regular torsional deformation is provided.

1‧‧‧生理用衛生棉(吸收性物品) 1‧‧‧Physical sanitary napkins (absorbent articles)

2‧‧‧頂部薄片(液體透過性薄片) 2‧‧‧Top sheet (liquid permeable sheet)

3‧‧‧背部薄片(液體不透過性薄片) 3‧‧‧ Back sheet (liquid impervious sheet)

4‧‧‧吸收體 4‧‧‧Acceptor

20‧‧‧***物被供給領域(液體被供給領域) 20‧‧‧Excretion is supplied to the field (liquid supply field)

21‧‧‧低剛性領域 21‧‧‧Low rigidity field

22‧‧‧高剛性領域 22‧‧‧High rigidity field

26‧‧‧液體透過孔 26‧‧‧ liquid through hole

210‧‧‧蛇腹部 210‧‧‧ snake belly

[圖1]圖1為本發明之一實施形態之生理用衛生棉的平面圖。 Fig. 1 is a plan view showing a sanitary napkin according to an embodiment of the present invention.

[圖2]圖2為圖1之A-A線斷面之模式斷面圖。 Fig. 2 is a schematic cross-sectional view showing a section taken along line A-A of Fig. 1.

[圖3]圖3為擴大表示本發明之一實施形態之生理用衛生棉中頂部薄片的高剛性領域及低剛性領域的部分斷面斜視圖。 Fig. 3 is a partially cutaway perspective view showing a high rigidity region and a low rigidity region of a top sheet in a sanitary napkin according to an embodiment of the present invention.

[圖4]圖4為使本發明之一實施形態之生理用衛生棉扭轉變形時的斜視圖。 Fig. 4 is a perspective view showing a state in which a sanitary napkin according to an embodiment of the present invention is torsionally deformed.

[圖5]圖5為本發明之一實施形態之使生理用衛生棉凸狀變形時的斜視圖。 Fig. 5 is a perspective view showing a state in which a sanitary napkin is deformed in a convex shape according to an embodiment of the present invention.

[圖6]圖6為用以說明本發明之一實施形態之生理用衛生棉的製造方法的圖。 Fig. 6 is a view for explaining a method of producing a sanitary napkin according to an embodiment of the present invention.

[圖7]圖7為用以說明本發明之一實施形態之生理用衛生棉的製造所使用的凹部形成輥的圖。 Fig. 7 is a view for explaining a recess forming roller used for the production of the sanitary napkin according to the embodiment of the present invention.

[圖8]圖8為用以說明頂部薄片中，藉由凹部形成輥形成有凹部的領域的圖。 8] FIG. 8 is a view for explaining a field in which a recess is formed by a recess forming roller in a top sheet.

[圖9]圖9為用以說明本發明之一實施形態之生理用衛生棉的製造所使用的延伸齒輥的上段輥的圖。 Fig. 9 is a view for explaining an upper roll of an extended tooth roll used for the production of the sanitary napkin according to the embodiment of the present invention.

[圖10]圖10為用以說明本發明之一實施形態之生理用衛生棉的製造所使用的延伸齒輥的下段輥的圖。 Fig. 10 is a view for explaining a lower roll of an extended tooth roll used for the production of the sanitary napkin according to the embodiment of the present invention.

[圖11]圖11為用以說明以延伸齒輥延伸的頂部薄片的圖。 Fig. 11 is a view for explaining a top sheet extending with an extending tooth roll.

[圖12]圖12為頂部薄片含有三C2L油脂肪酸甘油酯的生理用衛生棉中頂部薄片的肌膚接觸面的電子顯微鏡照片。 Fig. 12 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin of the top sheet containing the three C2L oil fatty acid glycerides.

[圖13]圖13為含有或不含血液改質劑的經血之顯微鏡照片。 Fig. 13 is a photomicrograph of menstrual blood with or without a blood modifying agent.

[圖14]圖14為用以說明表面張力之測定方法之圖。 Fig. 14 is a view for explaining a method of measuring surface tension.

[實施發明之最佳形態] [Best Mode for Carrying Out the Invention]

以下、說明本發明之吸收性物品。 Hereinafter, the absorbent article of the present invention will be described.

本發明之吸收性物品中，液體被供給領域為因應吸收性物品的種類、用途等，適宜設定在液體透過性薄片的領域，設定於液體透過性薄片的液體被供給領域的位置、面積等不特別限制。液體被供給領域，實際可設定為與液體供給領域略相同領域，或設定為比其大的領域，但由防止液體滲出至外部觀點，實際以設定為比液體供給領域大的領域為佳。 In the absorbent article of the present invention, the liquid supply region is preferably set in the field of the liquid permeable sheet in accordance with the type and use of the absorbent article, and is set in the position, area, etc. of the liquid supply region of the liquid permeable sheet. Special restrictions. The liquid is supplied to the field, and may be set to be slightly in the same field as the liquid supply field, or set to be larger than the field, but it is preferable to set it to be larger than the liquid supply field from the viewpoint of preventing liquid from oozing out to the outside.

本發明之吸收性物品中，高剛性領域為比低剛性領域剛性高的領域，低剛性領域為比高剛性領域剛性低的領域。亦即，「高剛性」及「低剛性」係指兩領域的 相對剛性的高低。 In the absorbent article of the present invention, the high rigidity field is a field having higher rigidity than the low rigidity field, and the low rigidity field is a field having lower rigidity than the high rigidity field. That is, "high rigidity" and "low rigidity" mean two areas. Relatively rigid height.

本發明之吸收性物品中，高剛性領域具有可 撓性(亦即，對變形之彈性復原力)。高剛性領域雖可因變形時施加的力而伸展，但由提高對變形之彈性復原力觀點，以因變形時施加的力而實質上不伸展為佳。 In the absorbent article of the present invention, the high rigidity field has Flexibility (ie, elastic restoring force to deformation). Although the high-rigidity field can be stretched by the force applied during deformation, it is preferable that the elastic restoring force against deformation is substantially not stretched by the force applied during the deformation.

本發明之吸收性物品中，低剛性領域的剛性 在比高剛性領域的剛性低之情形下，低剛性領域上形成的液體透過孔的大小、數等不特別限制。低剛性領域的剛性在比高剛性領域的剛性低之情形下，在高剛性領域可形成液體透過孔。 In the absorbent article of the present invention, rigidity in a low rigidity field In the case where the rigidity is lower than that in the high rigidity region, the size, number, and the like of the liquid permeation holes formed in the low rigidity region are not particularly limited. The rigidity of the low rigidity region can form a liquid permeation hole in a high rigidity region in the case where the rigidity is lower than that in the high rigidity region.

本發明之吸收性物品中，以高剛性領域的第1 領域不具有液體透過孔為佳(態樣1)。在態樣1，以高剛性領域的第1領域為起點的規則的扭轉變形有效生成。又，藉由高剛性領域的第1領域的彈性復原力，扭轉變形的吸收性物品易復原成原本之形狀。 In the absorbent article of the present invention, the first in the field of high rigidity It is preferred that the field does not have a liquid permeation hole (Stage 1). In the aspect 1, the torsional deformation of the rule starting from the first field of the high rigidity field is efficiently generated. Moreover, the torsionally deformable article is easily restored to its original shape by the elastic restoring force of the first field in the field of high rigidity.

本發明之吸收性物品中，以高剛性領域具有 在與第1領域交叉方向延伸設置、略平行並列設置的略直線狀的第2領域為佳(態樣2)。在態樣2，即使吸收性物品的扭轉方向改變，可以高剛性領域的第1領域或第2領域為起點規則的扭轉變形。 In the absorbent article of the present invention, it has a high rigidity field In the second field which is slightly linearly arranged in the direction intersecting the first field and arranged in parallel, it is preferable (the aspect 2). In the second aspect, even if the twist direction of the absorbent article is changed, the first field or the second field in the high rigidity field can be used as a starting point for the torsional deformation.

態樣2中，以高剛性領域的第2領域不具有 液體透過孔為佳(態樣3)。在態樣3，以高剛性領域的第2領域為起點的規則的扭轉變形有效生成。又，藉由高剛性領域的第2領域的彈性復原力，扭轉變形的吸收性物品易 復原成原本之形狀。 In the second aspect, the second field in the field of high rigidity does not have The liquid permeation hole is preferred (Stage 3). In the aspect 3, the torsional deformation of the rule starting from the second field in the field of high rigidity is efficiently generated. Moreover, by the elastic restoring force of the second field in the field of high rigidity, the twisted and deformed absorbent article is easy Restore to its original shape.

態樣2或3中，以第1領域與第2領域的交 叉而高剛性領域形成為網孔狀，在各網孔內側形成低剛性領域為佳(態樣4)。在態樣4，因形成為網孔狀的高剛性領域的彈性復原力，扭轉變形的吸收性物品易復原成原本之形狀。 In the second or third aspect, the first field and the second field The fork and the high-rigidity region are formed in a mesh shape, and it is preferable to form a low-rigidity region inside each mesh hole (state 4). In the aspect 4, the torsional deformation of the absorbent article is easily restored to the original shape due to the elastic restoring force in the high rigidity region formed into a mesh shape.

態樣4中，以在低剛性領域形成可伸展的蛇 腹部為佳(態樣5)。蛇腹部具有山摺部及谷摺部的重複構造，可於低剛性領域的面方向伸展。蛇腹部除伸展性外，亦可具有收縮性。又，即使蛇腹部具有收縮性之場合，因蛇腹部的材質、蛇腹數等而有經伸展的蛇腹部不完全收縮至原本狀態、維持比原本狀態稍稍伸展狀態之場合。在態樣5，吸收性物品在液體被供給領域被折曲，向液體被供給領域側凸狀變形時，因蛇腹部伸展，吸收體變得不易受到液體被供給領域之擠壓、防止因吸收性物品的變形造成的吸收體的過度壓縮及伴隨其之回滲。又，吸收性物品邊改變折曲角度邊變形的場合(例如吸收性物品的著用者因改變姿勢，吸收性物品的折曲角度成為銳角、或鈍角之場合)，因高剛性領域的彈性復原力，液體透過性薄片易隨吸收性物品的變形而變形，故防止蛇腹部的伸展造成的液體透過性薄片的撓曲。 In the fourth aspect, to form an extensible snake in the low rigidity field The abdomen is better (state 5). The snake abdomen has a repeating structure of a mountain fold and a valley fold, and can be stretched in the direction of the surface of the low rigidity field. In addition to stretchability, the snake's abdomen can also have contractility. Further, even when the snake abdomen has contractility, the stretched snake abdomen does not completely contract to the original state due to the material of the snake's abdomen or the number of the snake's abdomen, and maintains a state slightly extended compared with the original state. In the aspect 5, the absorbent article is bent in the field in which the liquid is supplied, and when the liquid is supplied to the field to be convexly deformed, the absorbent body becomes less susceptible to being squeezed by the liquid supply region and prevented from being absorbed due to the stretching of the snake abdomen. Excessive compression of the absorbent body caused by deformation of the sexual article and accompanying it back. Further, when the absorbent article is deformed while changing the bending angle (for example, when the wearer of the absorbent article changes his or her posture, the bending angle of the absorbent article becomes an acute angle or an obtuse angle), the elasticity is restored by the high rigidity region. The force, the liquid permeable sheet is easily deformed in accordance with the deformation of the absorbent article, thereby preventing the deflection of the liquid permeable sheet caused by the stretching of the snake's abdomen.

態樣5中，蛇腹部以具有在吸收性物品的長 度方向延伸設置、並排於吸收性物品的寬度方向，且沿著寬度方向的斷面為波浪狀之山摺部及谷摺部為佳(態樣6) 。在態樣6，吸收性物品沿其長度方向折曲、向液體被供給領域側凸狀變形時，蛇腹部向吸收性物品的寬度方向之伸展及高剛性領域的彈性復原力有效生成，故吸收體的過度壓縮被有效果地防止，同時蛇腹部的伸展造成的液體透過性薄片的撓曲被有效果地防止。 In the aspect 5, the snake abdomen has a long length in the absorbent article. The mountain direction is extended and arranged side by side in the width direction of the absorbent article, and the cross section along the width direction is wavy mountain folds and valley folds (state 6) . In the aspect 6, when the absorbent article is bent along the longitudinal direction thereof and convexly deformed toward the liquid supply region, the stretch of the snake abdomen in the width direction of the absorbent article and the elastic restoring force in the high rigidity region are effectively generated, so that absorption is performed. The excessive compression of the body is effectively prevented, and the deflection of the liquid permeable sheet caused by the stretching of the snake's abdomen is effectively prevented.

態樣6中，以液體透過孔形成於山摺部及谷 摺部的側面部為佳(態樣7)。在態樣7，吸收性物品的變形時，在不直接施加張力的部分形成液體透過孔，因此防止因張力造成液體透過孔被拉伸而吸收體露出。 In the aspect 6, the liquid perforation hole is formed in the mountain fold and the valley The side portion of the folded portion is preferred (Stage 7). In the case of the deformation of the absorbent article, the liquid permeation hole is formed in the portion where the tension is not directly applied. Therefore, the liquid permeation hole is prevented from being stretched by the tension and the absorber is exposed.

態樣6中，以液體透過孔形成於山摺部的最 上部或谷摺部的最下部為佳(態樣8)。在態樣8，吸收性物品的變形時，在不直接施加張力的部分形成液體透過孔，因此防止因張力造成液體透過孔被拉伸而吸收體露出。 In the sixth aspect, the liquid perforation hole is formed in the most mountain fold The lowermost part of the upper or valley fold is better (state 8). In the case 8, in the deformation of the absorbent article, the liquid permeation hole is formed in the portion where the tension is not directly applied, so that the liquid permeation hole is prevented from being stretched by the tension and the absorber is exposed.

本發明之吸收性物品中，以在液體被供給領 域的周緣部形成壓縮溝為佳(態樣9)。在態樣9，以壓縮溝為起點，吸收性物品易安定地變形，在吸收性物品變形時，蛇腹部的伸展及高剛性領域的彈性復原力有效生成，故吸收體的過度壓縮被有效果地防止，同時蛇腹部的伸展造成的液體透過性薄片的撓曲被有效果地防止。 In the absorbent article of the present invention, the liquid is supplied to the collar It is preferred that the peripheral portion of the domain form a compression groove (state 9). In the aspect 9, the absorbent article is used as a starting point, and the absorbent article is easily deformed stably. When the absorbent article is deformed, the stretch of the snake abdomen and the elastic restoring force in the high rigidity region are effectively generated, so that the excessive compression of the absorbent body is effective. The prevention of the deflection of the liquid permeable sheet caused by the stretching of the snake's abdomen is effectively prevented.

本發明之吸收性物品中，液體透過性薄片以 含有具有0.00~0.60之IOB、45℃以下之熔點、對25℃之水100g為0.00~0.05g之水溶解度之血液改質劑為佳(態樣10)。在態樣10，吸收性物品的吸收對象為經血時，因到達液體透過性薄片的經血與血液改質劑接觸被改質， 黏度高的經血不易殘留在液體透過性薄片，液體透過性薄片的黏膩感減少、清爽感提升，且著用者不易有視覺上的不愉快感。 In the absorbent article of the present invention, the liquid permeable sheet is A blood modifying agent containing a water solubility of 0.000 to 0.60 IOB, a melting point of 45 ° C or less, and a water content of 100 g of water at 25 ° C of 0.00 to 0.05 g is preferable (Stage 10). In the aspect 10, when the absorption object of the absorbent article is menstrual blood, the menstrual blood reaching the liquid permeable sheet is modified by contact with the blood modifying agent, The menstrual blood having a high viscosity is less likely to remain in the liquid permeable sheet, and the viscosity of the liquid permeable sheet is reduced, the refreshing feeling is improved, and the user is less likely to have a visual unpleasant feeling.

態樣10中，血液改質劑係例如由下述(i)~(iii)：(i)烴；(ii)具有(ii-1)烴部分、與(ii-2)前述烴部分的C-C單鍵間***的羰基(-CO-)及氧基(-O-)所成群中所選出的一個或複數個相同或相異的基之化合物；及(iii)具有(iii-1)烴部分、與(iii-2)於前述烴部分的C-C單鍵間***的羰基(-CO-)及氧基(-O-)所成群中所選出的一個或複數個相同或相異的基、與(iii-3)取代前述烴部分的氫原子的羧基(-COOH)及羥基(-OH)所成群中所選出的一個或複數個相同或相異的基之化合物；以及彼等之任意組合所構成的群中選出，在此，(ii)或(iii)之化合物中，在***2個以上氧基的場合，各氧基不相鄰(態樣11)。 In the aspect 10, the blood modifying agent is, for example, the following (i) to (iii): (i) a hydrocarbon; (ii) a CC having (ii-1) a hydrocarbon moiety and (ii-2) the hydrocarbon moiety; a compound of one or more of the same or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted between the single bonds; and (iii) having (iii-1) a hydrocarbon a portion or a plurality of identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted between the CC single bond of the hydrocarbon moiety (iii-2) And (iii-3) a compound which replaces one or a plurality of identical or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) of a hydrogen atom of the aforementioned hydrocarbon moiety; and In the group consisting of any combination, in the compound of (ii) or (iii), when two or more oxy groups are inserted, each oxy group is not adjacent (the aspect 11).

態樣10或11中，血液改質劑為例如由下述(i’)~(iii’)：(i’)烴；(ii’)具有(ii’-1)烴部分、與(ii’-2)於前述烴部分的C-C單鍵間***的羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結的化合物；及 (iii’)具有(iii’-1)烴部分、與(iii’-2)於前述烴部分的C-C單鍵間***的羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結、與(iii’-3)取代前述烴部分的氫原子的羧基(-COOH)及羥基(-OH)所成群中所選出的一個或複數個相同或相異的基之化合物；以及彼等之任意組合所構成的群中選出，在此，(ii’)或(iii’)之化合物中，在***2個以上的相同或相異的鍵結場合，各鍵結不相鄰(態樣12)。 In the aspect 10 or 11, the blood modifying agent is, for example, the following (i') to (iii'): (i') hydrocarbon; (ii') has (ii'-1) hydrocarbon moiety, and (ii' -2) a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-) inserted between the CC single bonds of the aforementioned hydrocarbon moiety One or more of the same or different bonded compounds selected in the population; and (iii') a carbonyl bond (-CO-), an ester bond (-COO-) having a (iii'-1) hydrocarbon moiety and (iii'-2) inserted between the CC single bonds of the hydrocarbon moiety, One or a plurality of identical or different bonds selected from the group consisting of carbonate linkages (-OCOO-) and ether linkages (-O-), and (iii'-3) hydrogen substituted for the aforementioned hydrocarbon moiety a compound of one or more of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) of an atom; and a group consisting of any combination thereof, selected herein, In the compound of ii') or (iii'), when two or more identical or different bonds are inserted, the bonds are not adjacent (the aspect 12).

態樣10~12中，血液改質劑為例如由下述(A)~(F)：(A)(A1)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的2~4個羥基的化合物與(A2)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的1個羧基的化合物之酯；(B)(B1)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的2~4個羥基的化合物與(B2)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的1個羥基的化合物之醚；(C)(C1)含有鏈狀烴部分與取代前述鏈狀烴部分的氫原子的2~4個羧基之羧酸、羥基酸、烷氧基酸或側氧酸與(C2)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的1個羥基的化合物之酯；(D)具有鏈狀烴部分、與前述鏈狀烴部分的C-C單鍵 間***的醚鍵(-O-)、羰基鍵結(-CO-)、酯鍵結(-COO-)、及碳酸酯鍵結(-OCOO-)所成群中選出的任一個鍵結的化合物；(E)聚氧化C2~6烷二醇、或其烷基酯或者烷基醚；及(F)鏈狀烴；以及彼等之任意組合所成群中所選出(態樣13)。 In the aspect 10 to 12, the blood modifying agent is, for example, 2 to 4 having a chain hydrocarbon portion and a hydrogen atom replacing the aforementioned chain hydrocarbon portion by (A) to (F): (A) (A1) a compound having a hydroxyl group and (A2) an ester having a chain hydrocarbon moiety and a compound which substitutes one carboxyl group of a hydrogen atom of the chain hydrocarbon moiety; (B) (B1) has a chain hydrocarbon moiety and a substituted chain a compound having 2 to 4 hydroxyl groups of a hydrogen atom of a hydrocarbon moiety and (B2) an ether having a chain hydrocarbon moiety and a compound having one hydroxyl group substituted for the hydrogen atom of the chain hydrocarbon moiety; (C) (C1) containing a chain a hydrocarbon moiety, a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid which replaces 2 to 4 carboxyl groups of a hydrogen atom of the aforementioned chain hydrocarbon moiety, and (C2) has a chain hydrocarbon moiety and a substituted chain hydrocarbon An ester of a compound having a hydroxyl group of a part of a hydrogen atom; (D) an ether bond (-O-) having a chain hydrocarbon moiety interposed between a CC single bond of the aforementioned chain hydrocarbon moiety, and a carbonyl bond (-CO-) a compound selected from the group consisting of ester linkage (-COO-) and carbonate linkage (-OCOO-); (E) polyoxygenated C 2-6 alkanediol, or an alkane thereof a base ester or an alkyl ether; and (F) a chain hydrocarbon; And any combination of their being in the selected groups (aspect 13).

態樣10~13中，血液改質劑為例如由(a1)鏈狀烴四醇與至少1個脂肪酸之酯、(a2)鏈狀烴三醇與至少1個脂肪酸之酯、(a3)鏈狀烴二醇與至少1個脂肪酸之酯、(b1)鏈狀烴四醇與至少1個脂肪族1元醇之醚、(b2)鏈狀烴三醇與至少1個脂肪族1元醇之醚、(b3)鏈狀烴二醇與至少1個脂肪族1元醇之醚、(c1)具有4個羧基的鏈狀烴四羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、(c2)具有3個羧基的鏈狀烴三羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、(c3)具有2個羧基的鏈狀烴二羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、(d1)脂肪族1元醇與脂肪族1元醇之醚、(d2)二烷基酮、(d3)脂肪酸與脂肪族1元醇之酯、(d4)二烷基碳酸酯、(e1)聚氧化C2~6烷二醇、(e2)聚氧化C2~6烷二醇與至少1個脂肪酸之酯、(e3)聚氧化C2~6烷二醇與至少1個脂肪族1元醇之醚、(e4)聚氧化C2~6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯、(e5)聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚、及(f1)鏈狀烷烴、以及彼等之 任意組合所成群中所選出(態樣14)。 In the aspects 10 to 13, the blood modifying agent is, for example, an ester of (a 1 ) chain hydrocarbon tetraol with at least one fatty acid, (a 2 ) chain hydrocarbon triol and at least one fatty acid ester, (a 3 ) an ester of a chain hydrocarbon diol with at least one fatty acid, (b 1 ) a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol ether, (b 2 ) a chain hydrocarbon triol and at least one fat a hydrocarbon of a monohydric alcohol, (b 3 ) a chain hydrocarbon diol and an ether of at least one aliphatic monohydric alcohol, (c 1 ) a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy group An acid or an acid ester of a oxo acid with at least one aliphatic monohydric alcohol, (c 2 ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or a oxo acid and at least one aliphatic a monohydric alcohol ester, (c 3 ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid and an ester of at least one aliphatic monohydric alcohol, (d 1 ) fat An ether of a monohydric alcohol and an aliphatic monohydric alcohol, (d 2 )dialkyl ketone, an ester of a (d 3 ) fatty acid and an aliphatic monohydric alcohol, (d 4 ) a dialkyl carbonate, (e 1 ) polyoxy C 2 ~ 6 alkanediols, (e 2) polyoxy C 2 ~ 6 alkylene glycol and at least one ester of fatty acid, (e 3) polyoxy C 2 ~ 6 alkanediol Ether least one of an aliphatic monohydric alcohol, (e 4) polyoxy C 2 ~ 6 alkylene glycol and a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, a dicarboxylic acid of chain hydrocarbon or ester, ( e 5 ) polyoxy C 2-6 alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or ether of chain hydrocarbon diol, and (f 1 ) chain alkane, and any combination thereof Selected in the group (Stage 14).

本發明之吸收性物品中，可組合態樣1~14中2種以上的態樣。 In the absorbent article of the present invention, two or more of the aspects 1 to 14 can be combined.

本發明之吸收性物品的種類及用途，並不特別限制，但可舉例如生理用衛生棉、衛生護墊、拋棄式尿布、失禁墊、失禁護墊、拭汗薄片等之衛生用品．生理用品，此等可以人為對象、或以寵物等之人以外的動物為對象。吸收性物品之吸收對象的液體不特別限制，例如使用者的液狀***物、體液等。 The type and use of the absorbent article of the present invention are not particularly limited, and examples thereof include sanitary napkins, sanitary pads, disposable diapers, incontinence pads, incontinence pads, and sweat-absorbent sheets. Physiological items, such as human beings, or animals other than people such as pets. The liquid to be absorbed by the absorbent article is not particularly limited, and is, for example, a liquid excrement of a user, a body fluid, or the like.

以下、以生理用衛生棉例，說明本發明之吸收性物品的實施形態。 Hereinafter, an embodiment of the absorbent article of the present invention will be described using a sanitary napkin as an example.

<第1實施形態> <First embodiment>

如圖1及圖2所示般，第1實施形態之生理用衛生棉1，具備液體透過性的頂部薄片2、液體不透過性的背部薄片3、在頂部薄片2及背部薄片3間設置的吸收體4。 As shown in FIG. 1 and FIG. 2, the sanitary napkin 1 of the first embodiment includes a liquid-permeable top sheet 2, a liquid-impermeable back sheet 3, and a top sheet 2 and a back sheet 3. Absorber 4.

圖1中，X軸方向為生理用衛生棉1之寬度方向，Y軸方向為生理用衛生棉1之長度方向，廣佈X軸Y軸的平面的方向為生理用衛生棉1之平面方向。其他圖中亦同。圖2為模式斷面圖，於頂部薄片2形成的蛇腹部210被省略。 In Fig. 1, the X-axis direction is the width direction of the sanitary napkin 1, the Y-axis direction is the longitudinal direction of the sanitary napkin 1, and the plane of the X-axis Y-axis is the plane direction of the sanitary napkin 1. The same is true in other figures. Fig. 2 is a schematic cross-sectional view in which the snake abdomen 210 formed on the top sheet 2 is omitted.

生理用衛生棉1，以吸收液狀***物(尤其經血)為目的，被使用者著用。此時，以頂部薄片2為使用者的肌膚側、背部薄片3為使用者的著衣(內褲)側之方式 ，被使用者著用。液狀***物透過頂部薄片2至吸收體4、被吸收體4吸收．保留。被吸收體4吸收．保留的液狀***物的滲漏藉由背部薄片3而被防止。 The sanitary napkin 1 is used by the user for the purpose of absorbing liquid excrement (especially menstrual blood). At this time, the top sheet 2 is the skin side of the user, and the back sheet 3 is the side of the user's clothing (panties). , used by users. The liquid excrement is absorbed through the top sheet 2 to the absorber 4 and absorbed by the absorber 4. Reserved. Absorbed by the absorber 4. Leakage of the retained liquid excrement is prevented by the back sheet 3.

如圖1及圖2所示般，頂部薄片2及背部薄 片3，長度方向之端部彼此以密封部7a，7b接合、形成本體部11，同時寬度方向之端部彼此以密封部8a，8b接合，形成由本體部11向寬度方向延伸出的略矩形狀的翼部12a及12b。藉由頂部薄片2及背部薄片3的周緣部以密封部7a，7b，8a及8b接合，防止生理用衛生棉1之變形時，兩薄片的分離。 As shown in Figure 1 and Figure 2, the top sheet 2 and the back are thin The sheet 3, the end portions in the longitudinal direction are joined to each other by the sealing portions 7a, 7b, and the body portion 11 is formed, while the end portions in the width direction are joined to each other by the sealing portions 8a, 8b, forming a substantially rectangular shape extending from the body portion 11 in the width direction. Wings 12a and 12b. The peripheral portions of the top sheet 2 and the back sheet 3 are joined by the sealing portions 7a, 7b, 8a, and 8b to prevent separation of the two sheets when the sanitary napkin 1 is deformed.

本體部11之形狀，可在配合女性的身體、內 褲等範圍適宜變更，例如可為略長方形、略橢圓形、略葫蘆形等。本體部11長度方向之延伸尺寸，通常100~500mm、較佳為150~350mm，本體部11之寬度方向之延伸尺寸，通常30~200mm、較佳為40~180mm。 The shape of the body portion 11 can be matched with the body of the woman. The range of pants and the like is suitably changed, and may be, for example, a slightly rectangular shape, a slightly elliptical shape, or a slightly gourd shape. The extension of the main body portion 11 in the longitudinal direction is usually 100 to 500 mm, preferably 150 to 350 mm, and the extension of the main body portion 11 in the width direction is usually 30 to 200 mm, preferably 40 to 180 mm.

密封部7a，7b，8a及8b之接合樣式，可舉 例如壓紋加工、超音波、熱熔型接著劑等。為了提高接合強度，可組合2種以上的接合樣式(例如經熱熔型接著劑接合後，施以壓紋加工等)。 The joint pattern of the sealing portions 7a, 7b, 8a and 8b can be mentioned For example, embossing, ultrasonic, hot-melt adhesives, and the like. In order to increase the bonding strength, two or more bonding patterns may be combined (for example, embossing or the like after bonding by a hot-melt type adhesive).

壓紋加工，可舉例如在經圖型化的壓紋輥與 平面輥間，使頂部薄片2及背部薄片3一併通過而進行壓紋加工之方法(被稱為所謂Round seal之方法)等。在該方法，因藉由壓紋輥及/或平面輥的加熱，各薄片軟化，密封部顯然變得容易形成。壓紋圖型，可舉例如格子狀圖型 、千鳥狀圖型、波浪狀圖型等。在密封部的邊界，以生理用衛生棉1變得不易折曲，且壓紋圖型為斷續、細長狀為佳。 The embossing process can be exemplified by a patterned embossing roll and Between the flat rolls, the top sheet 2 and the back sheet 3 are passed together to perform embossing (a method called a so-called Round seal). In this method, since the sheets are softened by the heating of the embossing roll and/or the flat roll, the sealing portion is apparently easily formed. An embossed pattern, such as a grid pattern , thousand bird pattern, wavy pattern, etc. At the boundary of the sealing portion, the sanitary napkin 1 becomes less likely to be bent, and the embossed pattern is preferably intermittent or elongated.

熱熔接著劑，可舉例如以苯乙烯-乙烯-丁二 烯-苯乙烯(SEBS)、苯乙烯-丁二烯-苯乙烯(SBS)、苯乙烯-異戊二烯-苯乙烯(SIS)等之橡膠系為主體的、或以直鏈狀低密度聚乙烯等之烯烴系為主體的感壓型接著劑或感熱型接著劑；水溶性高分子(例如聚乙烯基醇、羧基甲基纖維素、明膠等)或水膨潤性高分子(例如聚乙烯基乙酸酯、聚丙烯酸鈉等)所構成的感水性接著劑等。接著劑之塗佈方法，可舉例如螺旋塗佈、塗佈器塗佈、淋幕塗佈器塗佈、SUMMITGUN塗佈等。 Hot melt adhesive, for example, styrene-ethylene-butyl Rubber such as styrene-styrene (SEBS), styrene-butadiene-styrene (SBS), styrene-isoprene-styrene (SIS), or the like, or a linear low-density polymer An olefin such as ethylene is a main pressure-sensitive adhesive or a heat-sensitive adhesive; a water-soluble polymer (for example, polyvinyl alcohol, carboxymethyl cellulose, gelatin, etc.) or a water-swellable polymer (for example, a polyvinyl group) A water-sensitive adhesive or the like composed of acetate, sodium polyacrylate or the like. Examples of the coating method of the subsequent agent include spiral coating, applicator coating, curtain coater coating, and SUMMITGUN coating.

圖2所示般，在形成翼部12a及12b的背部 薄片3之著衣側，設計有黏著部9a及9b，在形成本體部11之背部薄片3之著衣側，設置黏著部9c。藉由黏著部9c黏貼於內褲的褲襠部，同時翼部12a及12b在內褲的外面側被折曲，黏著部9a及9b黏附在內褲的褲襠部，生理用衛生棉1被安定地固定於內褲。 As shown in Fig. 2, on the back forming the wings 12a and 12b Adhesive portions 9a and 9b are formed on the garment side of the sheet 3, and an adhesive portion 9c is provided on the garment side of the back sheet 3 on which the main body portion 11 is formed. The adhesive portion 9c is adhered to the crotch portion of the undergarment, and the wings 12a and 12b are bent on the outer side of the undergarment, and the adhesive portions 9a and 9b are adhered to the crotch portion of the undergarment, and the sanitary napkin 1 is stably fixed to the underwear. .

黏著部9a，9b及9c所含有的黏著劑，可舉 例如苯乙烯-乙烯-丁烯-苯乙烯嵌段共聚物、苯乙烯-丁烯聚合物、苯乙烯-丁烯-苯乙烯嵌段共聚物、苯乙烯-異丁烯-苯乙烯共聚物等之苯乙烯系聚合物；C5系石油樹脂、C9系石油樹脂、二環戊二烯系石油樹脂、松香系石油樹脂、聚萜烯樹脂、萜烯酚樹脂等之黏著賦予劑；磷酸三甲 苯酯、苯二甲酸二丁酯、苯二甲酸二辛基酯等之單體可塑劑；乙烯聚合物、聚酯等之聚合物可塑劑等。 Adhesives contained in the adhesive portions 9a, 9b and 9c, For example, styrene-ethylene-butylene-styrene block copolymer, styrene-butene polymer, styrene-butylene-styrene block copolymer, styrene-isobutylene-styrene copolymer, etc. Polymer; C5-based petroleum resin, C9-based petroleum resin, dicyclopentadiene petroleum resin, rosin-based petroleum resin, polydecene resin, terpene phenol resin, etc. A monomer plasticizer such as phenyl ester, dibutyl phthalate or dioctyl phthalate; a polymer plasticizer such as an ethylene polymer or a polyester.

頂部薄片2，以提升使用者著用生理用衛生棉1時的膚觸為目的，設置在與使用者的肌膚接觸之面。 The top sheet 2 is provided on the surface in contact with the user's skin for the purpose of enhancing the skin contact when the user uses the sanitary napkin 1.

如圖1及圖2所示般，在頂部薄片2，設定接受來自使用者之液狀***物供給的***物被供給領域20。***物被供給領域20包含接觸使用者的***口(例如小***、大***、***口等)的第1領域20a、與位在第1領域20a的周圍的第2領域20b，***物被供給領域20之長度，通常為50~200mm、較佳為70~150mm，寬通常為10~80mm、較佳為20~50mm。第1領域20a，為使液狀***物之吸收性提升，比實際接觸使用者的***口領域大。第2領域20b為了防止來自第1領域20a未被吸收的液狀***物的滲漏，配置於第1領域20a的周圍。第2領域20b在來自第1領域20a的未被吸收的液狀***物的滲漏中，尤其有效防止來自生理用衛生棉1之寬度方向的滲漏。 As shown in FIG. 1 and FIG. 2, in the top sheet 2, the excrement supply area 20 that receives the supply of the liquid excrement from the user is set. The excrement supply area 20 includes a first field 20a that contacts a user's excretory opening (for example, a labia minora, a labia majora, a vaginal opening, etc.), and a second field 20b that is located around the first field 20a, and the excrement is supplied. The length of the field 20 is usually 50 to 200 mm, preferably 70 to 150 mm, and the width is usually 10 to 80 mm, preferably 20 to 50 mm. In the first field 20a, in order to improve the absorbability of the liquid excrement, it is larger than the field of the excretory opening of the user actually contacting the user. The second field 20b is disposed around the first field 20a in order to prevent leakage of liquid excrement from the first field 20a that is not absorbed. The second field 20b is particularly effective in preventing leakage from the width direction of the sanitary napkin 1 in the leakage of the unabsorbed liquid excrement from the first field 20a.

頂部薄片2由可撓性材料所構成。可撓性材料為對變形具有彈性復原力(反彈力)之材料。可撓性材料雖可因變形時施加的力而伸展，但由提高對變形之彈性復原力觀點，以因變形時施加的力而實質上不伸展為佳。 The top sheet 2 is composed of a flexible material. The flexible material is a material that has elastic restoring force (rebounding force) to deformation. Although the flexible material can be stretched by the force applied during deformation, it is preferable that the elastic restoring force against deformation is substantially not stretched by the force applied during the deformation.

可撓性材料，可舉例如合成樹脂，合成樹脂，可舉例如烯烴與丙烯酸酯、乙酸乙烯酯等其他單體之共聚物；低密度聚乙烯、直鏈狀低密度聚乙烯、高密度聚乙 烯、聚丙烯等之聚烯烴；聚乙烯對苯二甲酸酯等之聚酯；聚醯胺；乙酸纖維素等，此等中，由柔軟性高且對肌膚刺激少觀點，以烯烴與其他單體之共聚物、聚烯烴等為佳。 可撓性材料為2種以上的合成樹脂之混合材料、例如可為低密度聚乙烯20~60%、直鏈狀低密度聚乙烯30~60%及高密度聚乙烯5~20%的混合材料。 Examples of the flexible material include synthetic resins and synthetic resins, and examples thereof include copolymers of olefins with other monomers such as acrylates and vinyl acetate; low density polyethylene, linear low density polyethylene, and high density polyethylene. Polyolefins such as olefins and polypropylene; polyesters such as polyethylene terephthalate; polyamines; cellulose acetate, etc., among which olefins and others are high in flexibility and less irritating to the skin. A copolymer of a monomer, a polyolefin, or the like is preferred. The flexible material is a mixed material of two or more kinds of synthetic resins, for example, a mixed material of 20 to 60% of low-density polyethylene, 30 to 60% of linear low-density polyethylene, and 5 to 20% of high-density polyethylene. .

如圖1及圖3所示般，在頂部薄片2，高剛性 領域22形成為網孔狀，在各網孔內側形成低剛性領域21。低剛性領域21及高剛性領域22雖以相同可撓性材料構成，但因於低剛性領域21形成液體透過孔，在高剛性領域22未形成液體透過孔，因此低剛性領域21之剛性比高剛性領域22的剛性低。 As shown in Figures 1 and 3, at the top sheet 2, high rigidity The field 22 is formed in a mesh shape, and a low rigidity region 21 is formed inside each mesh. Although the low rigidity region 21 and the high rigidity region 22 are made of the same flexible material, since the liquid passage hole is formed in the low rigidity region 21, the liquid permeation hole is not formed in the high rigidity region 22, so the rigidity ratio of the low rigidity region 21 is high. The rigidity of the rigid field 22 is low.

如圖3所示般，在低剛性領域21，形成具有 山摺部及谷摺部的重複構造的蛇腹部210。藉由山摺部及谷摺部被拉伸，蛇腹部210變得可在低剛性領域21之面方向伸展。又，圖3中，以頂部薄片2側為上側、背部薄片3側為下側時，於上側凸者為山摺部，於下側凸者為谷摺部。 As shown in FIG. 3, in the low rigidity field 21, formed with The snake abdomen 210 of the repeating structure of the mountain fold and the valley fold. By the mountain fold and the valley fold being stretched, the snake belly 210 becomes stretchable in the direction of the low rigidity field 21. In addition, in FIG. 3, when the top sheet 2 side is the upper side and the back sheet 3 side is the lower side, the upper side convex part is a mountain fold part, and the lower side convex part is a valley fold part.

如圖1及圖3所示般，蛇腹部210之山摺部 及谷摺部延伸設置在生理用衛生棉1之長度方向，同時並列設置於生理用衛生棉1之寬度方向。藉由如此配置，蛇腹部210變得易對生理用衛生棉1之寬度方向伸展，生理用衛生棉1沿著長度方向被折曲、向頂部薄片2側凸狀變形時，蛇腹部210之伸展有效產生，低剛性領域21之吸 收體4的過度壓縮被有效果地防止。 As shown in Figure 1 and Figure 3, the mountain part of the snake abdomen 210 The valley fold portion is extended in the longitudinal direction of the sanitary napkin 1 and is juxtaposed in the width direction of the sanitary napkin 1. With this arrangement, the snake abdomen 210 becomes easy to extend in the width direction of the sanitary napkin 1 and the sanitary napkin 1 is bent along the longitudinal direction and convexly deformed toward the top sheet 2 side, and the snake belly 210 is stretched. Effectively produced, low-rigidity field 21 Excessive compression of the body 4 is effectively prevented.

如圖3所示般，沿著頂部薄片2的寬度方向 的蛇腹部210之斷面成為略波浪狀。在略波浪狀中包含施以使U字狀的曲線成為直線、使U字狀成為逆C字狀、使U字狀成為V字狀的等之變形的形狀。 As shown in Figure 3, along the width of the top sheet 2 The section of the snake's abdomen 210 is slightly wavy. The slightly wavy shape includes a shape in which a U-shaped curve is formed into a straight line, a U-shaped shape is reversed C-shaped, and a U-shaped shape is formed into a V shape.

山摺部的最上部的寬及谷摺部的最下部的寬 通常為0.1~2.0mm、較佳為0.2~1.5mm，山摺部的高度及谷摺部的深度，通常為0.3~3.0mm、較佳為0.5~1.5mm，相鄰的山摺部的最上部彼此的寬及相鄰的谷摺部的最下部彼此的寬通常為0.3~3.0mm、較佳為0.5~2.0mm。 The width of the uppermost part of the mountain fold and the width of the lowermost part of the valley fold Usually 0.1 to 2.0 mm, preferably 0.2 to 1.5 mm, the height of the mountain fold and the depth of the valley fold are usually 0.3 to 3.0 mm, preferably 0.5 to 1.5 mm, and the most adjacent mountain folds are The width of the upper portions and the width of the lowermost portions of the adjacent valley-folding portions are usually 0.3 to 3.0 mm, preferably 0.5 to 2.0 mm.

蛇腹部210，除伸展性外亦可具有收縮性。但 ，在即使蛇腹部210具有收縮性之場合，因蛇腹部210之材質、蛇腹之數等，有經伸展的蛇腹部210不完全收縮至原本狀態、維持比原本狀態稍稍伸展狀態之場合。 The snake abdomen 210 can also have contractility in addition to stretchability. but In the case where the snake abdomen 210 has contractility, the stretched snake abdomen 210 does not completely contract to the original state and maintains a slightly extended state than the original state due to the material of the snake belly 210 and the number of the snake belly.

賦予蛇腹部210收縮性之場合，於構成頂部 薄片2的可撓性材料中混合彈性體材料即可。彈性體，可舉例如聚酯系、胺基甲酸乙酯系、烯烴系、苯乙烯系、聚醯胺系之熱可塑性彈性體、使用二茂金屬觸媒的低密度聚乙烯、乙烯-α-烯烴共聚物、此等之組合等。 Give the snake abdomen 210 contraction, at the top of the composition The elastic material of the sheet 2 may be mixed with an elastomer material. Examples of the elastomer include polyester-based, urethane-based, olefin-based, styrene-based, polyamido-based thermoplastic elastomers, low-density polyethylene using a metallocene catalyst, and ethylene-α- Olefin copolymers, combinations of these, and the like.

聚酯系彈性體，可舉例如含芳香族聚酯於硬 鏈節、含非晶性聚醚、脂肪族聚酯等於軟鏈節者，胺基甲酸乙酯系彈性體，可舉例如作為熱可塑性彈性體之聚酯、低分子二醇、伸甲基雙苯基異氰酸酯等所構成的聚胺基甲 酸乙酯，烯烴系彈性體，可舉例如乙烯與α-烯烴之無規共聚物、乙烯與α-烯烴與二烯之無規共聚物等，苯乙烯系彈性體，可舉例如SEBS、SIS、SEPS、SBS等之嵌段共聚物，作為聚醯胺系彈性體，可舉例如含有作為硬鏈節之尼龍與作為軟鏈節之聚酯或多元醇者。 The polyester elastomer may, for example, be an aromatic polyester-containing hard The chain link, the amorphous polyether, the aliphatic polyester is equal to the soft chain link, and the urethane type elastomer is, for example, a polyester as a thermoplastic elastomer, a low molecular weight diol, and a methyl bisexene. Polyamine based on phenyl isocyanate Examples of the acid ethyl ester and the olefin-based elastomer include a random copolymer of ethylene and an α-olefin, a random copolymer of ethylene and an α-olefin and a diene, and a styrene-based elastomer, and examples thereof include SEBS and SIS. Examples of the block copolymer such as SEPS and SBS include, as the polyamine-based elastomer, a nylon which is a hard chain link and a polyester or a polyol which is a soft chain link.

如圖1及圖3所示般，高剛性領域22，具有 延伸設置於與生理用衛生棉1之長度方向交叉的方向，略平行並列設置的略直線狀的m個領域(以下稱「領域A1-m」)、與在與領域A1-m交叉方向延伸設置且略平行並列設置的略直線狀的n個領域(以下稱「領域B1-n」)，領域A1-m及領域B1-n因交叉而成為網孔狀。因高剛性領域22形成為網孔狀，故藉由高剛性領域22的彈性復原力，扭轉變形的生理用衛生棉1易復原為原本之形狀。 As shown in Fig. 1 and Fig. 3, the high-rigidity region 22 has a slightly linear m area (hereinafter referred to as "field A" extending in a direction intersecting with the longitudinal direction of the sanitary napkin 1 and being arranged in parallel in parallel. 1-m ′′), and n fields (hereinafter referred to as “field B 1-n ”) which are slightly linearly arranged in parallel with the field A 1-m and are arranged in parallel, and the field A 1-m and the field B 1-n becomes a mesh shape due to the intersection. Since the high-rigidity region 22 is formed in a mesh shape, the physiological sanitary napkin 1 which is torsionally deformed by the elastic restoring force of the high-rigidity region 22 is easily restored to its original shape.

領域A1-m與生理用衛生棉1之長度方向交叉 的角度α1，通常為1°≦α1≦90°、較佳為10°≦α1≦80°、又更佳為30°≦α1≦60°，領域B1-n與生理用衛生棉1之長度方向交叉的角度α2(但，領域B1-n與領域A1-m交叉之角度為α1+α2)，通常為1°≦α2≦90°、較佳為10°≦α2≦80°、又更佳為30°≦α2≦60°。但，α1及α2之選擇不使α1+α2成為180°。α1及α2在上述範圍，則確保蛇腹部210之形成所必要的各網孔之尺寸。又，藉由形成為網孔狀的高剛性領域22的彈性復原力，扭轉變形的生理用衛生棉1易復原為原本之形狀。進而，領域A1-m及領域B1-n夾住生理用衛生棉1之長度方向而位於兩側，故生理 用衛生棉1沿著長度方向被折曲、凸狀變形時，變得易發揮對凸狀變形的高剛性領域22的彈性復原力(反彈力)。 The angle α 1 of the field A 1-m intersecting the longitudinal direction of the sanitary napkin 1 is usually 1 ° ≦ α 1 ≦ 90 °, preferably 10 ° ≦ α 1 ≦ 80 °, and more preferably 30 ° ≦ α 1 ≦ 60 °, the field B 1-n with a physiologically intersecting with the longitudinal direction of the sanitary napkin an angle α 2 (however, the field B 1-n to the angle of intersection a 1-m art to α 1 + α 2), It is usually 1 ° ≦ α 2 ≦ 90 °, preferably 10 ° ≦ α 2 ≦ 80 °, and more preferably 30 ° ≦ α 2 ≦ 60 °. However, the choice of α 1 and α 2 does not make α 1 + α 2 180°. When α 1 and α 2 are in the above range, the size of each mesh necessary for the formation of the snake abdomen 210 is ensured. Moreover, the physiological sanitary napkin 1 which is torsionally deformed is easily restored to its original shape by the elastic restoring force of the high-rigidity region 22 formed in the mesh shape. Further, the field A 1-m and the field B 1-n are sandwiched between the longitudinal direction of the sanitary napkin 1 and are located on both sides. Therefore, when the sanitary napkin 1 is bent and convexly deformed along the longitudinal direction, it becomes easy. The elastic restoring force (rebounding force) of the high rigidity region 22 that is convexly deformed is exerted.

領域A1-m之數(m)及領域B1-n之數(n)不限於 圖1所示之數，可因應頂部薄片2的大小等適宜變更。m及n為相同或相異的數值，m及n之數值範圍，通常為4~60、較佳為8~40、又更佳為10~35。 The number (m) of the domains A 1-m and the number (n) of the domains B 1-n are not limited to the numbers shown in Fig. 1, and may be appropriately changed depending on the size of the top sheet 2 and the like. m and n are the same or different values, and the numerical ranges of m and n are usually 4 to 60, preferably 8 to 40, and more preferably 10 to 35.

領域A1-m及領域B1-n的各領域的寬通常為 0.1~5mm、較佳為0.3~3mm、又更佳為0.5~2mm。領域A1-m及領域B1-n的寬在上述範圍，則確保蛇腹部210之形成所必要的各網孔之尺寸。又，藉由形成為網孔狀的高剛性領域22的彈性復原力，扭轉變形的生理用衛生棉1易復原為原本之形狀。進而，生理用衛生棉1沿著長度方向被折曲、凸狀變形時，變得易發揮對凸狀變形的高剛性領域22的彈性復原力(反彈力)。 The width of each of the fields A 1-m and the fields B 1-n is usually 0.1 to 5 mm, preferably 0.3 to 3 mm, and more preferably 0.5 to 2 mm. The width of the field A 1-m and the field B 1-n is in the above range, and the size of each mesh necessary for the formation of the snake abdomen 210 is ensured. Moreover, the physiological sanitary napkin 1 which is torsionally deformed is easily restored to its original shape by the elastic restoring force of the high-rigidity region 22 formed in the mesh shape. Further, when the sanitary napkin 1 is bent and deformed in the longitudinal direction, the elastic restoring force (rebounding force) of the high rigidity region 22 which is convexly deformed is easily exhibited.

領域A1-m及領域B1-n交叉後形成的各網孔之 形狀為如圖1及圖3所示般，略菱形狀。亦可對本實施形態加以變更，使各網孔之形狀成為略三角形狀、略四角形狀、略五角形狀等之略多角形狀。略多角形狀中，包含施加使角變圓滑、使構成一邊的直線成為曲線等之變形的形狀。又，亦可對本實施形態加以變更，使領域A1-m及領域B1-n為曲線狀、各網孔之形狀為略圓形狀、略橢圓形狀等。 The shape of each mesh formed after the intersection of the field A 1-m and the field B 1-n is as shown in FIGS. 1 and 3 and has a slightly diamond shape. The present embodiment can also be modified such that the shape of each mesh has a slightly polygonal shape such as a slightly triangular shape, a slightly square shape, or a slightly pentagonal shape. The slightly polygonal shape includes a shape in which a straight line is formed to be rounded, and a straight line constituting one side is deformed into a curve or the like. Further, the present embodiment may be modified such that the fields A 1-m and the fields B 1-n have a curved shape, and the shape of each mesh is a substantially circular shape or a slightly elliptical shape.

領域A1-m及領域B1-n交叉後形成的各網孔的 大小，生理用衛生棉1之長度方向及寬度方向皆通常為3 ~40mm、較佳為5~30mm、又更佳為10~20mm。各網孔的大小在上述範圍，則確保蛇腹部210之形成所必要的各網孔之尺寸。又，藉由形成為網孔狀的高剛性領域22的彈性復原力，扭轉變形的生理用衛生棉1易復原為原本之形狀。進而，生理用衛生棉1沿著長度方向被折曲、凸狀變形時，變得易發揮對凸狀變形的高剛性領域22的彈性復原力(反彈力)。 The size of each mesh formed after the intersection of the field A 1-m and the field B 1-n is generally 3 to 40 mm, preferably 5 to 30 mm, and more preferably the length and width direction of the sanitary napkin 1 10~20mm. The size of each mesh is in the above range, and the size of each mesh necessary for the formation of the snake abdomen 210 is ensured. Moreover, the physiological sanitary napkin 1 which is torsionally deformed is easily restored to its original shape by the elastic restoring force of the high-rigidity region 22 formed in the mesh shape. Further, when the sanitary napkin 1 is bent and deformed in the longitudinal direction, the elastic restoring force (rebounding force) of the high rigidity region 22 which is convexly deformed is easily exhibited.

各網孔上形成的山摺部及谷摺部的合計數， 通常為3以上、較佳為5~19、又更佳為7~15。但，山摺部及谷摺部的合計數為奇數。蛇腹部210之山摺部及谷摺部的合計數在上述範圍，則生理用衛生棉1沿著長度方向被折曲、凸狀變形時，對凸狀變形的蛇腹部210之伸展有效產生，吸收體4的過度壓縮被有效果地防止。 The total number of mountain folds and valley folds formed on each mesh, It is usually 3 or more, preferably 5 to 19, and more preferably 7 to 15. However, the total number of mountain folds and valley folds is an odd number. When the total number of the mountain folds and the valley folds of the snake belly 210 is in the above range, when the sanitary napkin 1 is bent and convexly deformed along the longitudinal direction, the extension of the convexly deformed snake belly 210 is effectively generated. Excessive compression of the absorbent body 4 is effectively prevented.

如圖1及圖3所示般，高剛性領域22包圍低 剛性領域21之周圍全體，隣接的低剛性領域彼此的接續被高剛性領域22遮斷。亦可對本實施形態加以變更，使低剛性領域21之周圍之一部份以高剛性領域22包圍。該場合，由有效產生蛇腹部210之伸展及高剛性領域22的彈性復原力觀點，高剛性領域22以包圍低剛性領域21之周圍全體中30%以上為佳、包圍50%以上又更佳。 As shown in Figures 1 and 3, the high rigidity field 22 is surrounded by low The entire periphery of the rigid region 21, the adjacent low-rigidity regions are interrupted by the high-rigidity region 22. This embodiment can also be modified such that one of the surrounding portions of the low rigidity region 21 is surrounded by the high rigidity region 22. In this case, from the viewpoint of effectively generating the elastic restoring force of the stretch and high rigidity region 22 of the snake abdomen 210, the high rigidity region 22 is preferably 30% or more of the entire circumference surrounding the low rigidity region 21, and more preferably 50% or more.

如圖1及圖3所示般，高剛性領域22與低剛 性領域21之周緣部接續。又，如圖3所示般，高剛性領域22與蛇腹部210之山摺部的最上部連續。亦可對本實施形態加以變更，使高剛性領域22與蛇腹部210之谷摺 部的最下部連續。但，若高剛性領域22在肌膚面側則由頂部薄片2的膚觸變滑順點，如圖3所示般，以高剛性領域22與蛇腹部210之山摺部的最上部連續為佳。 As shown in Figure 1 and Figure 3, high rigidity field 22 and low just The peripheral area of the sex field 21 continues. Further, as shown in FIG. 3, the high rigidity region 22 is continuous with the uppermost portion of the mountain fold of the snake belly 210. This embodiment can also be modified to fold the high rigidity field 22 and the snake belly 210 The lowermost part of the department is continuous. However, if the high-rigidity field 22 is on the skin side, the skin of the top sheet 2 becomes slippery, as shown in Fig. 3, it is preferable that the high-rigidity field 22 and the uppermost portion of the mountain portion of the snake belly 210 are continuous. .

如圖3所示般，在頂部薄片2，形成複數的液 體透過孔26，液狀***物，可通過液體透過孔26浸透吸收體4。如圖3所示般，液體透過孔26雖在頂部薄片2的***物被供給領域20中變形時不直接施加張力的低剛性領域21(蛇腹部210中，將山摺部的最上部與谷摺部的最下部接續的側面部25)形成，但不形成於變形時不直接施加張力的高剛性領域22。因此，液體透過孔26不易因張力而拉伸，防止吸收液狀***物的吸收體4露出與使用者的肌膚接觸，賦予使用者黏膩感及不愉快感。亦可對本實施形態加以變更，使蛇腹部210之山摺部的最上部或谷摺部的最下部形成液體透過孔26、或省略蛇腹部210使低剛性領域21成為略平坦狀，於略平坦狀的低剛性領域21形成液體透過孔26。 As shown in FIG. 3, at the top sheet 2, a plurality of liquids are formed. The body is permeated through the hole 26, and the liquid excrement can permeate the absorber 4 through the liquid permeation hole 26. As shown in Fig. 3, the liquid permeation hole 26 is a low-rigidity field 21 in which the tension is not directly applied when the excrement of the top sheet 2 is deformed in the supply field 20 (in the snake abdomen 210, the uppermost portion and the valley of the mountain fold portion) The lowermost continuous side surface portion 25) of the folded portion is formed, but is not formed in the high rigidity region 22 where the tension is not directly applied during deformation. Therefore, the liquid permeation hole 26 is less likely to be stretched by the tension, and the absorber 4 that absorbs the liquid excrement is prevented from coming into contact with the skin of the user, giving the user a sticky feeling and an unpleasant feeling. The present embodiment can be modified such that the liquid perforating hole 26 is formed at the uppermost portion of the mountain portion of the snake belly 210 or the lowermost portion of the valley portion, or the snake abdomen 210 is omitted, so that the low rigidity region 21 is slightly flat and slightly flat. The low rigidity region 21 of the shape forms a liquid permeation hole 26.

1個液體透過孔26的開口面積，較佳為0.001 ~1mm2、又更佳為0.01~0.1mm2。1個液體透過孔26的開口面積比0.001mm2小，則有液狀***物變得難以透過之場合，超過1mm2，則有一旦被吸收體4吸收的液狀***物通過頂部薄片2的液體透過孔26而逆流之場合，或頂部薄片2的隱蔽性變小之場合。 The opening area of one liquid permeation hole 26 is preferably 0.001 to 1 mm 2 , and more preferably 0.01 to 0.1 mm 2 . When the opening area of one liquid permeation hole 26 is smaller than 0.001 mm 2 , liquid excretion becomes difficult to permeate, and when it exceeds 1 mm 2 , liquid excrement absorbed by the absorber 4 passes through the top sheet 2 . When the liquid passes through the hole 26 and flows backward, or the concealability of the top sheet 2 becomes small.

相對頂部薄片2的面積之總開口面積的比例 ，亦即，頂部薄片2的開口率，較佳為5~20%。頂部薄 片2的開口率未達5%，則有頂部薄片2中體液之透過性變差的場合，頂部薄片2的開口率若超過20%，則有一旦被吸收體4吸收的體液通過頂部薄片2的液體透過孔26而逆流、通過液體透過孔26可見到吸收體4所吸收的液狀***物之場合。 Ratio of the total opening area of the area of the top sheet 2 That is, the aperture ratio of the top sheet 2 is preferably 5 to 20%. Top thin When the aperture ratio of the sheet 2 is less than 5%, the permeability of the body fluid in the top sheet 2 is deteriorated. When the aperture ratio of the top sheet 2 exceeds 20%, the body fluid absorbed by the absorber 4 passes through the top sheet 2 The liquid passes through the hole 26 and flows back through the liquid permeation hole 26 to the liquid excrement absorbed by the absorber 4.

頂部薄片2的厚度、坪量等，由低剛性領域 21之蛇腹部210之形成性、高剛性領域22的可撓性等之點被適宜調節。頂部薄片2的坪量，通常為10g/m2以上、較佳為10~40g/m2、又更佳為20~30g/m2，頂部薄片2的厚度通常為0.01~3.0mm、較佳為0.1~1.5mm。 The thickness, the amount of the flat sheet, and the like of the top sheet 2 are appropriately adjusted from the viewpoint of the formation of the snake abdomen 210 in the low rigidity region 21 and the flexibility of the high rigidity region 22. The amount of the top sheet 2 is usually 10 g/m 2 or more, preferably 10 to 40 g/m 2 , more preferably 20 to 30 g/m 2 , and the thickness of the top sheet 2 is usually 0.01 to 3.0 mm, preferably. It is 0.1~1.5mm.

由提高頂部薄片2的隱蔽性觀點，頂部薄片2 ，可含有氧化鈦、硫酸鋇、碳酸鈣等之無機填料。 From the viewpoint of improving the concealability of the top sheet 2, the top sheet 2 It may contain an inorganic filler such as titanium oxide, barium sulfate or calcium carbonate.

頂部薄片2可為層合薄膜。層合薄膜，可舉 例如合成樹脂薄膜層與其著衣側之面所設置的纖維集合層的層合薄膜。纖維集合層，含有例如為親水性纖維的集合體之紙、不織布等。作為纖維集合層所使用的不織布，較佳為織物。在此，織物係指以牛皮紙漿、人造絲等為主成分賦予濕潤強度的坪量為10g/m2以上、20g/m2以下的薄葉紙。纖維集合層的厚度，較佳為0.1~0.5mm。纖維集合層可賦予頂部薄片2親水性及柔軟性。在纖維集合層中使用織物之場合，織物與其他紙及不織布相比，價格便宜，又，因市場上多有進出而容易取得。織物層的強度雖低，但藉由與合成樹脂薄膜層一起使用，確保頂部薄片2的強度。 The top sheet 2 can be a laminated film. The laminated film may, for example, be a laminated film of a synthetic resin film layer and a fiber assembly layer provided on the side of the garment side. The fiber assembly layer contains, for example, a paper which is an aggregate of hydrophilic fibers, a nonwoven fabric, or the like. The nonwoven fabric used as the fiber assembly layer is preferably a woven fabric. The basis weight of the fabric refers to Kraft pulp, rayon or the like as the main component imparting wet strength of 10g / m 2 or more, 20g / m 2 or less of the thin paper. The thickness of the fiber collecting layer is preferably 0.1 to 0.5 mm. The fiber assembly layer imparts hydrophilicity and softness to the top sheet 2. In the case where a fabric is used in the fiber assembly layer, the fabric is inexpensive compared to other papers and non-woven fabrics, and is easily obtained because there are many in and out of the market. Although the strength of the fabric layer is low, the strength of the top sheet 2 is ensured by use together with the synthetic resin film layer.

背部薄片3，以防止吸收體4所吸收的液狀排 泄物的滲漏為目的，設置於與使用者的著衣(內褲)接觸之面。背部薄片3，為了使著用時的悶熱降低，除液體不透過性外，以具有透濕性為佳。 Back sheet 3 to prevent liquid absorption absorbed by the absorbent body 4 For the purpose of leakage of the waste, it is placed on the surface in contact with the user's clothes (underpants). The back sheet 3 preferably has moisture permeability in addition to liquid impermeability in order to reduce the sultry heat during use.

背部薄片3，可舉例如施加防水處理的不織布 、合成樹脂(例如聚乙烯、聚丙烯、聚乙烯對苯二甲酸酯等)薄膜、不織布與合成樹脂薄膜之複合薄片(例如在紡黏、水流交絡等之不織布接合通氣性的合成樹脂薄膜的複合薄膜)、亦可使用將耐水性高的熔噴不織布以高強度的紡黏不織布挾持的SMS不織布等。 The back sheet 3 may be, for example, a non-woven fabric to which a waterproof treatment is applied. , a synthetic resin (for example, polyethylene, polypropylene, polyethylene terephthalate, etc.) film, a composite sheet of a non-woven fabric and a synthetic resin film (for example, a synthetic resin film which is bonded to a non-woven fabric such as spunbond or water entanglement) As the composite film, an SMS nonwoven fabric in which a melt-resistant nonwoven fabric having high water resistance is held by a high-strength spunbonded nonwoven fabric can be used.

吸收體4，具有吸收性材料層。吸收性材料層 所含有的吸收性材料，在可吸收使用者的液狀***物下，不特別限制。吸收性材料，可舉例如吸水性纖維、高吸水性材料(例如高吸水性樹脂、高吸水性纖維等)。吸收性材料層，可含有抗黏著劑(anti-block agent)、紫外線吸收劑、增黏分枝劑、消光劑、著色劑、其他的各種改良劑。 The absorbent body 4 has a layer of absorbent material. Absorbent material layer The absorbent material contained is not particularly limited as long as it absorbs liquid excretion from the user. Examples of the absorbent material include water-absorbent fibers and superabsorbent materials (for example, superabsorbent resins, superabsorbent fibers, and the like). The absorbent material layer may contain an anti-block agent, an ultraviolet absorber, a viscosity-increasing branching agent, a matting agent, a coloring agent, and various other modifiers.

吸水性纖維，可舉例如以針葉樹或闊葉樹作 為原料得到的木材紙漿(例如碎木紙漿、精製原紙漿、熱磨機械紙漿、化學熱磨機械紙漿等之機械紙漿；牛皮紙漿、硫化物紙漿、鹼紙漿等之化學紙漿；半化學紙漿等)；對木材紙漿施加化學處理而得到的絲光化紙漿或交聯紙漿；甘蔗渣、洋麻、竹、麻、綿(例如棉花短絨)等之非木材紙漿；人造絲、原纖化人造絲等之再生纖維素；乙酸酯、三乙酸酯等之半合成纖維素等，但由花費低、易成形觀點 ，以粉碎紙漿為佳。 The water-absorbent fiber can be, for example, a conifer or a broad-leaved tree. Wood pulp obtained from raw materials (for example, mechanical pulp of crushed wood pulp, refined raw pulp, hot-milled mechanical pulp, chemical hot-milled mechanical pulp, etc.; chemical pulp of kraft pulp, sulfide pulp, alkali pulp, etc.; semi-chemical pulp, etc.) a mercerized pulp or crosslinked pulp obtained by chemically treating wood pulp; non-wood pulp such as bagasse, kenaf, bamboo, hemp, cotton (for example, cotton linters); rayon, fibrillated rayon, etc. Regenerated cellulose; semi-synthetic cellulose such as acetate, triacetate, etc., but with low cost and easy forming It is better to pulverize the pulp.

高吸水性材料，可舉例如澱粉系、纖維素系 、合成聚合物系之高吸水性材料。澱粉系或纖維素系之高吸水性材料，可舉例如澱粉-丙烯酸(鹽)接枝共聚物、澱粉-丙烯腈共聚物的皂化物、鈉羧基甲基纖維素的交聯物等，合成聚合物系之高吸水性材料，可舉例如聚丙烯酸鹽系、聚磺酸鹽系、無水馬來酸鹽系、聚丙烯醯胺系、聚乙烯基醇系、聚環氧乙烷系、聚天冬胺酸鹽系、聚麩胺酸鹽系、聚褐藻酸鹽系、澱粉系、纖維素系等之高吸水性樹脂(Superabsorbent Polymer：SAP)等，但此等中以聚丙烯酸鹽系(尤其聚丙烯酸鈉系)的高吸水性樹脂為佳。高吸水性材料之形狀，可舉例如粒子狀、纖維狀、鱗片狀等，為粒子狀之場合，粒徑，較佳為50~1000μm、又更佳為100~600μm。 The superabsorbent material may, for example, be a starch system or a cellulose system. A highly absorbent material that is a synthetic polymer. Examples of the starch-based or cellulose-based superabsorbent material include a starch-acrylic acid (salt) graft copolymer, a starch-acrylonitrile copolymer saponified product, and a sodium carboxymethyl cellulose crosslinked product. Examples of the superabsorbent material of the system include polyacrylate type, polysulfonate type, anhydrous maleate type, polypropylene amide type, polyvinyl alcohol type, polyethylene oxide type, poly day. a superabsorbent polymer (SAP) such as a glycoside, a polyglutamate, a polyalginate, a starch or a cellulose, but these are polyacrylates (especially A superabsorbent resin of sodium polyacrylate type is preferred. The shape of the superabsorbent material is, for example, a particulate form, a fibrous form, or a scaly shape. When it is in the form of particles, the particle diameter is preferably 50 to 1000 μm, and more preferably 100 to 600 μm.

吸收性材料層所含有的高吸水性材料的量， 可因應生理用衛生棉1應具備的特性(例如吸收性、輕量性等)適宜變更，通常為吸收性材料層的0~50質量%、較佳為3~30質量%、又更佳為5~15質量%。 The amount of superabsorbent material contained in the layer of absorbent material, It is preferable to change the characteristics (for example, absorbability, lightness, etc.) which the sanitary napkin 1 should have, and it is usually 0 to 50% by mass, preferably 3 to 30% by mass, and more preferably the absorbent material layer. 5~15% by mass.

吸收性材料層的厚度、基重、密度等，可因 應生理用衛生棉1應具備的特性(例如吸收性、輕量性等)適宜變更可能。吸收性材料層的厚度通常為1~20mm、較佳為2~15mm、又更佳為2~10mm，基重通常為100~1000g/m2、較佳為150~700g/m2、又更佳為200~500g/m2，密度通常為0.005~0.5g/cm3、較佳為0.01~ 0.2g/cm3、又更佳為0.01~0.1g/cm3。又，在壓縮溝5a，5b之形成前後，有吸收性材料層的厚度、基重、密度等變化之場合(例如吸收性材料層的厚度減少，基重及密度增加)。 The thickness, the basis weight, the density, and the like of the absorbent material layer may be appropriately changed depending on the characteristics (for example, absorbability, lightness, etc.) which the sanitary napkin 1 should have. The thickness of the layer of the absorbent material is usually 1 to 20 mm, preferably 2 to 15 mm, more preferably 2 to 10 mm, and the basis weight is usually 100 to 1000 g/m 2 , preferably 150 to 700 g/m 2 , and more Preferably, it is 200 to 500 g/m 2 , and the density is usually 0.005 to 0.5 g/cm 3 , preferably 0.01 to 0.2 g/cm 3 , and more preferably 0.01 to 0.1 g/cm 3 . Further, before and after the formation of the compression grooves 5a, 5b, there are cases where the thickness, the basis weight, the density, and the like of the absorbent material layer are changed (for example, the thickness of the absorbent material layer is reduced, and the basis weight and density are increased).

吸收體4可以被覆材被覆。被覆材在具有液 體透過性及吸收體保持性下，則不特別限制，由低花費性及吸收體保持性的觀點來看，以粉碎紙漿作為主材料且以濕式法成形的織物為佳。 The absorbent body 4 can be covered with a covering material. Covered material with liquid The body permeability and the absorbent body retainability are not particularly limited, and from the viewpoint of low cost and absorbent body retention, it is preferred to use a pulverized pulp as a main material and a wet-formed fabric.

如圖1及圖2所示般，頂部薄片2中，於排 泄物被供給領域20之第1領域20a及第2領域20b的周緣部，各自形成壓縮溝5a及5b。以壓縮溝5a，5b為起點，生理用衛生棉1易安定地變形，在生理用衛生棉1之變形時，蛇腹部210之伸展及高剛性領域22的彈性復原力有效生成，故吸收體4的過度壓縮被有效果地防止，同時蛇腹部210之伸展造成的頂部薄片2的撓曲被有效果地防止。 As shown in Figures 1 and 2, in the top sheet 2, in the row In the first region 20a of the supply region 20 and the peripheral portion of the second region 20b, the compression grooves 5a and 5b are formed. Starting from the compression grooves 5a, 5b, the sanitary napkin 1 is easily deformed stably. When the sanitary napkin 1 is deformed, the stretch of the snake abdomen 210 and the elastic restoring force of the high rigidity region 22 are effectively generated, so the absorbent body 4 is The excessive compression is effectively prevented, and the deflection of the top sheet 2 caused by the stretching of the snake abdomen 210 is effectively prevented.

壓縮溝5a及5b，藉由例如使用加熱輥的壓紋 加工，使***物被供給領域20之第1領域20a及第2領域20b的周緣部及吸收體4進行壓縮後一體化而形成。 Compression grooves 5a and 5b, for example, embossing using a heating roller The processing is performed by compressing and integrating the first portion 20a of the supply region 20 and the peripheral portion of the second region 20b and the absorber 4.

如圖1及圖2所示般，壓縮溝5a及5b各自 形成於液體被供給領域20a的第1領域20a及第2領域20b的周緣部全體。亦可對本實施形態加以變更，使壓縮溝5a及5b各自形成於液體被供給領域20a的第1領域20a及第2領域20b的周緣部的一部份。 As shown in Figures 1 and 2, each of the compression grooves 5a and 5b The entire peripheral portion of the first region 20a and the second region 20b of the liquid supply region 20a is formed. The present embodiment can be modified such that the compression grooves 5a and 5b are formed in a part of the peripheral portion of the first region 20a and the second region 20b of the liquid supply region 20a.

吸收體4，藉由壓縮溝5a，5b，分為位於排 泄物被供給領域20之第1領域20a之背部薄片3側的吸收體4a與位於***物被供給領域20之第2領域20b之背部薄片3側的吸收體4b。因吸收體4a而***物被供給領域20之厚度先得到，因壓縮溝5a，5b可誘導安定的***物被供給領域20之凸狀變形，故對使用者的***物被供給領域20之貼合性提高。吸收體4b比吸收體4a高密度化，即使***物吸收後仍易維持剛性，故防止***物吸收後之生理用衛生棉1全體的錯位。 The absorber 4 is divided into rows by the compression grooves 5a, 5b The absorber 4a on the back sheet 3 side of the first field 20a of the waste supply area 20 and the absorber 4b on the back sheet 3 side of the second field 20b of the excrement supply area 20 are provided. Due to the absorbent body 4a, the excrement is first obtained by the thickness of the supply field 20, and since the compression grooves 5a, 5b can induce the stable excrement to be convexly deformed by the supply field 20, the excrement to the user is supplied to the field 20 Improved compatibility. The absorber 4b is higher in density than the absorber 4a, and it is easy to maintain rigidity even after the excrement is absorbed, so that the dislocation of the entire sanitary napkin 1 after the excrement is absorbed is prevented.

生理用衛生棉1在扭轉變形時發揮以下的作 用效果。 The sanitary napkin 1 plays the following role in torsional deformation Use the effect.

圖4所示般，生理用衛生棉1扭轉變形時，可以比低剛性領域21剛性高的高剛性領域22的領域A1-m或領域B1-n為起點規則的扭轉變形。又，即使扭轉方向變化之場合(例如坐在椅子的著用者改變重疊的腳之場合，著用者步行時等)，可以高剛性領域22的領域A1-m或領域B1-n為起點規則的扭轉變形。進而，藉由高剛性領域22的彈性復原力，扭轉變形的生理用衛生棉1易復原成原本形狀。 As shown in Fig. 4, when the sanitary napkin 1 is torsionally deformed, the field A 1-m or the field B 1-n of the high rigidity region 22 which is higher in rigidity than the low rigidity region 21 can be used as a starting point to be subjected to the torsional deformation. Further, even in the case where the twisting direction changes (for example, when the wearer of the chair changes the overlapping feet, when the user walks, etc.), the field A 1-m or the field B 1-n of the high rigidity field 22 can be The torsional deformation of the starting point rule. Further, the physiological sanitary napkin 1 which is torsionally deformed by the elastic restoring force of the high rigidity region 22 is easily restored to its original shape.

生理用衛生棉1挾持在使用者的內股，在頂 部薄片2的***物被供給領域20被折曲，向***物被供給領域20側進行凸狀變形時，發揮以下的作用效果。 Physiological cotton 1 is held in the user's inner stock, at the top When the excrement of the partial sheet 2 is bent by the supply region 20 and is convexly deformed toward the excrement supply region 20 side, the following effects are exhibited.

圖5所示般，生理用衛生棉1之凸狀變形時，因蛇腹部210伸展，吸收體4變得不易受液體被供給領域20的擠壓，防止生理用衛生棉1之變形造成的吸收體4的過度 壓縮及伴隨其之回滲。又，生理用衛生棉1邊改變折曲角度邊變形場合(例如生理用衛生棉1之著用者因改變姿勢，生理用衛生棉1之折曲角度成為銳角、或鈍角之場合)，藉由高剛性領域22的彈性復原力，頂部薄片2易配合生理用衛生棉1之變形，因此防止蛇腹部210之伸展造成的頂部薄片2的撓曲。 As shown in Fig. 5, when the sanitary napkin 1 is convexly deformed, the absorbent body 4 is less likely to be squeezed by the liquid supply region 20 due to the expansion of the snake abdomen 210, and the absorption by the deformation of the sanitary napkin 1 is prevented. Excessive body 4 Compression and accompanying it back. In addition, when the sanitary napkin 1 is deformed while changing the bending angle (for example, when the user of the sanitary napkin 1 changes his or her posture, the bending angle of the sanitary napkin 1 becomes an acute angle or an obtuse angle), The elastic restoring force of the high rigidity region 22, the top sheet 2 is easily adapted to the deformation of the sanitary napkin 1, thereby preventing the deflection of the top sheet 2 caused by the stretching of the snake belly 210.

<第2實施形態> <Second embodiment>

在第2實施形態，於生理用衛生棉1之頂部薄片2的表面，塗佈血液改質劑。頂部薄片2所排出的經血，其黏度及表面張力因血液改質劑而下降，故由頂部薄片2快速移動至吸收體4、被吸收體4吸收。藉由吸收體4的經血吸收速度的提升，頂部薄片2變得不易殘留黏度高的經血，故頂部薄片2的黏膩感降低，頂部薄片2的表面乾爽性提升，同時著用者變得不易在視覺上感到不快。進而，防止頂部薄片2所排出的經血從生理用衛生棉1之寬度方向側滲漏出。 In the second embodiment, a blood modifying agent is applied to the surface of the top sheet 2 of the sanitary napkin 1 . The menstrual blood discharged from the top sheet 2 has a viscosity and a surface tension which are lowered by the blood modifying agent, so that the top sheet 2 is quickly moved to the absorbent body 4 and absorbed by the absorbent body 4. By the increase in the menstrual blood absorption rate of the absorbent body 4, the top sheet 2 becomes less likely to retain menstrual blood having a high viscosity, so that the sticky feeling of the top sheet 2 is lowered, the surface dryness of the top sheet 2 is improved, and the user becomes difficult I feel uncomfortable visually. Further, the menstrual blood discharged from the top sheet 2 is prevented from leaking from the width direction side of the sanitary napkin 1.

塗佈血液改質劑的領域雖可為頂部薄片2的 表面全體或一部份，但以至少包含接觸使用者的***口(***口)之領域為佳。血液改質劑以不阻塞頂部薄片2的液體透過孔之方式，使血液改質劑以液滴狀或粒子狀附著於頂部薄片2為佳。 The field of coating the blood modifying agent can be the top sheet 2 The entire surface or a part of the surface is preferably in the field of at least the excretory opening (vaginal opening) contacting the user. The blood modifying agent preferably adheres the blood modifying agent to the top sheet 2 in the form of droplets or particles so as not to block the liquid permeating holes of the top sheet 2.

塗佈於頂部薄片2的血液改質劑之基重，較佳為1~30g/m2、又更佳為3~10g/m2。血液改質劑之塗 佈基重比1g/m2小，則有難以使血液改質劑安定塗佈在頂部薄片2之場合，血液改質劑之塗佈基重比30g/m2大，則有頂部薄片2滑溜的場合。 The basis weight of the blood modifying agent applied to the top sheet 2 is preferably from 1 to 30 g/m 2 and more preferably from 3 to 10 g/m 2 . When the coating weight of the blood modifying agent is less than 1 g/m 2 , it is difficult to stably apply the blood modifying agent to the top sheet 2, and the coating weight of the blood modifying agent is larger than 30 g/m 2 . Then there is a case where the top sheet 2 is slippery.

血液改質劑之塗佈方法，可舉例如加熱至期 望溫度後，使用狹縫式塗佈器等之接觸式塗佈器、噴霧器塗佈器、淋幕塗佈器、螺旋塗佈器等之非接觸式塗佈器進行塗佈的方法。由在頂部薄片2，液滴狀的血液改質劑可均勻分散觀點、對頂部薄片2不造成損傷觀點等，以使用非接觸式塗佈器塗佈之方法為佳。 The coating method of the blood modifying agent can be, for example, heated to a period After the temperature is desired, a method of coating is carried out using a contact coater such as a slit coater, a spray applicator, a curtain coater, or a spiral coater. It is preferable to use a non-contact coater coating method from the viewpoint that the top sheet 2, the droplet-shaped blood modifying agent can be uniformly dispersed, and the top sheet 2 is not damaged.

塗佈血液改質劑在頂部薄片2的時點不特別 限制，但由減少設備投資等觀點，以在生理用衛生棉1之製造步驟塗佈血液改質劑於頂部薄片2為佳。在生理用衛生棉1之製造步驟將血液改質劑塗佈於頂部薄片2之場合，由抑制血液改質劑之減少等觀點，以在接近最終步驟的步驟，塗佈血液改質劑於頂部薄片2為佳。例如亦可在即將進行生理用衛生棉1之包裝步驟前，將血液改質劑塗佈於頂部薄片2。 Coating the blood modifying agent at the time of the top sheet 2 is not special However, it is preferable to apply a blood modifying agent to the top sheet 2 in the manufacturing step of the sanitary napkin 1 from the viewpoint of reducing equipment investment and the like. When the blood modifying agent is applied to the top sheet 2 in the manufacturing step of the sanitary napkin 1, the blood modifying agent is applied to the top in the step of approaching the final step from the viewpoint of suppressing the reduction of the blood modifying agent. Sheet 2 is preferred. For example, a blood modifying agent may be applied to the top sheet 2 immediately before the packaging step of the sanitary napkin 1 is performed.

頂部薄片2中，可使塗佈有血液改質劑的領 域以親水劑、撥水劑等塗佈，或經電暈處理、電漿處理等賦予親水性。藉此，血液改質劑為親油性的場合，在血液改質劑塗佈領域，親水性處與親油性處變得零星共存，經血之親水性成分(主為血漿)及親油性成分(主為血球)之兩者快速由頂部薄片2移動至吸收體4。 In the top sheet 2, the collar coated with the blood modifying agent can be coated The domain is coated with a hydrophilic agent, a water repellent, or the like, or imparted hydrophilicity by corona treatment, plasma treatment, or the like. Therefore, when the blood modifying agent is lipophilic, in the field of blood modifying agent application, the hydrophilic portion and the lipophilic portion become sporadically coexist, and the hydrophilic component (mainly plasma) and lipophilic component of the menstrual blood (main Both of the blood cells are quickly moved from the top sheet 2 to the absorber 4.

又，對血液改質劑另外進行詳細說明。 Further, the blood modifying agent will be described in detail.

<吸收性物品的製造方法> <Method of Manufacturing Absorbent Article>

以下，以生理用衛生棉的製造方法為例，說明吸收性物品的製造方法的實施形態。 Hereinafter, an embodiment of a method for producing an absorbent article will be described by taking a method for producing a sanitary napkin as an example.

本實施形態之製造方法，包含形成吸收體4的步驟(步驟1A)、在吸收體4層合頂部薄片2的步驟(步驟2A)、於層合體形成壓縮溝的步驟(步驟3A)、層合背部薄片3的步驟(步驟4A)、切出生理用衛生棉1的步驟(步驟5A)、在生理用衛生棉1塗佈血液改質劑的步驟(步驟6A)，且使用圖6所示之製造裝置100。 The manufacturing method of the present embodiment includes a step of forming the absorber 4 (step 1A), a step of laminating the top sheet 2 in the absorber 4 (step 2A), a step of forming a compression groove in the laminate (step 3A), and lamination. a step of the back sheet 3 (step 4A), a step of cutting out the sanitary napkin 1 (step 5A), a step of applying the blood modifying agent to the sanitary napkin 1 (step 6A), and using the method shown in FIG. The device 100 is manufactured.

[步驟1A] [Step 1A]

在向機械方向MD旋轉的吸式滾筒120之周面，作為聚集吸收體材料122之模型，在圓周方向以特定間距形成凹部124。吸式滾筒120進行旋轉而凹部124進入材料供給部121，則抽氣部126作用於凹部124，材料供給部121所供給的吸收體材料122真空吸引至凹部124。材料供給部121以包覆吸式滾筒120之方式形成，材料供給部121，使吸收體材料122藉由空氣運送而供給至凹部124，在凹部124形成吸收體4。凹部124所形成的吸收體4被轉印在沿機械方向MD前進的載體薄片110上。 On the circumferential surface of the suction drum 120 that rotates in the machine direction MD, as a model of the aggregated absorber material 122, the concave portion 124 is formed at a specific pitch in the circumferential direction. When the suction drum 120 rotates and the concave portion 124 enters the material supply portion 121, the suction portion 126 acts on the concave portion 124, and the absorbent material 122 supplied from the material supply portion 121 is vacuum-attracted to the concave portion 124. The material supply unit 121 is formed to cover the suction drum 120. The material supply unit 121 supplies the absorber material 122 to the concave portion 124 by air transportation, and forms the absorber 4 in the concave portion 124. The absorber 4 formed by the recess 124 is transferred onto the carrier sheet 110 which advances in the machine direction MD.

[步驟2A] [Step 2A]

頂部薄片2層合在吸收體4，形成層合體262。又， 關於頂部薄片2的製造方法如後述。 The top sheet 2 is laminated to the absorber 4 to form a laminate 262. also, The method of manufacturing the top sheet 2 will be described later.

[步驟3A] [Step 3A]

層合體262藉由通過壓紋加工裝置130之上段輥131與下段輥132之間，在層合體262上形成壓縮溝。在上段輥131之外周表面，設置對應壓縮溝的形狀的凸部(不圖示)。下段輥132為外周表面平滑的平面輥。層合體262通過壓紋加工裝置130之上段輥131與下段輥132之間時，層合體262在厚度方向被壓縮，壓縮溝5a及5b形成於層合體262。壓縮溝5a及5b在頂部薄片2中各自形成於***口接觸領域20a及周圍領域20b的周緣部，藉由壓縮溝5a及5b之形成，***口接觸領域20a及周圍領域20b的周緣部與吸收體4一體化。 The laminate 262 forms a compression groove on the laminate 262 by passing between the upper roller 131 and the lower roller 132 of the embossing device 130. A convex portion (not shown) corresponding to the shape of the compression groove is provided on the outer circumferential surface of the upper roller 131. The lower stage roller 132 is a flat roll having a smooth outer peripheral surface. When the laminate 262 passes between the upper roller 131 and the lower roller 132 of the embossing processing device 130, the laminate 262 is compressed in the thickness direction, and the compression grooves 5a and 5b are formed in the laminate 262. The compression grooves 5a and 5b are formed in the top sheet 2 at the peripheral portion of the excretory opening contact area 20a and the surrounding area 20b, respectively, and the peripheral portion of the excretory opening contact area 20a and the surrounding area 20b and the absorption are formed by the formation of the compression grooves 5a and 5b. Body 4 is integrated.

[步驟4A] [Step 4A]

使背部薄片輥140所供給的背部薄片3在形成有壓縮溝的層合體134的下側(頂部薄片的相反側)的面，透過接著劑層層合，形成生理用衛生棉1之連續體144。 The back sheet 3 supplied from the back sheet roll 140 is laminated on the lower side of the laminate 134 on which the compression groove is formed (opposite side of the top sheet) through the adhesive layer to form a continuous body 144 of the sanitary napkin 1 .

[步驟5A] [Step 5A]

使用裁切器150，將生理用衛生棉1之連續體144切斷，切出生理用衛生棉1。 The sterilized body 144 of the sanitary napkin 1 is cut by the cutter 150, and the sanitary napkin 1 is cut out.

[步驟6A] [Step 6A]

使用血液改質劑塗佈噴霧器160，在生理用衛生棉1之中央領域塗佈血液改質劑161，於頂部薄片2的表面，形成血液改質劑層。 The sprayer 160 is applied with a blood modifying agent, and the blood modifying agent 161 is applied to the central region of the sanitary napkin 1 to form a blood modifying agent layer on the surface of the top sheet 2.

血液改質劑層以形成在頂部薄片2的***口接觸領域20a中、至少***口接觸領域20a為佳。 The blood modifying agent layer is preferably formed in the excretory opening contact area 20a of the top sheet 2, at least the excretory opening contact area 20a.

在本實施形態，切出生理用衛生棉1後，塗佈血液改質劑，但可在切出前之任一階段塗佈、或在後述頂部薄片2的製造步驟塗佈。為了防止在製造途中塗佈的血液改質劑流下，在製造步驟之下游的階段、例如以接近包裝生理用衛生棉1前塗佈血液改質劑為佳。 In the present embodiment, after the sanitary napkin 1 is cut out, the blood modifying agent is applied, but it can be applied at any stage before the cutting or in the manufacturing step of the top sheet 2 to be described later. In order to prevent the flow of the blood modifying agent applied during the manufacturing process, it is preferred to apply the blood modifying agent at a stage downstream of the manufacturing step, for example, before the packaging sanitary napkin 1 is approached.

生理用衛生棉1之製造方法除步驟1A~6A外，包含形成密封部7a，7b，8a及8b之步驟、形成黏著部9a，9b及9c之步驟等。 The manufacturing method of the sanitary napkin 1 includes the steps of forming the sealing portions 7a, 7b, 8a, and 8b, the steps of forming the adhesive portions 9a, 9b, and 9c, in addition to the steps 1A to 6A.

<液體透過性薄片的製造方法> <Method for Producing Liquid Permeable Sheet>

以下，以生理用衛生棉1之頂部薄片2的製造方法為例，說明本發明之液體透過性薄片的製造方法的實施形態。 Hereinafter, an embodiment of the method for producing the liquid permeable sheet of the present invention will be described by taking a method of producing the top sheet 2 of the sanitary napkin 1 as an example.

本實施形態之製造方法包含於合成樹脂薄膜薄片形成凹部的步驟(1B)與將合成樹脂薄膜薄片進行齒延伸的步驟(2B)。 The manufacturing method of the present embodiment includes a step (1B) of forming a concave portion in the synthetic resin film sheet and a step (2B) of extending the synthetic resin film sheet.

[步驟1B] [Step 1B]

圖6所示般，輥210所供給的合成樹脂薄膜薄片212 ，通過凹部形成輥220，於合成樹脂薄膜薄片212形成凹 部2141(圖8作為參考)。凹部形成輥220係由壓花輥221與具有平滑表面的預熱輥222所構成。 As shown in FIG. 6, the synthetic resin film sheet 212 supplied from the roller 210 is as shown in FIG. Forming a roll 220 through the recess to form a concave shape on the synthetic resin film sheet 212 Part 2141 (Fig. 8 as a reference). The recess forming roller 220 is composed of an embossing roller 221 and a preheating roller 222 having a smooth surface.

圖7(a)及(b)為壓花輥221之一例的圖。圖 7(a)為壓花輥221之全體的圖，圖7(b)為擴大壓花輥221之外周表面的具有凹凸的部分223的圖。圖7(c)為具有平滑表面的預熱輥222的一例的圖。在壓花輥221之表面223，設置有格子狀的凸部224。藉此，於壓花輥221之表面形成有菱形之凹部225。又，壓花輥221之凹部225之形狀不限於菱形，可為正方形、長方形、平行四邊形、梯形、三角形、六角形等之形狀。 7(a) and 7(b) are views showing an example of the embossing roll 221. Figure 7(a) is a view showing the entirety of the embossing roll 221, and FIG. 7(b) is a view showing the enlarged portion 223 of the outer peripheral surface of the emboss roll 221. Fig. 7 (c) is a view showing an example of the preheating roller 222 having a smooth surface. On the surface 223 of the embossing roll 221, a lattice-like convex portion 224 is provided. Thereby, a rhombic recess 225 is formed on the surface of the embossing roll 221 . Further, the shape of the concave portion 225 of the embossing roll 221 is not limited to a rhombic shape, and may be a square, a rectangle, a parallelogram, a trapezoid, a triangle, a hexagon, or the like.

格子狀的凸部224中，平行排列的凸部224 的中心線間隔，亦即格子狀的凸部224的間距，較佳通常為0.2~10mm、又更佳為0.4~2mm。格子狀的凸部224的寬，較佳為0.01~1mm、又更佳為0.03~0.1mm。菱形之凹部225的一邊之長度，較佳為0.1~5mm、又更佳為0.2~1mm。此等之範圍在合成樹脂薄膜薄片之凹部的形成性提升觀點上為佳。 Among the lattice-like convex portions 224, the convex portions 224 arranged in parallel The center line spacing, that is, the pitch of the lattice-like convex portions 224, is preferably 0.2 to 10 mm, more preferably 0.4 to 2 mm. The width of the lattice-like convex portion 224 is preferably 0.01 to 1 mm, and more preferably 0.03 to 0.1 mm. The length of one side of the rhombic recess 225 is preferably 0.1 to 5 mm, and more preferably 0.2 to 1 mm. The range of these is preferably from the viewpoint of improving the formability of the concave portion of the synthetic resin film sheet.

具有平滑表面的預熱輥222，維持70℃~100 ℃之溫度，加熱被供給的合成樹脂薄膜薄片212。藉此，合成樹脂薄膜薄片212變得柔軟、容易成形。 Preheating roller 222 with smooth surface, maintaining 70 ° C ~ 100 At a temperature of °C, the supplied synthetic resin film sheet 212 is heated. Thereby, the synthetic resin film sheet 212 becomes soft and can be easily formed.

合成樹脂薄膜薄片212通過輥221及222間 時，合成樹脂薄膜薄片212中，與格子狀的凸部224相接部分，厚度方向受到強的壓力。藉此，如圖8所示般，在 合成樹脂薄膜薄片214形成細的凹部2141。又，實際上合成樹脂薄膜薄片212上形成的凹部2141比圖8所示小、單位面積的凹部2141之數比圖8所示多。凹部2141在合成樹脂薄膜薄片214中，對應生理用衛生棉1之中央領域的領域2143上形成。又，合成樹脂薄膜薄片214中，對應生理用衛生棉1的領域為以符號2142的虛線表示的領域。 Synthetic resin film sheet 212 passes between rolls 221 and 222 In the synthetic resin film sheet 212, a portion in contact with the lattice-like convex portion 224 receives a strong pressure in the thickness direction. Thereby, as shown in Figure 8, The synthetic resin film sheet 214 is formed into a thin recess 2141. Further, in actuality, the number of recesses 2141 formed in the synthetic resin film sheet 212 is smaller than that shown in Fig. 8, and the number of recesses 2141 per unit area is larger than that shown in Fig. 8. The concave portion 2141 is formed in the synthetic resin film sheet 214 corresponding to the field 2143 of the central region of the sanitary napkin 1. Further, in the synthetic resin film sheet 214, the field corresponding to the sanitary napkin 1 is a field indicated by a broken line of the symbol 2142.

[步驟2B] [Step 2B]

藉由使形成有凹部的合成樹脂薄膜薄片214通過延伸齒輥230，合成樹脂薄膜薄片214中對應頂部薄片2的低剛性領域21的領域被折曲，製作形成有蛇腹部210的合成樹脂薄膜薄片216。合成樹脂薄膜薄片216中，蛇腹部210在機械方向(MD)延伸設置、在寬度方向並列設置，且沿寬度方向的斷面的形狀為略U字狀的曲線組合的波浪狀。合成樹脂薄膜薄片216中，在機械方向延伸的蛇腹部210在複數處被中斷。亦即，合成樹脂薄膜薄片216中，蛇腹部210非連續地形成，在非連續部分，合成樹脂薄膜薄片214未被折曲。該非連續部分對應頂部薄片2的高剛性領域22。 By extending the synthetic resin film sheet 214 having the concave portion through the extending tooth roll 230, the field of the low rigidity region 21 of the synthetic resin film sheet 214 corresponding to the top sheet 2 is bent, and a synthetic resin film sheet having the snake belly 210 formed thereon is produced. 216. In the synthetic resin film sheet 216, the bellied abdomen 210 is extended in the machine direction (MD) and arranged in the width direction, and the shape of the cross section in the width direction is a wave shape in which a substantially U-shaped curve is combined. In the synthetic resin film sheet 216, the snake belly 210 extending in the machine direction is interrupted at a plurality of places. That is, in the synthetic resin film sheet 216, the snake belly portion 210 is formed discontinuously, and in the discontinuous portion, the synthetic resin film sheet 214 is not bent. This discontinuous portion corresponds to the high rigidity region 22 of the top sheet 2.

延伸齒輥230，包含上段輥231與下段輥232 。圖9(a)為用以說明延伸齒輥230之上段輥231的圖，圖9(b)為用以說明上段輥231之外周面上配置的齒輪齒233的圖，圖9(c)為圖9(b)的B-B線斷面圖。齒輪齒233在上 段輥231之圓周方向非連續地延伸。亦即，在上段輥231之圓周方向延伸的齒輪齒233在中途複數處被中斷。因該齒輪齒233中途被切斷處234，形成對應頂部薄片2的高剛性領域22之非連續部分。齒輪齒233中途被切斷處234以在相對齒輪齒233延伸方向，傾斜的方向之直線上排列之方式配置。 The extension tooth roller 230 includes an upper roller 231 and a lower roller 232 . Fig. 9(a) is a view for explaining the upper roller 231 of the extension tooth roller 230, and Fig. 9(b) is a view for explaining the gear teeth 233 disposed on the outer circumferential surface of the upper roller 231, and Fig. 9(c) is a view Fig. 9(b) is a cross-sectional view taken along line BB. Gear teeth 233 are on The circumferential direction of the segment roller 231 extends discontinuously. That is, the gear teeth 233 extending in the circumferential direction of the upper roller 231 are interrupted at a plurality of places. Since the gear teeth 233 are cut at the middle 234, a discontinuous portion of the high rigidity region 22 corresponding to the top sheet 2 is formed. The cut-away portion 234 of the gear teeth 233 is disposed so as to be aligned on a straight line in a direction in which the gear teeth 233 extend in the direction in which they are inclined.

齒輪齒233之寬度，例如0.3~0.5mm，相鄰 的齒輪齒233之中心間的距離為例如1.0~1.2mm。 The width of the gear teeth 233, for example, 0.3 to 0.5 mm, adjacent The distance between the centers of the gear teeth 233 is, for example, 1.0 to 1.2 mm.

圖10(a)為用以說明延伸齒輥230之下段輥 232的圖，圖10(b)為用以說明下段輥232的外周面上配置的齒輪齒235的圖，圖10(c)為圖10(b)的C-C線斷面圖。齒輪齒235在下段輥232的圓周方向延伸。下段輥232並無如上段輥231般，途中複數處被中斷。齒輪齒235之寬度，例如與上段輥231之齒輪齒233的寬度相等，相鄰的齒輪齒235之中心間的距離，例如與上段輥231之齒輪齒233之中心間的距離相等。 Figure 10 (a) is used to illustrate the lower roller of the extension tooth roller 230 FIG. 10(b) is a view for explaining the gear teeth 235 disposed on the outer circumferential surface of the lower roller 232, and FIG. 10(c) is a cross-sectional view taken along line C-C of FIG. 10(b). The gear teeth 235 extend in the circumferential direction of the lower roller 232. The lower roller 232 does not have the above-described roller 231, and the plurality of places are interrupted. The width of the gear teeth 235 is equal to, for example, the width of the gear teeth 233 of the upper roller 231, and the distance between the centers of the adjacent gear teeth 235 is, for example, equal to the distance between the centers of the gear teeth 233 of the upper roller 231.

上段輥231之齒輪齒233與下段輥232的齒 輪齒235咬合的部分之上段輥231之徑方向之長度，亦即咬合深度為例如1.25mm。上段輥231之齒輪齒233與下段輥232的齒輪齒235咬合時的上段輥231之齒輪齒233與下段輥232的齒輪齒235間的間隙為例如0.25~0.45mm。 Gear teeth 233 of the upper roller 231 and teeth of the lower roller 232 The length of the portion of the upper roller 231 that the teeth 235 engages in the radial direction, that is, the nip depth is, for example, 1.25 mm. The gap between the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 when the gear teeth 233 of the upper roller 231 are engaged with the gear teeth 235 of the lower roller 232 is, for example, 0.25 to 0.45 mm.

合成樹脂薄膜薄片214通過延伸齒輥230時 ，在合成樹脂薄膜薄片214的形成有凹部2141的領域 2143(圖8作為參考)，形成對應頂部薄片2的液體透過孔26(圖3作為參考)的開口部。 When the synthetic resin film sheet 214 is extended by the tooth roll 230 In the field in which the concave portion 2141 is formed in the synthetic resin film sheet 214 2143 (Fig. 8 for reference), an opening portion corresponding to the liquid permeation hole 26 (see Fig. 3 as a reference) of the top sheet 2 is formed.

參考圖11，說明使合成樹脂薄膜薄片214通 過延伸齒輥230時，於合成樹脂薄膜薄片214形成開口部的原理。又，該原理不限定本發明。 Referring to Fig. 11, the synthetic resin film sheet 214 is passed through. When the tooth roll 230 is extended, the principle of forming an opening in the synthetic resin film sheet 214 is obtained. Moreover, the principle does not limit the invention.

合成樹脂薄膜薄片214以上段輥231之齒輪 齒233與下段輥232的齒輪齒235咬合的部分236大幅被延伸。在上述凹部形成步驟，形成有凹部2141(圖8作為參考)的部分因係合成樹脂薄膜薄片214變薄、進而因壓花輥221之格子狀的凸部224而受傷的部分，強度弱，合成樹脂薄膜薄片214的凹部2141施以延伸則破裂。因此，在合成樹脂薄膜薄片214的施以延伸部分236，合成樹脂薄膜薄片214的凹部2141破裂、合成樹脂薄膜薄片214的破裂部分擴大、形成開口部。 Synthetic resin film sheet 214 gear of the upper roller 231 The portion 236 where the teeth 233 are engaged with the gear teeth 235 of the lower roller 232 is substantially extended. In the concave portion forming step, the portion where the concave portion 2141 (see FIG. 8 is referred to) is formed, and the synthetic resin film sheet 214 is thinned, and the portion of the embossing roll 221 is damaged by the lattice-like convex portion 224, and the strength is weak, and the synthesis is weak. The concave portion 2141 of the resin film sheet 214 is broken by being extended. Therefore, in the extending portion 236 of the synthetic resin film sheet 214, the concave portion 2141 of the synthetic resin film sheet 214 is broken, and the broken portion of the synthetic resin film sheet 214 is enlarged to form an opening.

合成樹脂薄膜薄片214在上段輥231之齒輪 齒233與下段輥232的齒輪齒235未咬合的部分237，238不太被延伸。因此，在合成樹脂薄膜薄片214中上段輥231之齒輪齒233與下段輥232的齒輪齒235未咬合的部分237，238，即使合成樹脂薄膜薄片214通過延伸齒輥230，在上述凹部形成步驟，形成的凹部2141不破裂、無法成為開口部。 Synthetic resin film sheet 214 in the gear of the upper roller 231 The portions 237, 238 of the teeth 233 and the gear teeth 235 of the lower roller 232 that are not engaged are less extended. Therefore, in the synthetic resin film sheet 214, the gear teeth 233 of the upper roller 231 and the portions 237, 238 where the gear teeth 235 of the lower roller 232 are not engaged, even if the synthetic resin film sheet 214 passes through the extending tooth roller 230, in the above-described concave portion forming step, The formed concave portion 2141 does not break and cannot be an opening portion.

在合成樹脂薄膜薄片214的未形成凹部2141 的領域，因上段輥231之齒輪齒233與下段輥232的齒輪齒235咬合的部分236，合成樹脂薄膜薄片214即使被大 幅延伸，合成樹脂薄膜薄片214不破裂，故不形成開口部。 The recess 2141 is not formed in the synthetic resin film sheet 214 The area of the synthetic resin film sheet 214 is large even if the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 are engaged with each other. Since the web is stretched, the synthetic resin film sheet 214 is not broken, so that no opening portion is formed.

<血液改質劑> <blood modifier>

本發明之血液改質劑為具有約0.00~約0.60之IOB、約45℃以下之熔點、對25℃之水100g為約0.00~約0.05g之水溶解度的血液改質劑。 The blood modifying agent of the present invention is a blood modifying agent having a water solubility of about 0.00 to about 0.60 IOB, a melting point of about 45 ° C or less, and a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C.

IOB(Inorganic Organic Balance)為表示親水性及親油性的平衡之指標，在本說明書，係指以小田氏們之下式：IOB=無機性值/有機性值所算出之值。又，無機性值及有機性值為基於藤田穆「有機化合物的預測與有機概念圖」化學領域Vol.11，No.10(1957)p.719-725)記載的有機概念圖。 IOB (Inorganic Organic Balance) is an index indicating the balance between hydrophilicity and lipophilicity, and in the present specification, the value calculated by the formula: IOB = inorganic value / organic value. In addition, the inorganic value and the organic value are organic concept maps based on Fujita Mu's "Estimation of Organic Compounds and Organic Concepts", Vol. 11, No. 10 (1957) p. 719-725.

藤田氏之主要基的有機性值及無機性值如下述表1。 The organic value and inorganic value of the main base of Fujita are as shown in Table 1 below.

例如在碳數14的十四烷酸與碳數12的十二 醇的酯之場合，因有機性值成為520(CH2，20×26個)、無機性值成為60(-COOR，60×1個)，故IOB=0.12。 For example, in the case of an ester of a tetradecanoic acid having a carbon number of 14 and a dodecyl alcohol having a carbon number of 12, the organic value is 520 (CH 2 , 20 × 26), and the inorganic value is 60 (-COOR, 60 ×). 1), so IOB=0.12.

本發明之血液改質劑中，IOB雖為約0.00~ 約0.60，但以約0.00~約0.50為佳、約0.00~約0.40又更佳、約0~約0.30特別佳。因認為IOB愈低，有機性高、與血球之親和性增高。 In the blood modifying agent of the present invention, although the IOB is about 0.00~ It is about 0.60, preferably about 0.00 to about 0.50, more preferably from about 0.00 to about 0.40, still more preferably from about 0 to about 0.30. Because of the lower IOB, the organicity is high and the affinity with blood cells is increased.

本說明書中，「熔點」係指示差掃瞄熱量分 析計中，以昇溫速度10℃/分鐘測定場合的由固形狀變為液狀時之吸熱峰的峰頂溫度。熔點，可使用例如島津製作所製之DSC-60型DSC測定裝置測定。 In this specification, the "melting point" indicates the differential scanning heat score. In the analysis, the peak top temperature of the endothermic peak when the solid shape was changed to a liquid state at the temperature increase rate of 10 ° C /min was measured. The melting point can be measured, for example, using a DSC-60 DSC measuring apparatus manufactured by Shimadzu Corporation.

本發明之血液改質劑，若具有約45℃以下之 熔點，在室溫可為液體或固體，亦即，熔點可在約25℃以上、或未達約25℃，而例如可具有約-5℃、約-20℃等之熔點。本發明之血液改質劑之熔點在約45℃以下的根 據如後述。 The blood modifying agent of the present invention has a temperature of about 45 ° C or less The melting point may be a liquid or a solid at room temperature, that is, the melting point may be above about 25 ° C, or less than about 25 ° C, and for example may have a melting point of about -5 ° C, about -20 ° C, or the like. The blood modifying agent of the present invention has a melting point of less than about 45 ° C As will be described later.

本發明之血液改質劑，其熔點雖不存在有下 限，但以其蒸氣壓低者為佳。本發明之血液改質劑之蒸氣壓在25℃(1大氣壓)以約0~約200Pa為佳、約0~約100Pa又更佳、約0~約10Pa再更佳、約0~約1Pa再更佳、約0.0~約0.1Pa特別佳。吸收性物品考量與人體接觸使用，蒸氣壓在40℃(1大氣壓)以約0~約700Pa為佳、約0~約100Pa又更佳、約0~約10Pa再更佳、約0~約1Pa再更佳、約0.0~約0.1Pa特別佳。蒸氣壓高則有產生保存中氣化、血液改質劑之量減少、著用時的臭氣等之問題之場合。 The blood modifying agent of the invention has a melting point which does not exist under Limited, but it is better for its low vapor pressure. The blood pressure modifier of the present invention has a vapor pressure of preferably from about 0 to about 200 Pa at 25 ° C (1 atm), more preferably from about 0 to about 100 Pa, more preferably from about 0 to about 10 Pa, still more preferably from about 0 to about 1 Pa. More preferably, about 0.0 to about 0.1 Pa is particularly preferred. The absorbent article is used in contact with the human body. The vapor pressure is preferably from about 0 to about 700 Pa at 40 ° C (1 atm), more preferably from about 0 to about 100 Pa, more preferably from about 0 to about 10 Pa, and even more preferably from about 0 to about 1 Pa. More preferably, it is particularly good from about 0.0 to about 0.1 Pa. When the vapor pressure is high, there is a problem that gasification during storage, reduction of the amount of the blood modifying agent, and odor during use are caused.

本發明之血液改質劑之熔點可因應氣候、著 用時間的長度等而有不同。例如在平均氣溫約10℃以下的地區，認為藉由採用具有約10℃以下之熔點的血液改質劑，經血***後，即使在因周圍溫度而冷卻的場合，血液改質劑可安定使血液改質。 The melting point of the blood modifying agent of the invention can be adapted to the climate, It varies with the length of time, etc. For example, in an area where the average temperature is about 10 ° C or less, it is considered that by using a blood modifying agent having a melting point of about 10 ° C or less, the blood modifying agent can stabilize the blood even after being cooled by the ambient temperature after excretion by blood. Upgraded.

吸收性物品被長時間使用場合，本發明之血 液改質劑之熔點在45℃以下的範圍以高者為佳。因不易受汗、著用時的摩擦等之影響，即使長時間著用的場合，血液改質劑不易移動。 When the absorbent article is used for a long time, the blood of the present invention The melting point of the liquid modifier is preferably in the range of 45 ° C or less. The blood modifying agent does not easily move even when it is used for a long period of time due to the influence of sweating and friction during use.

0.00~0.05g之水溶解度係25℃中，於100g之 去離子水中添加0.05g之試料後靜置24小時，24小時後因應必要輕輕攪拌，可藉由目視評估試料溶解與否來測量。 The water solubility of 0.00~0.05g is 25°C, at 100g After adding 0.05 g of the sample in deionized water, it was allowed to stand for 24 hours, and after 24 hours, it was gently stirred as necessary, and it was measured by visually evaluating whether the sample was dissolved or not.

又，在本說明書，關於水溶解度，「溶解」 包含試料完全溶解於去離子水，形成均勻混合物的場合、與試料完全乳化之場合。又，「完全」係指去離子水中無試料之團塊。 In addition, in this specification, regarding water solubility, "dissolution" The case where the sample is completely dissolved in deionized water to form a homogeneous mixture, and the sample is completely emulsified. Also, "completely" means a mass that has no sample in deionized water.

在該技術領域，以使血液的表面張力等改變 、使血液迅速吸收為目的，進行頂部薄片的表面以界面活性劑之塗佈。但是，因界面活性劑一般水溶解度高，塗佈有界面活性劑之頂部薄片與血液中之親水性成分(血漿等)相溶性佳，有使血液殘留頂部薄片作用的傾向。認為本發明之血液改質劑因水溶解度低，與以往習知界面活性劑不同，血液不殘留在頂部薄片，可迅速移動至吸收體。 In this technical field, to change the surface tension of blood, etc. For the purpose of rapidly absorbing blood, the surface of the top sheet is coated with a surfactant. However, since the surfactant generally has high water solubility, the top sheet coated with the surfactant tends to have good compatibility with hydrophilic components (plasma, etc.) in the blood, and tends to cause the blood to remain in the top sheet. It is considered that the blood modifying agent of the present invention has a low water solubility, and unlike conventional surfactants, blood does not remain in the top sheet and can be quickly moved to the absorber.

本說明書中，25℃中，對100g之水的溶解度 有單稱「水溶解度」之情形。 In this specification, the solubility in water of 100g at 25 ° C There is a single case of "water solubility".

本說明書中，「重量平均分子量」係包含由 多分散系之化合物(例如逐次聚合所製造的化合物、複數的脂肪酸與複數的脂肪族1元醇所生成的酯)與單一化合物(例如由1種的脂肪酸與1種的脂肪族1元醇所生成的酯)之概念，係指Ni個分子量Mi之分子(i=1、或i=1，2．．．)所構成的系中，以下式： Mw=ΣNiMi 2/ΣNiMi 所求得的Mw。 In the present specification, the "weight average molecular weight" includes a compound derived from a polydisperse system (for example, a compound produced by sequential polymerization, an ester of a plurality of fatty acids and a plurality of aliphatic monohydric alcohols) and a single compound (for example, one type) concept fatty acids with one kind of aliphatic monohydric alcohol esters generated), the mean molecular weight molecules N i of M i (i = 1, or i = 1,2 ...) composed of lines, The following formula: M w = Σ N i M i 2 / Σ N i M i obtained M w .

本說明書中，重量平均分子量意指經膠體滲 透層析(GPC)求得的聚苯乙烯換算之值。 In this specification, the weight average molecular weight means the colloidal seepage The value of polystyrene conversion obtained by transmission chromatography (GPC).

GPC之測定條件，可舉例如下。 The measurement conditions of GPC can be exemplified as follows.

機種：Hitachi High-Technologies製高速液體層析圖Lachrom Elite Model: High-speed liquid chromatogram by Hitachi High-Technologies Lachrom Elite

管柱：昭和電工(股)製SHODEX KF-801、KF-803及KF-804 Pipe column: SHODEX KF-801, KF-803 and KF-804 made by Showa Denko Electric Co., Ltd.

溶離液：THF Dissolution: THF

流量：1.0mL/分鐘 Flow rate: 1.0mL/min

注入量：100μL Injection volume: 100 μ L

檢測：RI(示差折射計) Detection: RI (differential refractometer)

又，本說明書的實施例記載的重量平均分子量為以上述條件測定者。 Moreover, the weight average molecular weight described in the examples of the present specification is measured under the above conditions.

本發明之血液改質劑，較佳為由下述(i)~(iii)、(i)烴、(ii)具有(ii-1)烴部分、與(ii-2)上述烴部分的C-C單鍵間***的由羰基(-CO-)及氧基(-O-)所成群中所選出的一個或複數個相同或相異的基的化合物、及(iii)具有(iii-1)烴部分、與(iii-2)上述烴部分的C-C單鍵間***的由羰基(-CO-)及氧基(-O-)所成群中所選出的一個或複數個相同或相異的基、與(iii-3)取代上述烴部分的氫原子的由羧基(-COOH)及羥基(-OH)所成群中所選出的一個或複數個相同或相異的基之化合物、 以及彼等之任意組合所成群中所選出。 The blood modifying agent of the present invention preferably has the following (i) to (iii), (i) hydrocarbons, (ii) a hydrocarbon having (ii-1) a hydrocarbon moiety, and (ii-2) the above hydrocarbon moiety. a compound of one or a plurality of identical or different groups selected from a group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted between a single bond, and (iii) having (iii-1) a hydrocarbon moiety, one or a plurality of the same or different selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted between the CC single bond of the above hydrocarbon moiety (iii-2) a compound of one or more of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) in place of the hydrogen atom of the above hydrocarbon moiety, and (iii-3) And selected from any group of them.

本說明書中，「烴」為碳與氫所構成的化合 物，鏈狀烴，可舉例如液態石蠟系烴(亦稱不含雙鍵及三鍵的烷烴)、烯烴系烴(亦稱含1個雙鍵之烯類)、乙炔系烴(亦稱含1個三鍵之炔)、及含2個以上雙鍵及三鍵所成之群所選出的鍵結之烴、以及環狀烴，可舉例如芳香族烴、脂環式烴。 In this specification, "hydrocarbon" is a combination of carbon and hydrogen. Examples of the chain hydrocarbons include liquid paraffinic hydrocarbons (also known as alkanes containing no double bonds and triple bonds), olefinic hydrocarbons (also known as olefins containing one double bond), and acetylene hydrocarbons (also known as Examples of the hydrocarbon selected from the group consisting of one or more double bonds and three bonds, and the cyclic hydrocarbon may, for example, be an aromatic hydrocarbon or an alicyclic hydrocarbon.

上述烴，以鏈狀烴及脂環式烴為佳、鏈狀烴 更佳、液態石蠟系烴、烯烴系烴、及含2個以上雙鍵之烴(不含三鍵)又更佳、而液態石蠟系烴最佳。 The above hydrocarbons, preferably chain hydrocarbons and alicyclic hydrocarbons, chain hydrocarbons More preferably, liquid paraffinic hydrocarbons, olefinic hydrocarbons, and hydrocarbons having two or more double bonds (excluding triple bonds) are preferred, and liquid paraffinic hydrocarbons are preferred.

上述鏈狀烴中，包含直鏈狀烴及分枝鏈狀烴。 The chain hydrocarbons include linear hydrocarbons and branched chain hydrocarbons.

上述(ii)及(iii)之化合物中，在***2個以上 氧基(-O-)的場合，各氧基(-O-)不相鄰。因此，上述(ii)及(iii)之化合物中，不包含氧基連續的化合物(所謂的過氧化物)。 Among the compounds of (ii) and (iii) above, two or more are inserted. In the case of an oxy group (-O-), each oxy group (-O-) is not adjacent. Therefore, among the compounds of the above (ii) and (iii), a compound having a continuous oxy group (so-called peroxide) is not contained.

又，在上述(iii)的化合物，相較於烴部分的至 少1個氫原子被羧基(-COOH)所取代的化合物，以烴部分的至少1個氫原子被羥基(-OH)所取代的化合物者為佳。 如表1所示般，因羧基與經血中之金屬等鍵結，而無機性值由150大幅上升至400以上，故具有羧基的血液改質劑，使用時IOB之值超過約0.60，有與血球親和性降低之可能性。 Further, in the compound of the above (iii), compared to the hydrocarbon moiety A compound in which one hydrogen atom is substituted by a carboxyl group (-COOH) is preferred, and a compound in which at least one hydrogen atom of a hydrocarbon moiety is substituted with a hydroxyl group (-OH) is preferred. As shown in Table 1, since the carboxyl group is bonded to the metal in the menstrual blood, and the inorganic value is greatly increased from 150 to 400 or more, the blood modifying agent having a carboxyl group has a value of IOB of more than about 0.60 when used. The possibility of a decrease in blood cell affinity.

本發明之血液改質劑，更佳為由下述(i’)~ (iii’)、 (i’)烴、(ii’)具有(ii’-1)烴部分、與(ii’-2)上述烴部分的C-C單鍵間***的由羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結之化合物、及(iii’)具有(iii’-1)烴部分、與(iii’-2)上述烴部分的C-C單鍵間***的由羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結、與(iii’-3)取代上述烴部分的氫原子的由羧基(-COOH)及羥基(-OH)所成群中所選出的一個或複數個相同或相異的基之化合物、以及彼等之任意組合所成群中所選出。 The blood modifying agent of the present invention is more preferably (i')~ (iii’), a (i') hydrocarbon, (ii') having a (ii'-1) hydrocarbon moiety, and a carbonyl bond (-CO-), an ester bond inserted between the CC single bond of (ii'-2) the above hydrocarbon moiety One or a plurality of identical or different bonded compounds selected in the group of (-COO-), carbonate linkage (-OCOO-), and ether linkage (-O-), and (iii') A carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond having a (iii'-1) hydrocarbon moiety and a CC single bond intercalated with (iii'-2) the above hydrocarbon moiety One or a plurality of identical or different linkages selected in the group of (-OCOO-) and ether linkages (-O-), and a carboxyl group substituted with (iii'-3) a hydrogen atom of the above hydrocarbon moiety The compound selected from the group consisting of (-COOH) and hydroxyl (-OH), or a plurality of identical or different groups, and any combination thereof, are selected in the group.

上述(ii’)及(iii’)之化合物中，在***2個以上的相同或相異的鍵結之場合，亦即，在***2個以上選自羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)及醚鍵(-O-)的相同或相異的鍵結之場合，各鍵結不相鄰、在各鍵結間至少有1個碳原子。 In the above compounds (ii') and (iii'), when two or more identical or different linkages are inserted, that is, two or more carbonyl linkages (-CO-) and esters are inserted. Where the bond (-COO-), carbonate bond (-OCOO-), and ether bond (-O-) are the same or different bonds, the bonds are not adjacent, and there is at least a bond between the bonds. 1 carbon atom.

本發明之血液改質劑，又更佳可為烴部分中，每10個碳原子，具有羰基鍵結(-CO-)約1.8個以下、酯鍵結(-COO-)2個以下、碳酸酯鍵結(-OCOO-)約1.5個以下、醚鍵(-O-)約6個以下、羧基(-COOH)約0.8個以下、及/或羥基(-OH)約1.2個以下的化合物。 The blood modifying agent of the present invention may further preferably have a carbonyl bond (-CO-) of about 1.8 or less, an ester bond (-COO-) of 2 or less, and carbonic acid per 10 carbon atoms in the hydrocarbon moiety. The ester bond (-OCOO-) is about 1.5 or less, the ether bond (-O-) is about 6 or less, the carboxyl group (-COOH) is about 0.8 or less, and/or the hydroxyl group (-OH) is about 1.2 or less.

本發明之血液改質劑，又更佳為由下述(A)~(F)、 (A)(A1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(A2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羧基的化合物之酯、(B)(B1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(B2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之醚、(C)(C1)含有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羧基的羧酸、羥基酸、烷氧基酸或側氧酸與(C2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之酯、(D)具有鏈狀烴部分、與上述鏈狀烴部分的C-C單鍵間***的醚鍵(-O-)、羰基鍵結(-CO-)、酯鍵結(-COO-)、及碳酸酯鍵結(-OCOO-)所成群中選出的任一個鍵結之化合物、(E)聚氧化C2~6烷二醇、或其烷基酯或者烷基醚、及(F)鏈狀烴、以及彼等之任意組合所成群中所選出。 Further, the blood modifying agent of the present invention is more preferably 2 to 4 hydroxyl groups having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety by the following (A) to (F) and (A) (A1). And (A) a compound having a chain hydrocarbon moiety and a compound which substitutes one carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety, (B) (B1) having a chain hydrocarbon moiety and a hydrogen replacing the above chain hydrocarbon moiety; a compound having 2 to 4 hydroxyl groups of an atom and (B2) an ether having a chain hydrocarbon moiety and a hydroxyl group substituted for a hydrogen atom of the chain hydrocarbon moiety; (C) (C1) containing a chain hydrocarbon moiety and a substitution a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid having 2 to 4 carboxyl groups of a hydrogen atom of the above-mentioned chain hydrocarbon moiety and (C2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety An ester of a hydroxyl group compound, (D) having a chain hydrocarbon moiety, an ether bond (-O-), a carbonyl bond (-CO-), an ester bond interposed between a CC single bond of the above chain hydrocarbon moiety ( -COO-), and a compound selected from a group of carbonate linkages (-OCOO-), (E) polyoxy C 2-6 alkanediol, or an alkyl ester or alkyl ether thereof And (F) chain hydrocarbons, and Any combination of the selected groups.

以下、詳細說明(A)~(F)之血液改質劑。 Hereinafter, the blood modifying agents of (A) to (F) will be described in detail.

[(A)(A1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(A2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羧基的化合物之酯] [(A) (A1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (A2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety; Ester of a carboxy compound]

(A)(A1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(A2)具有鏈狀烴部分與取 代上述鏈狀烴部分的氫原子的1個羧基的化合物之酯(以下、有亦稱「化合物(A)」之場合)在具有上述之IOB、熔點及水溶解度下，羥基可不全被酯化。 (A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace a hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (A2) having a chain hydrocarbon moiety and An ester of a compound having one carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (A)") may have a hydroxyl group which may not be esterified under the above-mentioned IOB, melting point and water solubility. .

(A1)具有鏈狀烴部分與取代上述鏈狀烴部分的 氫原子的2~4個羥基的化合物(以下、有亦稱「化合物(A1)」之場合)，可舉例如鏈狀烴四醇、例如烷烴四醇、例如季戊四醇、鏈狀烴三醇、例如烷烴三醇、例如甘油、及鏈狀烴二醇、例如烷烴二醇、例如二醇。 (A1) having a chain hydrocarbon moiety and replacing the above chain hydrocarbon moiety A compound having 2 to 4 hydroxyl groups of a hydrogen atom (hereinafter also referred to as "compound (A1)") may, for example, be a chain hydrocarbon tetraol, for example, an alkanetetraol, for example, pentaerythritol or a chain hydrocarbon triol, for example. Alkane triols, such as glycerol, and chain hydrocarbon diols, such as alkane diols, such as diols.

(A2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羧基的化合物(以下、有亦稱「化合物(A2)」之情形)，可舉例如烴上的1個氫原子以1個羧基(-COOH)所取代的化合物、例如脂肪酸。 (A2) A compound having a chain hydrocarbon moiety and one carboxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (A2)"), for example, one hydrogen atom on a hydrocarbon A compound substituted with one carboxy group (-COOH), for example, a fatty acid.

化合物(A)，可舉例如(a1)鏈狀烴四醇與至少1個脂肪酸之酯、(a2)鏈狀烴三醇與至少1個脂肪酸之酯、及(a3)鏈狀烴二醇與至少1個脂肪酸之酯。 The compound (A) may, for example, be an ester of (a 1 ) chain hydrocarbon tetraol with at least one fatty acid, (a 2 ) a chain hydrocarbon triol with at least one fatty acid ester, and (a 3 ) a chain hydrocarbon. An ester of a diol with at least one fatty acid.

[(a1)鏈狀烴四醇與至少1個脂肪酸之酯] [(a 1 ) an ester of a chain hydrocarbon tetraol with at least one fatty acid]

上述鏈狀烴四醇與至少1個脂肪酸之酯，可舉例如下式(1)： 之季戊四醇與脂肪酸之四酯、下式(2)： The ester of the above chain hydrocarbon tetraol and at least one fatty acid can be exemplified by the following formula (1): a tetraester of pentaerythritol and a fatty acid, the following formula (2):

之季戊四醇與脂肪酸之三酯、下式(3)： 之季戊四醇與脂肪酸之二酯、下式(4)： 之季戊四醇與脂肪酸之單酯。(式中、R1~R4各自為鏈狀烴) a pentaerythritol and a fatty acid triester, the following formula (3): Diester of pentaerythritol and fatty acid, the following formula (4): a monoester of pentaerythritol and a fatty acid. (wherein, R 1 to R 4 are each a chain hydrocarbon)

構成上述季戊四醇與脂肪酸之酯的脂肪酸(R1COOH、R2COOH，R3COOH，及R4COOH)，若季戊四醇與脂肪酸之酯滿足上述IOB、熔點及水溶解度的要件，則不特別限制。例如飽和脂肪酸、例如C2~C30之飽和脂肪酸、例如乙酸(C2)(C2表示碳數，相當R1C、R2C，R3C或R4C之碳數，以下相同)、丙烷酸(C3)、丁烷酸(C4)及其 異構物、例如2-甲基丙烷酸(C4)、戊烷酸(C5)及其異構物、例如2-甲基丁烷酸(C5)、2，2-二甲基丙烷酸(C5)、己烷酸(C6)、庚烷酸(C7)、辛烷酸(C8)及其異構物、例如2-乙基己烷酸(C8)、壬烷酸(C9)、癸烷酸(C10)、十二烷酸(C12)、十四烷酸(C14)、十六烷酸(C16)、十七烷酸(C17)、十八烷酸(C18)、二十烷酸(C20)、二十二烷酸(C22)、二十四烷酸(C24)、二十六烷酸(C26)、二十八烷酸(C28)、三十烷酸(C30)等、以及此等之異構物(除上述者外)。 The fatty acid (R 1 COOH, R 2 COOH, R 3 COOH, and R 4 COOH) constituting the ester of pentaerythritol and a fatty acid is not particularly limited as long as the ester of pentaerythritol and a fatty acid satisfies the above requirements of IOB, melting point, and water solubility. For example, a saturated fatty acid, for example, a C 2 - C 30 saturated fatty acid, such as acetic acid (C 2 ) (C 2 represents a carbon number, and is equivalent to a carbon number of R 1 C, R 2 C, R 3 C or R 4 C, the same applies hereinafter) , propane acid (C 3 ), butanoic acid (C 4 ) and isomers thereof, such as 2-methylpropanic acid (C 4 ), pentanoic acid (C 5 ) and isomers thereof, such as 2-A Butyric acid (C 5 ), 2,2-dimethylpropane acid (C 5 ), hexane acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ) and their isomers For example, 2-ethylhexane acid (C 8 ), decanoic acid (C 9 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), myristic acid (C 14 ), ten Hexanoic acid (C 16 ), heptadecanoic acid (C 17 ), octadecanoic acid (C 18 ), eicosanoic acid (C 20 ), behenic acid (C 22 ), tetracosanoic acid (C 24 ), dihexadecanoic acid (C 26 ), octadecanoic acid (C 28 ), tridecanoic acid (C 30 ), and the like, and the isomers thereof (other than the above).

上述脂肪酸可為不飽和脂肪酸。上述不飽和 脂肪酸，可舉例如C3~C20之不飽和脂肪酸、例如單不飽和脂肪酸、例如巴豆酸(C4)、十四碳烯酸(C14)、十六碳烯酸(C16)、油酸(C18)、反式十八碳烯酸(C18)、十八碳烯酸(C18)、二十碳烯酸(C20)、二十烯酸(C20)等，二不飽和脂肪酸、例如亞油酸(C18)、二十碳二烯酸(C20)等，三不飽和脂肪酸、例如亞麻油酸、例如α-亞麻油酸(C18)及γ-亞麻油酸(C18)、松子油酸(C18)、桐油酸、例如α-桐油酸(C18)及β-桐油酸(C18)、米德酸(C20)、二同-γ-亞麻油酸(C20)、二十碳三烯酸(C20)等，四不飽和脂肪酸、例如硬脂四烯酸(C20)、花生烯四酸(C20)、二十碳四烯酸(C20)等，五不飽和脂肪酸、例如波西爾番他安酸(bosseopentaenoic acid)(C18)、二十碳五烯酸(C20)等、以及此等之部分氫加成物。 The above fatty acid may be an unsaturated fatty acid. The above unsaturated fatty acid may, for example, be a C 3 - C 20 unsaturated fatty acid such as a monounsaturated fatty acid such as crotonic acid (C 4 ), tetradecenoic acid (C 14 ) or hexadecenoic acid (C 16). ), oleic acid (C 18 ), trans-octadecenoic acid (C 18 ), octadecenoic acid (C 18 ), eicosenoic acid (C 20 ), eicosenoic acid (C 20 ), etc. a di-unsaturated fatty acid such as linoleic acid (C 18 ), eicosadienoic acid (C 20 ), etc., a triunsaturated fatty acid such as linoleic acid, such as α-linolenic acid (C 18 ) and γ- Linoleic acid (C 18 ), pine nut oleic acid (C 18 ), tung oil, such as α-tricoleic acid (C 18 ) and β-ternic acid (C 18 ), metic acid (C 20 ), di- γ - linoleic acid (C 20 ), eicosatrienoic acid (C 20 ), etc., tetraunsaturated fatty acids, such as stearic acid (C 20 ), arachidonic acid (C 20 ), twenty carbon four Acetate (C 20 ), etc., penta-unsaturated fatty acids, such as bosseopentaenoic acid (C 18 ), eicosapentaenoic acid (C 20 ), etc., and some of these hydrogen additions Things.

作為上述季戊四醇與脂肪酸之酯，若考量因 氧化等而變性的可能性，以來自飽和脂肪酸的季戊四醇與 脂肪酸之酯，亦即，季戊四醇與飽和脂肪酸之酯為佳。 As the ester of the above pentaerythritol and fatty acid, The possibility of denaturation by oxidation, etc., with pentaerythritol from saturated fatty acids The ester of a fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid is preferred.

又，作為上述季戊四醇與脂肪酸之酯，為了使IOB變小、且更為疏水性，以二酯、三酯或四酯為佳、三酯或四酯更佳、而四酯再佳。 Further, as the ester of pentaerythritol and a fatty acid, in order to make IOB smaller and more hydrophobic, a diester, a triester or a tetraester is preferred, a triester or a tetraester is more preferable, and a tetraester is more preferable.

在上述季戊四醇與脂肪酸之四酯，構成季戊 四醇與脂肪酸之四酯的脂肪酸之碳數合計，亦即，上述式(1)中，R1C、R2C、R3C及R4C部分的碳數合計為15之場合，IOB成為0.60。因此，在上述季戊四醇與脂肪酸之四酯，在上述碳數合計為約15以上的場合，IOB滿足約0.00~約0.60之要件。 In the above tetrakis pentaerythritol and a fatty acid tetraester, the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and the fatty acid, that is, the R 1 C, R 2 C, R 3 C and R 4 C portions in the above formula (1) When the total carbon number is 15, the IOB becomes 0.60. Therefore, in the case where the above-mentioned pentaerythritol and the fatty acid tetraester have a total carbon number of about 15 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

在上述季戊四醇與脂肪酸之四酯，可舉例如季戊四醇與己烷酸(C6)、庚烷酸(C7)、辛烷酸(C8)、例如2-乙基己烷酸(C8)、壬烷酸(C9)、癸烷酸(C10)及/或十二烷酸(C12)之四酯。 In the above tetraester of pentaerythritol and a fatty acid, for example, pentaerythritol and hexane acid (C 6 ), heptanoic acid (C 7 ), octanoic acid (C 8 ), for example, 2-ethylhexane acid (C 8 ) may be mentioned. , nonanoic acid (C 9), capric acid (C 10) and / or lauric acid (C 12) of the tetraester.

在上述季戊四醇與脂肪酸之三酯，構成季戊 四醇與脂肪酸之三酯之脂肪酸的碳數合計，亦即，上述式(2)中，R1C、R2C及R3C部分的碳數合計為19之場合，IOB成為0.58。因此，在上述季戊四醇與脂肪酸之三酯，脂肪酸的碳數合計為約19以上的場合，IOB滿足約0.00~約0.60之要件。 In the above-mentioned formula (2), the total number of carbon atoms of the R 1 C, R 2 C and R 3 C moieties is the total number of carbon atoms of the fatty acid triester of the pentaerythritol and the fatty acid. In the case of 19, the IOB became 0.58. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid triester and fatty acid is about 19 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

在上述季戊四醇與脂肪酸之二酯，構成季戊 四醇與脂肪酸之二酯之脂肪酸的碳數合計，亦即，上述式(3)中，R1C及R2C部分的碳數合計為22的場合，IOB成為0.59。因此，在上述季戊四醇與脂肪酸之二酯，脂肪酸 的碳數合計為約22以上之場合，IOB滿足約0.00~約0.60之要件。 In the above formula (3), the carbon number of the R 1 C and R 2 C moieties is 22 in total, in the case where the diester of the pentaerythritol and the fatty acid is a total of the carbon number of the fatty acid of the diester of the pentaerythritol and the fatty acid. The IOB became 0.59. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid diester and fatty acid is about 22 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

在上述季戊四醇與脂肪酸之單酯，構成季戊 四醇與脂肪酸之單酯之脂肪酸的碳數，亦即，上述式(4)中，R1C部分的碳數為25之場合，IOB成為0.60。因此，在上述季戊四醇與脂肪酸之單酯，脂肪酸的碳數為約25以上之場合，IOB滿足約0.00~約0.60之要件。 In the monoester of pentaerythritol and a fatty acid, the carbon number of the fatty acid constituting the monoester of pentaerythritol and a fatty acid, that is, in the above formula (4), when the carbon number of the R 1 C moiety is 25, the IOB is 0.60. Therefore, in the case where the above-mentioned pentaerythritol and a monoester of a fatty acid have a carbon number of about 25 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

又，在上述計算，不考慮雙鍵、三鍵、iso分枝、及tert分枝的影響。 Also, in the above calculation, the effects of double bonds, triple bonds, iso branches, and tert branches are not considered.

上述季戊四醇與脂肪酸之酯的市售品，可舉 例如UNISTAR H-408BRS、H-2408BRS-22(混合品)等(以上、日油股份公司製)。 A commercial product of the above-mentioned ester of pentaerythritol and a fatty acid, For example, UNISTAR H-408BRS, H-2408BRS-22 (mixed product), etc. (above, manufactured by Nippon Oil Co., Ltd.).

[(a2)鏈狀烴三醇與至少1個脂肪酸之酯] [(a 2 ) an ester of a chain hydrocarbon triol with at least one fatty acid]

上述鏈狀烴三醇與至少1個脂肪酸之酯，可舉例如下式(5)： 之甘油與脂肪酸之三酯、下式(6)： 之甘油與脂肪酸之二酯、及下式(7)： (式中、R5~R7各自為鏈狀烴)之甘油與脂肪酸之單酯。 The ester of the above chain hydrocarbon triol and at least one fatty acid can be exemplified by the following formula (5): The triglyceride of glycerol and fatty acid, the following formula (6): The diester of glycerol and fatty acid, and the following formula (7): (wherein, R 5 to R 7 are each a chain hydrocarbon) a monoester of glycerin and a fatty acid.

構成上述甘油與脂肪酸之酯的脂肪酸(R5COOH、R6COOH及R7COOH)方面，甘油與脂肪酸之酯為滿足上述IOB、熔點及水溶解度要件者，即不特別限制，例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中所列舉的脂肪酸，亦即，可舉例如飽和脂肪酸及不飽和脂肪酸，若考量因氧化等而變性的可能性，以來自飽和脂肪酸的甘油與脂肪酸之酯，亦即，甘油與飽和脂肪酸之酯為佳。 In the case of the fatty acid (R 5 COOH, R 6 COOH, and R 7 COOH) constituting the ester of glycerin and a fatty acid, the ester of glycerin and a fatty acid is not particularly limited as long as it satisfies the above requirements of IOB, melting point, and water solubility, for example, "(a 1 ) The fatty acid exemplified in the ester of a chain hydrocarbon tetraol and at least one fatty acid, that is, a saturated fatty acid or an unsaturated fatty acid, for example, may be denatured by oxidation or the like, and may be derived from a saturated fatty acid. An ester of glycerin with a fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferred.

又，上述甘油與脂肪酸的酯方面，為了使IOB變小、且更為疏水性，以二酯或三酯為佳、接著三酯更佳。 Further, in order to make the IOB smaller and more hydrophobic, the ester of the glycerin and the fatty acid is preferably a diester or a triester, and more preferably a triester.

上述甘油與脂肪酸之三酯，亦稱三甘油酯，例如甘油與辛烷酸(C8)之三酯、甘油與癸烷酸(C10)之三酯、甘油與十二烷酸(C12)之三酯、及甘油與2種或3種之脂 肪酸之三酯、以及此等之混合物。 The above triglyceride of glycerol and fatty acid, also known as triglyceride, such as triester of glycerol and octanoic acid (C 8 ), triester of glycerol and decanoic acid (C 10 ), glycerol and dodecanoic acid (C 12 a triester, and a triester of glycerin with two or three fatty acids, and mixtures thereof.

上述甘油與2種以上的脂肪酸之三酯，可舉 例如甘油與辛烷酸(C8)及癸烷酸(C10)之三酯、甘油與辛烷酸(C8)、癸烷酸(C10)及十二烷酸(C12)之三酯、甘油與辛烷酸(C8)、癸烷酸(C10)、十二烷酸(C12)、十四烷酸(C14)、十六烷酸(C16)及十八烷酸(C18)之三酯等。 Examples of the glycerin and the triester of two or more kinds of fatty acids include triglycerides of glycerol and octanoic acid (C 8 ) and decanoic acid (C 10 ), glycerin and octanoic acid (C 8 ), and decanoic acid ( C 10 ) and the triester of dodecanoic acid (C 12 ), glycerol and octanoic acid (C 8 ), decanoic acid (C 10 ), dodecanoic acid (C 12 ), myristic acid (C 14 ), a triester of palmitic acid (C 16 ) and octadecanoic acid (C 18 ).

上述甘油與脂肪酸之三酯方面，為了使熔點 在約45℃以下，構成甘油與脂肪酸之三酯的脂肪酸的碳數合計，亦即，式(5)中，R5C、R6C及R7C部分的碳數合計以約40以下為佳。 In the above-mentioned glycerin and fatty acid triester, in order to make the melting point be lower than about 45 ° C, the carbon number of the fatty acid constituting the triester of glycerin and fatty acid is total, that is, in the formula (5), R 5 C, R 6 C and R The total carbon number of the 7 C portion is preferably about 40 or less.

又，在上述甘油與脂肪酸之三酯，構成甘油 與脂肪酸之三酯的脂肪酸的碳數合計，亦即，式(5)中，R5C、R6C及R7C部分的碳數合計為12的場合，IOB成為0.60。因此，在上述甘油與脂肪酸之三酯，脂肪酸的碳數合計在約12以上之場合，IOB滿足約0.00~約0.60之要件。 Further, in the above-mentioned triglyceride of glycerin and fatty acid, the carbon number of the fatty acid constituting the triester of glycerin and fatty acid is total, that is, the total carbon number of the R 5 C, R 6 C and R 7 C portions in the formula (5) In the case of 12, the IOB becomes 0.60. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid triester and the fatty acid is about 12 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

上述甘油與脂肪酸之三酯為所謂的脂肪，因為係可構成人體的成分，在安全性的觀點為佳。 The above-mentioned triglyceride of glycerin and fatty acid is a so-called fat, and it is a component of a human body, and it is preferable from a viewpoint of safety.

上述甘油與脂肪酸之三酯之市售品，可舉例 如三椰子油脂肪酸甘油酯、NA36、Panasate800、Panasate800B及Panasate810S、以及三C2L油脂肪酸甘油酯及三CL油脂肪酸甘油酯(以上、日油股份公司製)等。 Commercial products of the above glycerin and fatty acid triester can be exemplified For example, tricocohol fatty acid glyceride, NA36, Panaseate 800, Panasate 800B, and Panasate 810S, and three C2L oil fatty acid glycerides and tri-CL oil fatty acid glycerides (above, manufactured by Nippon Oil Co., Ltd.).

上述甘油與脂肪酸之二酯亦稱二甘油酯，例 如甘油與癸烷酸(C10)之二酯、甘油與十二烷酸(C12)之二酯 、甘油與十六烷酸(C16)之二酯、及甘油與2種之脂肪酸之二酯、以及此等之混合物。 The above diglycerides of glycerol and fatty acid are also called diglycerides, such as diesters of glycerol and decanoic acid (C 10 ), diesters of glycerol and dodecanoic acid (C 12 ), glycerol and palmitic acid (C 16 a diester, and a diester of glycerin and two fatty acids, and mixtures thereof.

在上述甘油與脂肪酸之二酯，構成甘油與脂 肪酸之二酯的脂肪酸的碳數合計，亦即，式(6)中，R5C及R6C部分的碳數合計為16之場合，IOB成為0.58。因此，在上述甘油與脂肪酸之二酯，脂肪酸的碳數合計為約16以上之場合，IOB滿足約0.00~約0.60之要件。 In the case where the glycerin and the fatty acid diester are combined with the carbon number of the fatty acid constituting the diester of the glycerin and the fatty acid, that is, in the formula (6), when the total carbon number of the R 5 C and R 6 C moieties is 16, IOB Become 0.58. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid diester and the fatty acid is about 16 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

上述甘油與脂肪酸之單酯，亦稱單甘油酯， 例如甘油之二十烷酸(C20)單酯、甘油之二十二烷酸(C22)單酯等。 The monoester of the above glycerin and fatty acid is also called a monoglyceride, for example, a monoalcoholic acid (C 20 ) monoester of glycerin, a behenic acid (C 22 ) monoester of glycerin or the like.

在上述甘油與脂肪酸之單酯，構成甘油與脂肪酸之單酯的脂肪酸的碳數，亦即，式(7)中，R5C部分的碳數為19之場合，IOB成為0.59。因此，在上述甘油與脂肪酸之單酯，脂肪酸的碳數為約19以上的場合，IOB滿足約0.00~約0.60之要件。 In the case where the monoester of glycerin and a fatty acid constitutes a carbon number of a fatty acid which constitutes a monoester of glycerin and a fatty acid, that is, in the formula (7), when the carbon number of the R 5 C moiety is 19, IOB is 0.59. Therefore, in the case where the carbon number of the glycerin and the fatty acid monoester and the fatty acid is about 19 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

[(a3)鏈狀烴二醇與至少1個脂肪酸之酯] [(a 3 ) an ester of a chain hydrocarbon diol with at least one fatty acid]

上述鏈狀烴二醇與至少1個脂肪酸之酯，可舉例如C2~C6之鏈狀烴二醇、例如C2~C6之二醇、例如乙二醇、丙二醇、丁二醇、戊二醇或己二醇與脂肪酸之單酯或二酯。 The ester of the chain hydrocarbon diol and at least one fatty acid may, for example, be a C 2 to C 6 chain hydrocarbon diol, for example, a C 2 to C 6 diol such as ethylene glycol, propylene glycol or butylene glycol. a monoester or diester of pentanediol or hexanediol with a fatty acid.

具體上，上述鏈狀烴二醇與至少1個脂肪酸之酯，可舉例如下式(8)： R8COOCkH2kOCOR9 (8) (式中、k為2~6之整數，而R8及R9各自為鏈狀烴)之C2~C6二醇與脂肪酸之二酯、及下式(9)： R8COOCkH2kOH (9) (式中、k為2~6之整數，而R8為鏈狀烴)之C2~C6二醇與脂肪酸之單酯。 Specifically, the ester of the above chain hydrocarbon diol and at least one fatty acid can be exemplified by the following formula (8): R 8 COOC k H 2k OCOR 9 (8) (wherein k is an integer of 2 to 6, and R 8 and R 9 are each a chain hydrocarbon; a diester of a C 2 -C 6 diol and a fatty acid, and the following formula (9): R 8 COOC k H 2k OH (9) (wherein k is 2-6) An integer of the formula, and R 8 is a chain hydrocarbon) of a C 2 -C 6 diol and a monoester of a fatty acid.

上述C2~C6二醇與脂肪酸之酯中，欲酯化脂 肪酸(式(8)及式(9)中，相當R8COOH及R9COOH)方面，C2~C6二醇與脂肪酸之酯為滿足上述IOB、熔點及水溶解度要件者，即不特別限制，例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中列舉的脂肪酸，亦即飽和脂肪酸及不飽和脂肪酸，若考量因氧化等變性之可能性，以飽和脂肪酸較佳。 Among the above-mentioned esters of C 2 -C 6 diols and fatty acids, it is desired to esterify fatty acids (in the formulas (8) and (9), which are equivalent to R 8 COOH and R 9 COOH), C 2 -C 6 diols and fatty acids. The ester is not particularly limited as long as it satisfies the above requirements for IOB, melting point and water solubility, for example, the fatty acid listed in "(a 1 ) chain hydrocarbon tetraol and at least one fatty acid ester", that is, saturated fatty acid and unsaturated For fatty acids, it is preferred to use saturated fatty acids in consideration of the possibility of denaturation by oxidation or the like.

在式(8)所示之丁二醇(k=4)與脂肪酸之二酯， R8C及R9C部分的碳數合計為6之場合，IOB成為0.60。 因此，在式(8)所示之丁二醇(k=4)與脂肪酸之二酯，上述碳數合計為約6以上的場合，IOB滿足約0.00~約0.60之要件。又，在式(9)所示之乙二醇(k=2)與脂肪酸之單酯，R8C部分的碳數為12的場合，IOB成為0.57。因此，在式(9)所示之乙二醇(k=2)與脂肪酸之單酯，脂肪酸的碳數在約12以上之場合，IOB滿足約0.00~約0.60之要 件。 When the total number of carbon atoms of the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid, and the R 8 C and R 9 C portions is 6, the IOB becomes 0.60. Therefore, in the case where the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid have a total carbon number of about 6 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Further, in the case of the ethylene glycol (k=2) represented by the formula (9) and the monoester of the fatty acid, and the carbon number of the R 8 C moiety is 12, the IOB is 0.57. Therefore, in the case of the ethylene glycol (k=2) represented by the formula (9) and the monoester of the fatty acid, and the carbon number of the fatty acid is about 12 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

上述C2~C6二醇與脂肪酸之酯方面，若考量 因氧化等而變性的可能性，以來自飽和脂肪酸的C2~C6二醇與脂肪酸之酯，亦即C2~C6二醇與飽和脂肪酸之酯為佳。 In the case of the above-mentioned ester of a C 2 -C 6 diol and a fatty acid, considering the possibility of denaturation by oxidation or the like, an ester of a C 2 -C 6 diol derived from a saturated fatty acid and a fatty acid, that is, a C 2 -C 6 II Esters of alcohols and saturated fatty acids are preferred.

又，上述C2~C6二醇與脂肪酸之酯方面，為 了使IOB變小、且更為疏水性，以來自大碳數的二醇的醇與脂肪酸之酯、例如來自丁二醇、戊二醇或己二醇的醇與脂肪酸之酯為佳。 Further, in terms of the ester of the C 2 -C 6 diol and the fatty acid, in order to make the IOB smaller and more hydrophobic, an ester of an alcohol and a fatty acid derived from a diol having a large carbon number, for example, from butanediol or pentane Esters of alcohols and fatty acids of diol or hexanediol are preferred.

進而，上述C2~C6二醇與脂肪酸之酯方面， 為了使IOB變小、且更為疏水性，以二酯為佳。 Further, in terms of the ester of the C 2 -C 6 diol and the fatty acid, in order to make the IOB smaller and more hydrophobic, a diester is preferred.

上述C2~C6二醇與脂肪酸之酯的市售品，可舉例如科母波魯BL、科母波魯BS(以上、日油股份公司製)等。 The commercially available product of the above-mentioned ester of a C 2 -C 6 diol and a fatty acid may, for example, be a Cobopol BL or a Cotomboru BS (above, manufactured by Nippon Oil Co., Ltd.).

[(B)(B1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(B2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之醚] [(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety; Ether of a hydroxy compound]

(B)(B1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物與(B2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之醚(以下、有亦稱「化合物(B)」之情形)在具有上述之IOB、熔點及水溶解度下，羥基可不全被醚化。 (B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) 1 having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety The ether of a hydroxy group compound (hereinafter also referred to as "compound (B)") may have an ether group which is not completely etherified by having the above-mentioned IOB, melting point and water solubility.

(B1)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羥基的化合物方面，可舉例如「化合物 (A)」中作為化合物(A1)所列舉者，例如季戊四醇、甘油、及二醇。 (B1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, for example, "compound" Among the compounds (A1) in (A), for example, pentaerythritol, glycerin, and diol are mentioned.

(B2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物(以下、有亦稱「化合物(B2)」之情形)，可舉例如烴之1個氫原子被1個羥基(-OH)所取代的化合物、例如脂肪族1元醇、例如飽和脂肪族1元醇及不飽和脂肪族1元醇。 (B2) A compound having a chain hydrocarbon moiety and a hydroxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety (hereinafter, also referred to as "compound (B2)"), for example, one hydrogen atom of a hydrocarbon is A compound substituted with one hydroxy group (-OH), for example, an aliphatic monohydric alcohol, for example, a saturated aliphatic monohydric alcohol and an unsaturated aliphatic monohydric alcohol.

上述飽和脂肪族1元醇，可舉例如C1~C20之 飽和脂肪族1元醇、例如甲基醇(C1)(C1表示碳數，以下相同)、乙基醇(C2)、丙基醇(C3)及其異構物、例如異丙基醇(C3)、丁基醇(C4)及其異構物、例如sec-丁基醇(C4)及tert-丁基醇(C4)、戊基醇(C5)、己基醇(C6)、庚基醇(C7)、辛基醇(C8)及其異構物、例如2-乙基己基醇(C8)、壬基醇(C9)、癸基醇(C10)、十二醇(C12)、十四基醇(C14)、十六基醇(C16)、十七基醇(C17)、十八基醇(C18)、及二十烷基醇(C20)、以及此等之未列舉的異構物。 The saturated aliphatic monohydric alcohol may, for example, be a C 1 to C 20 saturated aliphatic monohydric alcohol, for example, methyl alcohol (C 1 ) (C 1 represents a carbon number, the same applies hereinafter), and ethyl alcohol (C 2 ) , propyl alcohol (C 3 ) and isomers thereof, such as isopropyl alcohol (C 3 ), butyl alcohol (C 4 ) and isomers thereof, such as sec-butyl alcohol (C 4 ) and tert- Butyl alcohol (C 4 ), pentyl alcohol (C 5 ), hexyl alcohol (C 6 ), heptyl alcohol (C 7 ), octyl alcohol (C 8 ) and isomers thereof, such as 2-ethylhexyl Alcohol (C 8 ), mercapto alcohol (C 9 ), mercapto alcohol (C 10 ), dodecyl alcohol (C 12 ), tetradecyl alcohol (C 14 ), hexadecanol (C 16 ), seventeen alcohol (C 17), octadecyl alcohol (C 18), and eicosyl alcohol (C 20), and of these isomers thereof not enumerated.

上述不飽和脂肪族1元醇，可舉例如將上述 飽和脂肪族1元醇之C-C單鍵之1個以C=C雙鍵取代者，例如油基醇，例如新日本理化股份公司以Rikacol系列及安捷可魯系列名稱販售。 The unsaturated aliphatic monohydric alcohol may, for example, be as described above One of the C-C single bonds of the saturated aliphatic monohydric alcohol is substituted by a C=C double bond, such as an oleyl alcohol, for example, the New Japan Physical and Chemical Co., Ltd. is sold under the Rikacol series and the Agilent series name.

化合物(B)，可舉例如(b1)鏈狀烴四醇與至少1 個脂肪族1元醇之醚、例如單醚、二醚、三醚及四醚、較佳為二醚、三醚及四醚、更佳為三醚及四醚、再佳為四醚、(b2)鏈狀烴三醇與至少1個脂肪族1元醇之醚、例如單 醚、二醚及三醚、較佳為二醚及三醚、而更佳為三醚、以及(b3)鏈狀烴二醇與至少1個脂肪族1元醇之醚、例如單醚及二醚、而較佳為二醚。 The compound (B) may, for example, be an ether of a (b 1 ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, for example, a monoether, a diether, a triether and a tetraether, preferably a diether or a triether. And a tetraether, more preferably a triether and a tetraether, more preferably a tetraether, (b 2 ) a chain hydrocarbon triol and an ether of at least one aliphatic monohydric alcohol, such as a monoether, a diether and a triether, preferably diether ether and three, three and more preferably an ether, and (b 3) a chain hydrocarbon diol and at least one of an aliphatic monohydric alcohol ethers, monoethers and diethers, for example, and preferably two ether.

上述鏈狀烴四醇與至少1個脂肪族1元醇之醚，可舉例如下式(10)~(13)： (式中、R10~R13各自為鏈狀烴。)的季戊四醇與脂肪族1元醇之四醚、三醚、二醚及單醚。 The ether of the above chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol can be exemplified by the following formulas (10) to (13): (wherein, R 10 to R 13 are each a chain hydrocarbon) a pentaerythritol and an aliphatic monohydric alcohol, a tetraether, a triether, a diether, and a monoether.

上述鏈狀烴三醇與至少1個脂肪族1元醇之醚，可舉例如下式(14)~(16)： (式中、R14~R16各自為鏈狀烴。)的甘油與脂肪族1元醇之三醚、二醚及單醚。 The ether of the above chain hydrocarbon triol and at least one aliphatic monohydric alcohol can be exemplified by the following formulas (14) to (16): (wherein, R 14 to R 16 are each a chain hydrocarbon) glycerol and an aliphatic monohydric alcohol triether, diether and monoether.

上述鏈狀烴二醇與至少1個脂肪族1元醇之醚，可舉例如下式(17)：R17OCnH2nOR18 (17)(式中、n為2~6之整數，而R17及R18各自為鏈狀烴)之C2~C6二醇與脂肪族1元醇之二醚、及下式(18)：R17OCnH2nOH (18)(式中、n為2~6之整數，而R17為鏈狀烴)之C2~C6二醇與脂肪族1元醇之單醚。 The ether of the above chain hydrocarbon diol and at least one aliphatic monohydric alcohol can be exemplified by the following formula (17): R 17 OC n H 2n OR 18 (17) (wherein n is an integer of 2 to 6, and R 17 and R 18 are each a chain hydrocarbon (C 2 -C 6 diol) and an aliphatic 1 -valent alcohol diether, and the following formula (18): R 17 OC n H 2n OH (18) (wherein n is an integer of 2 to 6, and R 17 is a chain hydrocarbon (C 2 -C 6 diol) and a monoether of an aliphatic monohydric alcohol.

在上述季戊四醇與脂肪族1元醇之四醚，構 成季戊四醇與脂肪族1元醇之四醚的脂肪族1元醇的碳數合計，亦即，上述式(10)中，R10、R11、R12及R13部分的碳數合計為4之場合，IOB成為0.44。因此，在上述季戊四醇與脂肪族1元醇之四醚，脂肪族1元醇的碳數合計為約4以上之場合，IOB滿足約0.00~約0.60之要件。 In the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R 10 and R 11 in the above formula (10) When the total carbon number of the R 12 and R 13 portions is 4, the IOB becomes 0.44. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 4 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

在上述季戊四醇與脂肪族1元醇之三醚，構 成季戊四醇與脂肪族1元醇之三醚的脂肪族1元醇的碳數合計，亦即，上述式(11)中，R10、R11及R12部分的碳數合計為9之場合，IOB成為0.57。因此，在上述季戊四醇與脂肪族1元醇之三醚，脂肪族1元醇的碳數合計在約9以上之場合，IOB滿足約0.00~約0.60之要件。 The total number of carbon atoms of the aliphatic monohydric alcohol forming the pentaerythritol and the triether of the aliphatic monohydric alcohol in the above-mentioned pentaerythritol and the aliphatic trihydric alcohol triol, that is, in the above formula (11), R 10 and R 11 When the total carbon number of the R 12 portion is 9, the IOB becomes 0.57. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic trihydric alcohol and the aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

在上述季戊四醇與脂肪族1元醇之二醚，構 成季戊四醇與脂肪族1元醇之二醚的脂肪族1元醇的碳數合計，亦即，上述式(12)中，R10及R11部分的碳數合計為15之場合，IOB成為0.60。因此，在上述季戊四醇與脂肪族1元醇之二醚，脂肪族1元醇的碳數合計為約15以上之場合，IOB滿足約0.00~約0.60之要件。 In the diether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R 10 and R 11 in the above formula (12) When the total carbon number is 15 in total, the IOB becomes 0.60. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic dihydric alcohol and the aliphatic monohydric alcohol is about 15 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

在上述季戊四醇與脂肪族1元醇之單醚，構 成季戊四醇與脂肪族1元醇之單醚的脂肪族1元醇的碳數，亦即，上述式(13)中，R10部分的碳數為22的場合，IOB成為0.59。因此，在上述季戊四醇與脂肪族1元醇之單醚，脂肪族1元醇的碳數為約22以上之場合，IOB滿足約0.00~約0.60之要件。 The carbon number of the aliphatic monohydric alcohol which constitutes the monoether of pentaerythritol and the aliphatic monohydric alcohol in the monoether of the pentaerythritol and the aliphatic monohydric alcohol, that is, the carbon number of the R 10 moiety in the above formula (13) For the case of 22, the IOB becomes 0.59. Therefore, in the case where the carbon number of the above-mentioned pentaerythritol and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 22 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

又，在上述甘油與脂肪族1元醇之三醚，構 成甘油與脂肪族1元醇之三醚的脂肪族1元醇的碳數合計，亦即，式(14)中，R14、R15及R16部分的碳數合計為3之場合，IOB成為0.50。因此，在上述甘油與脂肪族1元醇之三醚，脂肪族1元醇的碳數合計為約3以上之場合，IOB滿足約0.00~約0.60之要件。 Further, in the triether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the triether of glycerin and the aliphatic monohydric alcohol, that is, R 14 and R in the formula (14) When the total carbon number of the 15 and R 16 portions is 3, the IOB becomes 0.50. Therefore, when the total number of carbon atoms of the glycerin and the aliphatic trihydric alcohol and the aliphatic monohydric alcohol is about 3 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

在上述甘油與脂肪族1元醇之二醚，構成甘 油與脂肪族1元醇之二醚的脂肪族1元醇的碳數合計，亦即，式(15)中，R14及R15部分的碳數合計為9之場合，IOB成為0.58。因此，在上述甘油與脂肪族1元醇之二醚，脂肪族1元醇的碳數合計在約9以上之場合，IOB滿足約0.00~約0.60之要件。 In the diether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of the glycerin and the aliphatic monohydric alcohol, that is, the R 14 and R 15 portions in the formula (15) When the total carbon number is 9, the IOB becomes 0.58. Therefore, in the case where the total number of carbon atoms of the glycerin and the aliphatic dihydric alcohol and the aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

在上述甘油與脂肪族1元醇之單醚，構成甘 油與脂肪族1元醇之單醚的脂肪族1元醇的碳數，亦即，式(16)中，R14部分的碳數為16之場合，IOB成為0.58。 因此，在上述甘油與脂肪族1元醇之單醚，脂肪族1元醇的碳數為約16以上之場合，IOB滿足約0.00~約0.60之要件。 In the monoether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of the glycerin and the aliphatic monohydric alcohol, that is, in the formula (16), the carbon number of the R 14 moiety is On the 16th occasion, the IOB became 0.58. Therefore, in the case where the carbon number of the monoglyceride of the glycerin and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 16 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

在式(17)所示之丁二醇(n=4)與脂肪族1元醇 之二醚，R17及R18部分的碳數合計為2的場合，IOB成為0.33。因此，在式(17)所示之丁二醇(n=4)與脂肪族1元醇之二醚，脂肪族1元醇的碳數合計為2以上的場合，IOB滿足約0.00~約0.60之要件。又，在式(18)所示之乙二醇(n=2)與脂肪族1元醇之單醚，R17部分的碳數為8之 場合，IOB成為0.60。因此，在式(18)所示之乙二醇(n=2)與脂肪族1元醇之單醚，脂肪族1元醇的碳數為約8以上之場合，IOB滿足約0.00~約0.60之要件。 When the total number of carbon atoms of the diphenyl diol (n = 4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol and the R 17 and R 18 portions is 2, the IOB is 0.33. Therefore, when the total number of carbon atoms of the butanediol (n=4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is 2 or more, the IOB satisfies about 0.00 to about 0.60. The essentials. Further, in the case of the ethylene glycol (n = 2) represented by the formula (18) and the monoether of the aliphatic monohydric alcohol, when the carbon number of the R 17 moiety is 8, the IOB is 0.60. Therefore, in the case where the ethylene glycol (n=2) represented by the formula (18) and the monoether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol have a carbon number of about 8 or more, the IOB satisfies about 0.00 to about 0.60. The essentials.

化合物(B)，可藉由使化合物(B1)與化合物(B2)在酸觸媒存在下進行脫水縮合而生成。 The compound (B) can be produced by subjecting the compound (B1) and the compound (B2) to dehydration condensation in the presence of an acid catalyst.

[(C)(C1)含有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羧基的羧酸、羥基酸、烷氧基酸或側氧酸與(C2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之酯] [(C)(C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a oxo acid having a chain hydrocarbon moiety and 2 to 4 carboxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) have a chain shape An ester of a hydrocarbon moiety and a compound substituted with one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety]

(C)(C1)含有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的2~4個羧基的羧酸、羥基酸、烷氧基酸或側氧酸與(C2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物之酯(以下、有亦稱「化合物(C)」之情形)在具有上述之IOB、熔點及水溶解度下，羧基可不全被酯化。 (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid having a chain hydrocarbon moiety and 2 to 4 carboxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) having a chain hydrocarbon An ester of a compound partially substituted with one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (C)") may have a carboxyl group which may have a carboxyl group having a melting point and a water solubility as described above. Esterification.

(C1)含有鏈狀烴部分與取代上述鏈狀烴部分的 氫原子的2~4個羧基的羧酸、羥基酸、烷氧基酸或側氧酸(以下、有亦稱「化合物(C1)」之情形)，可舉例如具有2~4個羧基的鏈狀烴羧酸、例如鏈狀烴二羧酸、例如烷烴二羧酸、例如乙烷二酸、丙烷二酸、丁烷二酸、戊烷二酸、己烷二酸、庚烷二酸、辛烷二酸、壬烷二酸及癸烷二酸、鏈狀烴三羧酸、例如烷烴三羧酸、例如丙烷三酸、丁烷三酸、戊烷三酸、己烷三酸、庚烷三酸、辛烷三酸、壬 烷三酸及癸烷三酸、以及鏈狀烴四羧酸、例如烷烴四羧酸、例如丁烷四酸、戊烷四酸、己烷四酸、庚烷四酸、辛烷四酸、壬烷四酸及癸烷四酸。 (C1) containing a chain hydrocarbon moiety and replacing the above chain hydrocarbon moiety A carboxylic acid having 2 to 4 carboxyl groups of a hydrogen atom, a hydroxy acid, an alkoxy acid or a side oxyacid (hereinafter also referred to as "the compound (C1)") may, for example, be a chain having 2 to 4 carboxyl groups. a hydrocarbon carboxylic acid, such as a chain hydrocarbon dicarboxylic acid, such as an alkane dicarboxylic acid, such as ethanedioic acid, propane diacid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octane Alkanoic acid, decanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acid, such as alkane tricarboxylic acid, such as propane triacid, butane tricarboxylic acid, pentane tricarboxylic acid, hexane tricarboxylic acid, heptane three Acid, octane triacid, hydrazine Alkanetricarboxylic acid and decanetricarboxylic acid, and chain hydrocarbon tetracarboxylic acid, such as an alkanetetracarboxylic acid, such as butane tetracarboxylic acid, pentanetetracarboxylic acid, hexanetetracarboxylic acid, heptanetetracarboxylic acid, octane tetracarboxylic acid, hydrazine Alkanetetracarboxylic acid and decane tetracarboxylic acid.

又，化合物(C1)中，包含具有2~4個羧基的 鏈狀烴羥基酸、例如蘋果酸、酒石酸、檸檬酸、異檸檬酸等、具有2~4個羧基的鏈狀烴烷氧基酸、例如O-乙醯基檸檬酸、及具有2~4個羧基的鏈狀烴側氧酸。 Further, the compound (C1), a 2 to 4 comprising a chain hydrocarbon hydroxy carboxyl acids, such as malic acid, tartaric acid, citric acid, isocitric acid, chain hydrocarbon having 2 to 4 carboxyl groups alkoxy acid For example, O-acetyl citrate and a chain hydrocarbon side oxyacid having 2 to 4 carboxyl groups.

(C2)具有鏈狀烴部分與取代上述鏈狀烴部分的氫原子的1個羥基的化合物方面，可舉例如在「化合物(B)」之中所列舉者、例如脂肪族1元醇。 (C2) The compound having a chain hydrocarbon moiety and a hydroxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety, for example, those listed in "Compound (B)", for example, an aliphatic monohydric alcohol.

化合物(C)，可舉例如(c1)具有4個羧基的鏈 狀烴四羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、例如單酯、二酯、三酯及四酯、較佳為二酯、三酯及四酯、更佳為三酯及四酯、再佳為四酯、(c2)具有3個羧基的鏈狀烴三羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、例如單酯、二酯及三酯、較佳為二酯及三酯、而更佳為三酯、以及(c3)具有2個羧基的鏈狀烴二羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、例如單酯及二酯、較佳為二酯。 The compound (C) may, for example, be (c 1 ) a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or an ester of a side acid and at least one aliphatic monohydric alcohol, for example, a monoester. , diester, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and triesters, more preferably tetraesters, (c 2 ) chain hydrocarbons having 3 carboxyl groups An ester of a carboxylic acid, a hydroxy acid, an alkoxy acid or a oxo acid with at least one aliphatic monohydric alcohol, such as a monoester, a diester or a triester, preferably a diester and a triester, and more preferably three. And an ester of (c 3 ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a oxo acid with at least one aliphatic monohydric alcohol, such as a monoester or a diester, Jia is a diester.

化合物(C)的例子方面，如己二酸二辛基酯、O-乙醯基檸檬酸三丁酯等、市售品。 Examples of the compound (C) include commercially available products such as dioctyl adipate, tributyl butyl ethoxide and the like.

[(D)具有鏈狀烴部分、與上述鏈狀烴部分的C-C單鍵間***的醚鍵(-O-)、羰基鍵結(-CO-)、酯鍵結(-COO-)、 及碳酸酯鍵結(-OCOO-)所成群中選出的任一個鍵結之化合物] [(D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) having a chain hydrocarbon moiety and a C-C single bond interposed between the above-mentioned chain hydrocarbon moiety, And a compound selected from a group of carbonate linkages (-OCOO-)]

(D)具有鏈狀烴部分、與上述鏈狀烴部分的C-C單鍵間***的醚鍵(-O-)、羰基鍵結(-CO-)、酯鍵結(-COO-)、及碳酸酯鍵結(-OCOO-)所成群中選出的任一個鍵結之化合物(以下、有亦稱「化合物(D)」之情形)，可舉例如(d1)脂肪族1元醇與脂肪族1元醇之醚、(d2)二烷基酮、(d3)脂肪酸與脂肪族1元醇之酯、及(d4)二烷基碳酸酯。 (D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonic acid having a chain hydrocarbon moiety and a CC single bond intercalated with the above chain hydrocarbon moiety Any of the compounds selected in the group in which the ester bond (-OCOO-) is selected (hereinafter, also referred to as "compound (D)"), for example, (d 1 ) aliphatic monohydric alcohol and fat An ether of a monohydric alcohol, a (d 2 ) dialkyl ketone, an ester of a (d 3 ) fatty acid and an aliphatic monohydric alcohol, and (d 4 ) a dialkyl carbonate.

[(d1)脂肪族1元醇與脂肪族1元醇之醚] [(d 1 ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol]

上述脂肪族1元醇與脂肪族1元醇之醚，可舉例如具有下式(19)：R19OR20 (19)(式中、R19及R20各自為鏈狀烴)之化合物。 The ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (19): R 19 OR 20 (19) (wherein each of R 19 and R 20 is a chain hydrocarbon).

構成上述醚的脂肪族1元醇(式(19)中，相當R19OH及R20OH)方面，上述醚為滿足上述IOB、熔點及水溶解度要件者，即不特別限制，可舉例如「化合物(B)」之中所列舉的脂肪族1元醇。 In the case of the aliphatic monohydric alcohol (equivalent to R 19 OH and R 20 OH in the formula (19)), the ether is not particularly limited as long as it satisfies the above-mentioned requirements for IOB, melting point and water solubility, and for example, The aliphatic monohydric alcohol exemplified in the compound (B).

在脂肪族1元醇與脂肪族1元醇之醚，構成該醚的脂肪族1元醇的碳數合計，亦即，上述式(19)中，R19及R20部分的碳數合計為2的場合，IOB成為0.50， 所以該碳數合計為約2以上，則滿足上述IOB的要件。但，上述碳數合計在6左右，水溶解度為高約2g、在蒸氣壓的觀點上亦有問題。為了滿足水溶解度為約0.00~約0.05g的要件，上述碳數合計以約8以上為佳。 In the ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether, that is, in the above formula (19), the total carbon number of the R 19 and R 20 moieties is In the case of 2, since the IOB is 0.50, the total number of carbon atoms is about 2 or more, and the requirements of the above IOB are satisfied. However, the total carbon number is about 6, and the water solubility is about 2 g higher, which is also problematic from the viewpoint of vapor pressure. In order to satisfy the requirement that the water solubility is from about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more.

[(d2)二烷基酮] [(d 2 )dialkyl ketone]

上述二烷基酮，可舉例如具有下式(20)：R21COR22 (20)(式中、R21及R22各自為烷基)之化合物。 The dialkyl ketone may, for example, be a compound having the following formula (20): R 21 COR 22 (20) (wherein each of R 21 and R 22 is an alkyl group).

在上述二烷基酮，R21及R22的碳數合計為5之場合，IOB成為0.54，因此若該碳數合計為約5以上，則滿足上述IOB的要件。但是，在上述碳數合計為5左右，水溶解度為高至約2g。因此，為了滿足水溶解度為約0.00~約0.05g之要件，以上述碳數合計為約8以上為佳。又，若考量蒸氣壓，則上述碳數以約10以上為佳、而約12以上為佳。 In the case where the total number of carbon atoms of R 21 and R 22 is 5, the IOB is 0.54. Therefore, if the total number of carbon atoms is about 5 or more, the requirements of the above IOB are satisfied. However, the total carbon number is about 5, and the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement that the water solubility is from about 0.00 to about 0.05 g, it is preferred that the total carbon number is about 8 or more. Further, when the vapor pressure is considered, the carbon number is preferably about 10 or more, and more preferably about 12 or more.

又，上述碳數合計為約8之場合，例如在5-壬酮，熔點為約-50℃、蒸氣壓在20℃約為230Pa。 Further, when the total carbon number is about 8, for example, 5-nonanone has a melting point of about -50 ° C and a vapor pressure of about 230 Pa at 20 ° C.

上述二烷基酮除市售者外，可藉由習知方法、例如將第二級醇以鉻酸等氧化而得到。 The above dialkyl ketone can be obtained by a conventional method, for example, by oxidizing a second-stage alcohol with chromic acid or the like, in addition to a commercially available one.

[(d3)脂肪酸與脂肪族1元醇之酯] [(d 3 ) ester of fatty acid with aliphatic monohydric alcohol]

上述脂肪酸與脂肪族1元醇之酯，可舉例如具有下式(21)：R23COOR24 (21)(式中、R23及R24各自為鏈狀烴)之化合物。 The ester of the above-mentioned fatty acid and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (21): R 23 COOR 24 (21) (wherein each of R 23 and R 24 is a chain hydrocarbon).

構成上述酯的脂肪酸(式(21)中，相當R23COOH)，可舉例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中所列舉的脂肪酸，亦即，飽和脂肪酸或不飽和脂肪酸，若考量因氧化等而變性的可能性，以飽和脂肪酸為佳。構成上述酯的脂肪族1元醇(式(21)中，相當R24OH)，可舉例如「化合物(B)」之中所列舉的脂肪族1元醇。 The fatty acid constituting the above-mentioned ester (corresponding to R 23 COOH in the formula (21)) may, for example, be a fatty acid as exemplified in the "(a 1 ) chain hydrocarbon tetraol and at least one fatty acid ester", that is, a saturated fatty acid. Or unsaturated fatty acids, if considering the possibility of denaturation by oxidation, etc., it is preferable to use a saturated fatty acid. The aliphatic monohydric alcohol (e.g., R 24 OH in the formula (21)) constituting the above-mentioned ester may, for example, be an aliphatic monohydric alcohol as exemplified in the "compound (B)".

又，在上述脂肪酸與脂肪族1元醇之酯，脂肪酸及脂肪族1元醇的碳數合計，亦即，式(21)中，R23C及R24部分的碳數合計為5之場合，IOB成為0.60，故R23C及R24部分的碳數合計為約5以上之場合，滿足上述IOB的要件。但是，例如在上述碳數合計為6之乙酸丁酯，蒸氣壓高至超過2,000Pa。因此，若考量蒸氣壓，以上述碳數合計為約12以上為佳。又，若上述碳數合計為約11以上，可滿足水溶解度為約0.00~約0.05g之要件。 In addition, in the case where the carbon number of the fatty acid and the aliphatic monohydric alcohol, the fatty acid and the aliphatic monohydric alcohol are in total, that is, in the formula (21), the total carbon number of the R 23 C and R 24 moieties is 5 When the IOB is 0.60, the total number of carbon atoms in the R 23 C and R 24 portions is about 5 or more, and the requirements of the above IOB are satisfied. However, for example, in the case of the above-mentioned butyl acetate having a total carbon number of 6, the vapor pressure is as high as more than 2,000 Pa. Therefore, in consideration of the vapor pressure, it is preferred that the total carbon number is about 12 or more. Moreover, when the total carbon number is about 11 or more, the water solubility is about 0.00 to about 0.05 g.

上述脂肪酸與脂肪族1元醇之酯之例，可舉例如十二烷酸(C12)與十二醇(C12)之酯、十四烷酸(C14)與 十二醇(C12)之酯等，上述脂肪酸與脂肪族1元醇之酯的市售品，可舉例如在雷特魯WE20、及雷特魯WE40(以上、日油股份公司製)。 Examples of the ester of the above fatty acid and the aliphatic monohydric alcohol include, for example, an ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), myristic acid (C 14 ) and dodecyl alcohol (C 12 ). The commercial product of the ester of the above-mentioned fatty acid and the aliphatic monohydric alcohol is, for example, a Retru WE20 and a Retru WE40 (manufactured by Nippon Oil Co., Ltd.).

[(d4)二烷基碳酸酯] [(d 4 )Dialkyl carbonate]

上述二烷基碳酸酯方面，可舉例如具有下式(22)：R25OC(=O)OR26 (22)(式中、R25及R26各自為烷基)之化合物。 The dialkyl carbonate may, for example, be a compound having the following formula (22): R 25 OC(=O)OR 26 (22) (wherein each of R 25 and R 26 is an alkyl group).

在上述二烷基碳酸酯，R25及R26的碳數合計為6之場合，IOB成為0.57，故R25及R26的碳數合計在約6以上則滿足IOB的要件。 In the case where the total number of carbon atoms of R 25 and R 26 is 6 in the above dialkyl carbonate, the IOB is 0.57. Therefore, the total carbon number of R 25 and R 26 is about 6 or more to satisfy the requirements of IOB.

若考量水溶解度，則R25及R26的碳數合計為約7以上為佳、而約9以上更佳。 When the water solubility is considered, the total carbon number of R 25 and R 26 is preferably about 7 or more, and more preferably about 9 or more.

上述二烷基碳酸酯除市售者外，可藉由光氣與醇之反應、氯化甲酸酯與醇或醇鹽之反應、及碳酸銀與碘化烷基酯之反應來合成。 The above dialkyl carbonates can be synthesized by the reaction of phosgene with an alcohol, the reaction of a chlorinated formate with an alcohol or an alkoxide, and the reaction of silver carbonate with an alkyl iodide, in addition to those commercially available.

[(E)聚氧化C2~6烷二醇、或其酯或者醚] [(E) Polyoxygenated C 2-6 alkanediol, or its ester or ether]

上述聚氧化C2~6烷二醇、或其酯或者醚(以下、化合物(E)之情形)，可舉例如(e1)聚氧化C2~6烷二醇、(e2)聚氧化C2~6烷二醇與至少1個脂肪酸之酯、(e3)聚氧化C2~6烷 二醇與至少1個脂肪族1元醇之醚、(e4)聚氧化C2~6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯、及(e5)聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚。以下、進行說明。 The polyoxy C 2-6 alkanediol, or an ester or ether thereof (hereinafter, in the case of the compound (E)), for example, (e 1 ) polyoxygenated C 2-6 alkanediol, (e 2 ) polyoxidation An ester of C 2-6 alkanediol with at least one fatty acid, (e 3 ) a polyoxy C 2-6 alkanediol and an ether of at least one aliphatic monohydric alcohol, (e 4 ) a polyoxygenated C 2-6 An alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid ester, and (e 5 ) a polyoxygenated C 2-6 alkanediol and a chain hydrocarbon tetraol, a chain An ether of a hydrocarbon triol or a chain hydrocarbon diol. The following description will be made.

[(e1)聚氧化C2~6烷二醇] [(e 1 ) polyoxygenated C 2-6 alkanediol]

上述聚氧化C2~6烷二醇係指i)氧化C2~6烷烯骨架，亦即，具有由氧化乙烯骨架、氧化丙烯骨架、氧化丁烯骨架、氧化戊烯骨架、及氧化己烯骨架所成群中所選出的任1種之骨架且兩末端具有羥基的同聚物、ii)具有由上述群所選出的2種以上的骨架且兩末端具有羥基的嵌段共聚物、或iii)具有由上述群所選出的2種以上的骨架且兩末端具有羥基的無規共聚物。 The above polyoxygenated C 2-6 alkanediol refers to i) an oxidized C 2-6 alkene skeleton, that is, having an oxyethylene skeleton, an oxypropylene skeleton, a oxidized butene skeleton, a pentene oxide skeleton, and an oxyhexene oxide. a homopolymer having a skeleton selected from a group of skeletons and having a hydroxyl group at both terminals, ii) a block copolymer having two or more kinds of skeletons selected from the above group and having a hydroxyl group at both terminals, or iii A random copolymer having two or more kinds of skeletons selected from the above groups and having hydroxyl groups at both terminals.

上述氧化C2~6烷烯骨架，由聚氧化C2~6烷二醇之IOB降低的觀點來看，以氧化丙烯骨架、氧化丁烯骨架、氧化戊烯骨架、或氧化己烯骨架為佳、氧化丁烯骨架、氧化戊烯骨架、或氧化己烯骨架更佳。 The oxidized C 2-6 alkene skeleton is preferably an oxypropylene skeleton, a oxidized butene skeleton, a pentene oxide skeleton, or an oxyhexene skeleton from the viewpoint of a decrease in IOB of the polyoxygenated C 2-6 alkanediol. The oxidized butene skeleton, the pentene oxide skeleton, or the hexene oxide skeleton is more preferable.

上述聚氧化C2~6烷二醇可以下式(23)：HO-(CmH2mO)n-H (23)(式中、m為2~6之整數)來表示。 The polyoxygenated C 2-6 alkanediol can be represented by the following formula (23): HO-(C m H 2m O) n -H (23) (wherein m is an integer of 2 to 6).

又，本發明者確認，在聚乙二醇(式(23)中， 相當m=2之同聚物)為n≧45(重量平均分子量約超過2,000)之場合，雖滿足約0.00~約0.60之IOB之要件，但即使重量平均分子量超過約4,000之場合，仍不滿足水溶解度之要件。因此，認為(e1)聚氧化C2~6烷二醇中，不包含乙二醇的同聚物，乙二醇應作為與其他之二醇的嵌段共聚物或無規共聚物，包含於(e1)聚氧化C2~6烷二醇。 Moreover, the inventors of the present invention confirmed that when polyethylene glycol (the homopolymer of m=2 in the formula (23)) is n≧45 (weight average molecular weight is more than 2,000), it satisfies about 0.00 to about 0.60. The requirements of the IOB, but even where the weight average molecular weight exceeds about 4,000, the water solubility requirements are not met. Therefore, it is considered that (e 1 ) polyoxygenated C 2-6 alkanediol does not contain a homopolymer of ethylene glycol, and ethylene glycol should be used as a block copolymer or random copolymer with other diols, including (e 1 ) polyoxidized C 2-6 alkanediol.

因此，式(23)之同聚物中，可包含丙二醇、丁 二醇、戊二醇或己二醇的同聚物。 Therefore, the homopolymer of the formula (23) may contain propylene glycol and butyl a homopolymer of a diol, pentanediol or hexanediol.

由以上，式(23)中，m為約3~約6，接著約4~約6更佳、而n為2以上。 From the above, in the formula (23), m is from about 3 to about 6, more preferably from about 4 to about 6, and n is 2 or more.

上述式(23)中，n之值為聚C2~6烷二醇具有約 0.00~約0.60之IOB、約45℃以下之熔點、對25℃之水100g為約0.00~約0.05g之水溶解度的值。 In the above formula (23), the value of n is a poly C 2-6 alkanediol having an IOB of from about 0.00 to about 0.60, a melting point of about 45 ° C or less, and a water of from about 0.00 to about 0.05 g for 100 g of water at 25 ° C. The value of the solubility.

例如在式(23)為聚丙二醇(m=3之同聚物)的場合，n=12的場合，IOB成為0.58。因此，在式(23)為聚丙二醇(m=3之同聚物)的場合，m≧約12的場合，滿足上述IOB的要件。 For example, when the formula (23) is polypropylene glycol (m=3 homopolymer), when n=12, IOB is 0.58. Therefore, when the formula (23) is a polypropylene glycol (m=3 homopolymer), when m≧ is about 12, the requirements of the above IOB are satisfied.

又，在式(21)為聚丁二醇(m=4的同聚物)的場合，n=7之場合，IOB成為0.57。因此，式(23)為聚丁二醇(m=4的同聚物)的場合，n≧約7之場合，滿足上述IOB的要件。 Further, when the formula (21) is polytetramethylene glycol (m=4 homopolymer), when n=7, IOB is 0.57. Therefore, when the formula (23) is polytetramethylene glycol (m=4 homopolymer), when n≧ is about 7, the requirements of the above IOB are satisfied.

由IOB、熔點及水溶解度的觀點，聚氧化 C4~6烷二醇的重量平均分子量，較佳為約200~約10,000、更佳為約250~約8,000、再佳為約250~約5,000之範圍。 The weight average molecular weight of the polyoxy C 4-6 alkanediol is preferably from about 200 to about 10,000, more preferably from about 250 to about 8,000, still more preferably from about 250 to about 5,000, from the viewpoints of IOB, melting point and water solubility. The scope.

又，由IOB、熔點及水溶解度的觀點，聚氧化C3烷二醇，亦即，聚丙二醇的重量平均分子量，較佳為約1,000~約10,000、更佳為約3,000~約8,000、再佳為約4,000~約5,000之範圍。上述重量平均分子量未達約1,000，則水溶解度不符合要件，而重量平均分子量愈大，則尤其有吸收體移動速度及頂部薄片的潔白度提升傾向。 Further, from the viewpoints of IOB, melting point and water solubility, the weight average molecular weight of the polyoxy C 3 alkylene glycol, that is, polypropylene glycol, is preferably from about 1,000 to about 10,000, more preferably from about 3,000 to about 8,000, more preferably. It is in the range of about 4,000 to about 5,000. If the weight average molecular weight is less than about 1,000, the water solubility does not conform to the requirements, and the larger the weight average molecular weight, the higher the moving speed of the absorbent and the whiteness of the top sheet tend to increase.

上述聚氧化C2~6烷二醇的市售品，可舉例如 UNIOL(商標)D-1000，D-1200，D-2000，D-3000，D-4000，PB-500，PB-700，PB-1000及PB-2000(以上、日油股份公司製)。 Commercial products of the above-mentioned polyoxygenated C 2-6 alkanediol include, for example, UNIOL (trademark) D-1000, D-1200, D-2000, D-3000, D-4000, PB-500, PB-700, PB-1000 and PB-2000 (above, manufactured by Nippon Oil Co., Ltd.).

[(e2)聚氧化C2~6烷二醇與至少1個脂肪酸之酯] [(e 2 ) an ester of polyoxygenated C 2-6 alkanediol with at least one fatty acid]

上述聚氧化C2~6烷二醇與至少1個脂肪酸之酯，可舉例如「(e1)聚氧化C2~6烷二醇」之中說明的聚氧化C2~6烷二醇的OH末端的一者或兩者經脂肪酸酯化者，亦即，單酯及二酯。 The above-mentioned polyoxyalkylene alkylene glycol C 2 ~ 6 with at least one ester of a fatty acid includes, for example in "(e 1) polyoxy C 2 ~ 6 alkanediol" described polyoxyalkylene C 2 ~ 6 alkanediols One or both of the OH ends are esterified with fatty acids, that is, monoesters and diesters.

聚氧化C2~6烷二醇與至少1個脂肪酸之酯中 ，欲酯化脂肪酸，可舉例如「(a1)鏈狀烴四醇與至少1個脂肪酸之酯」中所列舉的脂肪酸，亦即，飽和脂肪酸或不飽和脂肪酸，若考量因氧化等而變性的可能性，以飽和脂肪酸為佳。 In the ester of polyoxy C 2-6 alkanediol and at least one fatty acid, the fatty acid to be esterified, for example, the fatty acid listed in "(a 1 ) chain hydrocarbon tetraol and at least one fatty acid ester", That is, a saturated fatty acid or an unsaturated fatty acid is preferably a saturated fatty acid in consideration of the possibility of denaturation by oxidation or the like.

上述聚氧化C2~6烷二醇與脂肪酸之酯的市售品，可舉例如WILBRIDE cp9(日油股份公司製)。 A commercially available product of the above-mentioned ester of a polyoxy-C 2-6 alkanediol and a fatty acid is, for example, WILBRIDE cp9 (manufactured by Nippon Oil Co., Ltd.).

[(e3)聚氧化C2~6烷二醇與至少1個脂肪族1元醇之醚] [(e 3 ) an ether of polyoxygenated C 2-6 alkanediol and at least one aliphatic monohydric alcohol]

上述聚氧化C2~6烷二醇與至少1個脂肪族1元醇之醚，可舉例如「(e1)聚氧化C2~6烷二醇」之中說明的聚氧化C2~6烷二醇的OH末端的一者或兩者經脂肪族1元醇所醚化者，亦即，單醚及二醚。 The above-mentioned polyoxyalkylene alkylene glycol C 2 ~ 6 with at least one of an aliphatic monohydric alcohol ether includes, for example, "(e 1) polyoxy C 2 ~ 6 alkanediol" described in the polyoxyalkylene C 2 ~ 6 One or both of the OH ends of the alkanediol are etherified with an aliphatic monohydric alcohol, that is, a monoether and a diether.

聚氧化C2~6烷二醇與至少1個脂肪族1元醇之醚中，欲醚化的脂肪族1元醇，可舉例如「化合物(B)」中所列舉的脂肪族1元醇。 In the ether of the polyoxygenated C 2 - 6 alkanediol and the at least one aliphatic monohydric alcohol, the aliphatic monohydric alcohol to be etherified may, for example, be an aliphatic monohydric alcohol listed in the "compound (B)". .

[(e4)聚氧化C2~6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯] [(e 4 ) an ester of polyoxygenated C 2-6 alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid]

上述聚氧化C2~6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯中，欲酯化聚氧化C2~6烷二醇，可舉例如「(e1)聚氧化C2~6烷二醇」之中說明的聚氧化C2~6烷二醇。又，欲酯化鏈狀烴四羧酸、鏈狀烴三羧酸、及鏈狀烴二羧酸，可舉例如「(化合物(C)」中所說明者。 In the ester of the polyoxy C 2-6 alkanediol and the chain hydrocarbon tetracarboxylic acid, the chain hydrocarbon tricarboxylic acid, or the chain hydrocarbon dicarboxylic acid, the polyoxy C 2-6 alkanediol may be esterified. among the Examples as "(e 1) polyoxy C 2 ~ 6 alkanediol" described polyoxyalkylene C 2 ~ 6 alkanediol. Further, the chain hydrocarbon tetracarboxylic acid, the chain hydrocarbon tricarboxylic acid, and the chain hydrocarbon dicarboxylic acid are preferably esterified, for example, as described in "(Compound (C)".

上述聚氧化C2~6烷二醇與鏈狀烴四羧酸、鏈 狀烴三羧酸、或鏈狀烴二羧酸之酯除市售品外，可使鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸與氧化C2~6烷二醇在習知條件下進行聚縮合而製造。 The above-mentioned polyoxy C 2-6 alkanediol and an ester of a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid may be a chain hydrocarbon tetracarboxylic acid or a chain, in addition to a commercially available product. The hydrocarbon hydrocarbon tricarboxylic acid or the chain hydrocarbon dicarboxylic acid and the oxidized C 2-6 alkanediol are produced by polycondensation under a known condition.

[(e5)聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀烴三醇 、或鏈狀烴二醇之醚] [(e 5 ) polyoxygenated C 2-6 alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or ether of chain hydrocarbon diol]

上述聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚中，欲醚化的聚氧化C2~6烷二醇，可舉例如「(e1)聚氧化C2~6烷二醇」之中說明的聚氧化C2~6烷二醇。又，欲醚化的鏈狀烴四醇、鏈狀烴三醇、及鏈狀烴二醇，可舉例如「(化合物(A)」中所說明者、例如季戊四醇、甘油、及二醇。 In the ether of the polyoxy C 2-6 alkanediol and the chain hydrocarbon tetraol, the chain hydrocarbon triol or the chain hydrocarbon diol, the polyoxy C 2-6 alkanediol to be etherified may, for example, be mentioned. among "(e 1) polyoxy C 2 ~ 6 alkanediol" described polyoxyalkylene C 2 ~ 6 alkanediol. Further, examples of the chain hydrocarbon tetraol, the chain hydrocarbon triol, and the chain hydrocarbon diol to be etherified include "the compound (A)", for example, pentaerythritol, glycerin, and a diol.

上述聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀 烴三醇、或鏈狀烴二醇之醚的市售品，可舉例如UNILUBE(商標)5TP-300KB，以及UNIOL(商標)TG-3000及TG-4000(日油股份公司製)。 Commercial products of the above-mentioned polyoxy C 2-6 alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol may, for example, be UNILUBE (trademark) 5 TP-300 KB, and UNIOL ( Trademarks) TG-3000 and TG-4000 (made by Nippon Oil Co., Ltd.).

UNILUBE(商標)5TP-300KB為使季戊四醇1莫耳與丙二醇65莫耳與乙二醇5莫耳進行聚縮合的化合物，其IOB為0.39、熔點未達45℃、而水溶解度未達0.05g。 UNILUBE (Trade Mark) 5TP-300KB is a compound which polycondenses pentaerythritol 1 molar with propylene glycol 65 mole and ethylene glycol 5 mole, and has an IOB of 0.39, a melting point of less than 45 ° C, and a water solubility of less than 0.05 g.

Uniol(商標)TG-3000為甘油1莫耳與丙二醇 50莫耳聚縮合之化合物，其IOB為0.42、熔點為未達45℃、水溶解度為未達0.05g、而重量平均分子量約3,000。 Uniol (trademark) TG-3000 is glycerol 1 molar and propylene glycol A 50 molar condensation product having an IOB of 0.42, a melting point of less than 45 ° C, a water solubility of less than 0.05 g, and a weight average molecular weight of about 3,000.

Uniol(商標)TG-4000為甘油1莫耳與丙二醇70莫耳聚縮合之化合物、其IOB為0.40、熔點為未達45℃、水溶解度為未達0.05g、而重量平均分子量約4,000。 Uniol (trademark) TG-4000 is a compound in which glycerol 1 molar is condensed with propylene glycol 70, having an IOB of 0.40, a melting point of less than 45 ° C, a water solubility of less than 0.05 g, and a weight average molecular weight of about 4,000.

上述聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀 烴三醇、或鏈狀烴二醇之醚，又可藉由使鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇與C2~6環氧烷在習知條件下進行加成而製造。 The polyoxy C 2-6 alkanediol and the chain hydrocarbon tetraol, the chain hydrocarbon triol, or the ether of the chain hydrocarbon diol can be further obtained by chain hydrocarbon tetraol, chain hydrocarbon triol, or The chain hydrocarbon diol and C 2-6 alkylene oxide are produced by addition under conventional conditions.

[(F)鏈狀烴] [(F) chain hydrocarbon]

上述鏈狀烴，因上述無機性值為0，IOB為0.00、而水溶解度為約0g，故熔點為約45℃以下者，可含於上述血液改質劑。上述鏈狀烴，可舉例如(f1)鏈狀烷烴、例如直鏈烷烴及分枝鏈烷烴，例如直鏈烷烴之場合，若考量熔點為約45℃以下，大抵含有碳數為22以下者。又，若考量蒸氣壓，大抵含有碳數為13以上者。分枝鏈烷烴之場合，因比直鏈烷烴在同一碳數中，有熔點低之情形，故亦可包含碳數為22以上者。 The chain hydrocarbon may be contained in the blood modifying agent because the inorganic value is 0, the IOB is 0.00, and the water solubility is about 0 g. Therefore, the melting point is about 45 ° C or lower. Examples of the chain hydrocarbons include (f 1 ) chain alkanes, for example, linear alkanes and branched paraffins. For example, in the case of linear alkanes, when the melting point is about 45 ° C or less, the carbon number is 22 or less. . Further, when the vapor pressure is considered, it is likely to contain a carbon number of 13 or more. In the case of a branched paraffin, since the melting point is low in the same carbon number as the linear alkane, it is also possible to include a carbon number of 22 or more.

上述烴之市售品，可舉例如PARLEAM6(日油股份公司)。 The commercial product of the above hydrocarbons may, for example, be PARLEAM6 (Nippon Oil Co., Ltd.).

本發明之血液改質劑與實施例一同詳細考察 ，發現至少具有降低血液黏度及表面張力的作用。吸收性物品欲吸收的經血與一般的血液比較，因含子宮內膜壁等之蛋白質，彼等以血球彼此相連繋之方式作用，血球易成為連續排列的狀態。因此，吸收性物品欲吸收之經血易變得高黏度、頂部薄片為不織布或織布的場合，經血易阻塞在纖維間、著用者易感到黏膩感、而在頂部薄片的表面經血擴散、變得易滲漏。對於此，藉由將本發明之血液改質劑塗佈於頂部薄片，在頂部薄片的纖維間經血不易阻塞、可使經血由頂部薄片迅速移動至吸收體。 The blood modifying agent of the present invention is examined in detail together with the embodiment. It has been found to have at least a function of lowering blood viscosity and surface tension. The menstrual blood to be absorbed by the absorbent article is compared with the general blood, and the blood cells are connected to each other by the proteins such as the endometrial wall, and the blood cells are easily in a state of continuous alignment. Therefore, when the menstrual blood to be absorbed by the absorbent article tends to become highly viscous and the top sheet is non-woven or woven, the menstrual blood tends to block between the fibers, and the user tends to feel sticky, and the blood spreads on the surface of the top sheet. It becomes easy to leak. In this case, by applying the blood modifying agent of the present invention to the top sheet, the menstrual blood between the fibers of the top sheet is not easily blocked, and the menstrual blood can be quickly moved from the top sheet to the absorbent body.

IOB為約0.00~約0.60的本發明之血液改質 劑因有機性高、容易進入血球間，認為可使血球安定化、 血球不易形成連鏈構造。認為本發明之血液改質劑藉由使血球安定化、血球不易形成連鏈構造，吸收體變得易吸收經血。例如已知丙烯酸系高吸收聚合物，亦即在含SAP的吸收性物品，吸收經血，則連續排列的血球包覆SAP表面，SAP變得難以發揮吸收性能，但藉由使血球安定化，SAP變得易發揮吸收性能。又，認為因與紅血球親和性高的血液改質劑保護紅血球膜，紅血球變得不易被破壞。 IOB is a blood modification of the present invention of from about 0.00 to about 0.60 Because of its high organicity and easy entry into the blood cells, it is believed that the blood cells can be stabilized. Blood cells are not easy to form a chain structure. It is considered that the blood modifying agent of the present invention makes it easy to absorb menstrual blood by calming the blood cells and making the blood cells difficult to form a linked structure. For example, an acrylic high-absorbent polymer is known, that is, in an absorbent article containing SAP, which absorbs menstrual blood, the continuously arranged blood cells coat the surface of the SAP, and it becomes difficult for SAP to exert absorption performance, but by stabilizing the blood cells, SAP It becomes easy to exert absorption performance. Further, it is considered that the red blood cell membrane is not easily destroyed by the blood modifying agent having a high affinity with red blood cells to protect the red blood cell membrane.

本發明之血液改質劑以具有約2,000以下的重 量平均分子量為佳、而具有1,000以下的重量平均分子量更佳。重量平均分子量增大，則血液改質劑之黏度變得難以降至適合塗佈的黏度、產生需以溶劑稀釋的情形。又，重量平均分子量增大，則血液改質劑產生黏性、賦予著用者不愉快感之情形。 The blood modifying agent of the present invention has a weight of about 2,000 or less The amount average molecular weight is preferably and the weight average molecular weight of 1,000 or less is more preferable. When the weight average molecular weight is increased, the viscosity of the blood modifying agent becomes difficult to fall to a viscosity suitable for coating, and it is required to be diluted with a solvent. Further, when the weight average molecular weight is increased, the blood modifying agent is sticky and gives the user an unpleasant feeling.

藉由以下的實施例，確認血液改質劑具有使血液的黏度及表面張力下降之機轉。 According to the following examples, it was confirmed that the blood modifying agent has a function of lowering the viscosity and surface tension of blood.

[實施例] [Examples]

以下、舉例說明本發明，但本發明不限於此等例。 Hereinafter, the present invention will be exemplified, but the present invention is not limited to these examples.

[例1] [example 1]

[血液改質劑之數據] [Data of blood modifying agent]

準備市售生理用衛生棉。該生理用衛生棉係由以親水 劑處理的熱風不織布(聚酯及聚乙烯對苯二甲酸酯所構成的複合纖維、坪量：35g/m2)所形成的頂部薄片、熱風不織布(聚酯及聚乙烯對苯二甲酸酯所構成的複合纖維、坪量：30g/m2)所形成的第二薄片、紙漿(坪量：150~450g/m2、中央部較多)、丙烯酸系高吸收聚合物(坪量：15g/m2)及含有作為核心包層之織物的吸收體、經撥水劑處理的側邊薄片、聚乙烯薄膜所構成的背部薄片所形成。 Prepare commercially available sanitary napkins. The sanitary tampon is a top sheet formed by a hot air non-woven fabric treated with a hydrophilic agent (composite fiber composed of polyester and polyethylene terephthalate, and a flat weight: 35 g/m 2 ), and a hot air non-woven fabric (polymerized) a composite fiber composed of an ester and a polyethylene terephthalate, a flat sheet of 30 g/m 2 ), a pulp (powder: 150 to 450 g/m 2 , a large central portion), and acrylic acid It is formed of a high-absorbent polymer (pound amount: 15 g/m 2 ) and a back sheet composed of an absorbent body containing a fabric as a core cladding, a water-repellent-treated side sheet, and a polyethylene film.

以下列舉實驗所使用的血液改質劑。 The blood modifying agents used in the experiments are listed below.

[(a1)鏈狀烴四醇與至少1個脂肪酸之酯] [(a 1 ) an ester of a chain hydrocarbon tetraol with at least one fatty acid]

．UNISTAR H-408BRS，日油股份公司製 . UNISTAR H-408BRS, manufactured by Nippon Oil Co., Ltd.

四2-乙基己烷酸季戊四醇，重量平均分子量：約640 Tetrakilyl tetraethyl 4-hexyl carboxylate, weight average molecular weight: about 640

．UNISTAR H-2408BRS-22，日油股份公司製 . UNISTAR H-2408BRS-22, manufactured by Nippon Oil Co., Ltd.

四2-乙基己烷酸季戊四醇與二2-乙基己烷酸新戊基二醇之混合物(58：42，重量比)，重量平均分子量：約520 Mixture of pentaerythritol tetrakis(2-ethyl)hexane acid and neopentyl glycol di-2-ethylhexaneate (58:42, weight ratio), weight average molecular weight: about 520

[(a2)鏈狀烴三醇與至少1個脂肪酸之酯] [(a 2 ) an ester of a chain hydrocarbon triol with at least one fatty acid]

．Cetiol SB45DEO，Cognis Japan Ltd.製 . Cetiol SB45DEO, manufactured by Cognis Japan Ltd.

脂肪酸為油酸或硬脂酸的甘油與脂肪酸之三酯 Fatty acid is glycerol and fatty acid triester of oleic acid or stearic acid

．SOY42，日油股份公司製 . SOY42, made by Nippon Oil Co., Ltd.

C14之脂肪酸：C16之脂肪酸：C18之脂肪酸：C20之脂肪酸(包含飽和脂肪酸及不飽和脂肪酸之兩者)含有大約為0.2：11：88：0.8重量比的甘油與脂肪酸之三酯，重量平均分子量：880 C 14 fatty acids: C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated and unsaturated fatty acids) contain approximately 0.2:11:88:0.8 by weight of glycerol and fatty acid triesters , weight average molecular weight: 880

．三C2L油脂肪酸甘油酯，日油股份公司製 . Three C2L oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

C8之脂肪酸：C10之脂肪酸：C12之脂肪酸含有大約為37：7：56重量比的甘油與脂肪酸之三酯，重量平均分子量：約570 C 8 fatty acid: C 10 fatty acid: C 12 fatty acid contains about 37:7:56 by weight of glycerol and fatty acid triester, weight average molecular weight: about 570

．三CL油脂肪酸甘油酯，日油股份公司製 . Tri-CL oil fatty acid glyceride, manufactured by Nippon Oil Co., Ltd.

C8之脂肪酸：C12之脂肪酸含有大約為44：56重量比的甘油與脂肪酸之三酯，重量平均分子量：約570 C 8 fatty acid: C 12 fatty acid contains about 44:56 by weight of glycerol and fatty acid triester, weight average molecular weight: about 570

．Panasate 810s，日油股份公司製 . Panasate 810s, manufactured by Nippon Oil Corporation

C8之脂肪酸：C10之脂肪酸含有大約為85：15重量比的甘油與脂肪酸之三酯，重量平均分子量：約480 C 8 fatty acid: C 10 fatty acid contains about 85:15 by weight of glycerol and fatty acid triester, weight average molecular weight: about 480

．Panasate 800，日油股份公司製 . Panasate 800, manufactured by Nippon Oil Corporation

脂肪酸全為辛烷酸(C8)的甘油與脂肪酸之三酯，重量平均分子量：約470 Fatty acid is all octane acid (C 8 ) glycerol and fatty acid triester, weight average molecular weight: about 470

．Panasate 800B，日油股份公司製 . Panasate 800B, manufactured by Nippon Oil Corporation

脂肪酸全為2-乙基己烷酸(C8)的甘油與脂肪酸之三酯，重量平均分子量：約470 The fatty acid is all 2-ethyl hexane acid (C 8 ) glycerol and fatty acid triester, weight average molecular weight: about 470

．NA36，日油股份公司製 . NA36, manufactured by Nippon Oil Co., Ltd.

C16之脂肪酸：C18之脂肪酸：C20之脂肪酸(包含飽和脂肪酸及不飽和脂肪酸之兩者)含有大約為5：92：3重量比的甘油與脂肪酸之三酯，重量平均分子量：約880 C 16 fatty acids: C 18 fatty acids: C 20 fatty acids (including both saturated and unsaturated fatty acids) contain about 5:92:3 by weight of glycerol and fatty acid triesters, weight average molecular weight: about 880

．三椰子油脂肪酸甘油酯，日油股份公司製 . Three coconut oil fatty acid glyceride, manufactured by Nippon Oil Co., Ltd.

C8之脂肪酸：C10之脂肪酸：C12之脂肪酸：C14之脂肪酸：C16之脂肪酸(包含飽和脂肪酸及不飽和脂肪酸之兩者)含有大約為4：8：60：25：3重量比的甘油與脂肪 酸之三酯，重量平均分子量：670 C 8 fatty acids: C 10 fatty acids: C 12 fatty acids: C 14 fatty acids: C 16 fatty acids (including both saturated and unsaturated fatty acids) contain a weight ratio of about 4:8:60:25:3 Glycerol and fatty acid triester, weight average molecular weight: 670

．辛酸二甘油酯，日油股份公司製 . Dioctyl octanoate, manufactured by Nippon Oil Co., Ltd.

脂肪酸為辛烷酸的甘油與脂肪酸之二酯，重量平均分子量：340 Fatty acid is a diester of glycerol and fatty acid of octanoic acid, weight average molecular weight: 340

[(a3)鏈狀烴二醇與至少1個脂肪酸之酯] [(a 3 ) an ester of a chain hydrocarbon diol with at least one fatty acid]

．科母波魯BL，日油股份公司製 . Kemubolu BL, made by Nippon Oil Co., Ltd.

丁二醇的十二烷酸(C12)單酯，重量平均分子量：約270 Butyric acid (C 12 ) monoester of butanediol, weight average molecular weight: about 270

．科母波魯BS，日油股份公司製 . Kemubolu BS, manufactured by Nippon Oil Co., Ltd.

丁二醇的十八烷酸(C18)單酯，重量平均分子量：約350 Octadecanoic acid (C 18 ) monoester of butanediol, weight average molecular weight: about 350

．UNISTAR H-208BRS，日油股份公司製 . UNISTAR H-208BRS, manufactured by Nippon Oil Co., Ltd.

二2-乙基己烷酸新戊基二醇，重量平均分子量：約360 Diethyl 2-ethylhexane acid neopentyl glycol, weight average molecular weight: about 360

[(c2)具有3個羧基的鏈狀烴三羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯] [(c 2 ) an ester of a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid and at least one aliphatic monohydric alcohol]

．O-乙醯基檸檬酸三丁酯，東京化成工業股份公司製 . O-acetyl tributyl tributyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

重量平均分子量：約400 Weight average molecular weight: about 400

[(c3)具有2個羧基的鏈狀烴二羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯] [(c 3 ) an ester of a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid and at least one aliphatic monohydric alcohol]

．己二酸二辛基酯，和光純藥工業製 . Dioctyl adipate, manufactured by Wako Pure Chemical Industries

重量平均分子量：約380 Weight average molecular weight: about 380

[(d3)脂肪酸與脂肪族1元醇之酯] [(d 3 ) ester of fatty acid with aliphatic monohydric alcohol]

．在雷特魯WE20，日油股份公司製 . At Retru WE20, Nippon Oil Co., Ltd.

十二烷酸(C12)與十二醇(C12)之酯，重量平均分子量：約360 Ester of dodecanoic acid (C 12 ) and dodecyl alcohol (C 12 ), weight average molecular weight: about 360

．在雷特魯WE40，日油股份公司製 . At Leitru WE40, made by Nippon Oil Co., Ltd.

十四烷酸(C14)與十二醇(C12)之酯，重量平均分子量：約390 Ester of tetradecanoic acid (C 14 ) and dodecyl alcohol (C 12 ), weight average molecular weight: about 390

[(e1)聚氧化C2~6烷二醇] [(e 1 ) polyoxygenated C 2-6 alkanediol]

．UNIOL D-1000，日油股份公司製 . UNIOL D-1000, manufactured by Nippon Oil Co., Ltd.

聚丙二醇，重量平均分子量：約1,000 Polypropylene glycol, weight average molecular weight: about 1,000

．UNIOL D-1200，日油股份公司製 . UNIOL D-1200, manufactured by Nippon Oil Co., Ltd.

聚丙二醇，重量平均分子量：約1，200 Polypropylene glycol, weight average molecular weight: about 1,200

．UNIOL D-3000，日油股份公司製 . UNIOL D-3000, manufactured by Nippon Oil Co., Ltd.

聚丙二醇，重量平均分子量：約3,000 Polypropylene glycol, weight average molecular weight: about 3,000

．UNIOL D-4000，日油股份公司製 . UNIOL D-4000, manufactured by Nippon Oil Co., Ltd.

聚丙二醇，重量平均分子量：約4,000 Polypropylene glycol, weight average molecular weight: about 4,000

．UNIOL PB500，日油股份公司製 . UNIOL PB500, manufactured by Nippon Oil Co., Ltd.

聚丁二醇，重量平均分子量：約500 Polytetramethylene glycol, weight average molecular weight: about 500

．UNIOL PB700，日油股份公司製 . UNIOL PB700, manufactured by Nippon Oil Co., Ltd.

聚氧化丁烯聚氧化丙二醇，重量平均分子量：約700 Polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700

．UNIOL PB1000R，日油股份公司製 . UNIOL PB1000R, manufactured by Nippon Oil Co., Ltd.

聚丁二醇，重量平均分子量：約1000 Polytetramethylene glycol, weight average molecular weight: about 1000

[(e2)聚氧化C2~6烷二醇與至少1個脂肪酸之酯] [(e 2 ) an ester of polyoxygenated C 2-6 alkanediol with at least one fatty acid]

．WILBRIDE cp9，日油股份公司製 . WILBRIDE cp9, manufactured by Nippon Oil Co., Ltd.

聚丁二醇的兩末端的OH基被十六烷酸(C16)所酯化的化合物，重量平均分子量：約1，150 a compound in which an OH group at both ends of polytetramethylene glycol is esterified with palmitic acid (C 16 ), weight average molecular weight: about 1,150

[(e3)聚氧化C2~6烷二醇與至少1個脂肪酸之醚] [(e 3 ) polyoxygenated C 2-6 alkanediol with at least one fatty acid ether]

．UNILUBE MS-70K，日油股份公司製 . UNILUBE MS-70K, manufactured by Nippon Oil Co., Ltd.

聚丙二醇的硬脂醯基醚，約15之重複單位，重量平均分子量：約1,140 Stearic acid decyl ether of polypropylene glycol, about 15 repeating units, weight average molecular weight: about 1,140

[(e5)聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚] [(e 5 ) polyoxygenated C 2-6 alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or ether of chain hydrocarbon diol]

．UNILUBE 5TP-300KB . UNILUBE 5TP-300KB

藉由於季戊四醇1莫耳加成環氧乙烷5莫耳與環氧丙烷65莫耳所生成的聚氧化乙烯聚氧化丙烯季戊四醇醚，重量平均分子量：4,130 Polyoxyethylene polyoxypropylene pentaerythritol ether formed by pentaerythritol 1 molar addition of ethylene oxide 5 moles and propylene oxide 65 moles, weight average molecular weight: 4,130

．UNIOL TG-3000，日油股份公司製 . UNIOL TG-3000, manufactured by Nippon Oil Co., Ltd.

聚丙二醇的甘油基醚，約16之重複單位，重量平均分子量：約3,000 Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 3,000

．UNIOL TG-4000，日油股份公司製 . UNIOL TG-4000, manufactured by Nippon Oil Co., Ltd.

聚丙二醇的甘油基醚，約16之重複單位，重量平 均分子量：約4,000 Glyceryl ether of polypropylene glycol, about 16 repeating units, weight flat Average molecular weight: about 4,000

[(f1)鏈狀烷烴] [(f 1 )chain alkane]

．PARLEAM6，日油股份公司製 . PARLEAM6, manufactured by Nippon Oil Co., Ltd.

藉由使流動異石蠟、異丁烯及n-丁烯共聚合，接著加成氫而生成的分枝鏈烴、聚合度：約5~約10，重量平均分子量：約330 a branched chain hydrocarbon formed by copolymerizing a flowing isoparaffin, isobutylene and n-butene, followed by addition of hydrogen, a degree of polymerization: about 5 to about 10, and a weight average molecular weight of about 330

[其他的材料] [other materials]

．NA50，日油股份公司製 . NA50, manufactured by Nippon Oil Co., Ltd.

使NA36加成氫，降低來自原料之不飽和脂肪酸的雙鍵比率的甘油與脂肪酸之三酯，重量平均分子量：約880 Adding hydrogen to NA36, reducing the double bond ratio of glycerol and fatty acid from the unsaturated fatty acid of the raw material, weight average molecular weight: about 880

．(辛酸/癸酸)單甘油酯，日油股份公司製 . (octanoic acid/capric acid) monoglyceride, manufactured by Nippon Oil Co., Ltd.

辛烷酸(C8)及癸烷酸(C10)含有大約為85：15重量比的甘油與脂肪酸之單酯，重量平均分子量：約220 Octanoic acid (C 8 ) and decanoic acid (C 10 ) contain a monoester of glycerol and fatty acid in a weight ratio of about 85:15, weight average molecular weight: about 220

．Monomuls 90-L2月桂酸單甘油酯，Cognis Japan Ltd.製 . Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan Ltd.

．檸檬酸異丙酯，東京化成工業股份公司製 . Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

重量平均分子量：約230 Weight average molecular weight: about 230

．蘋果酸二異硬脂醯基酯 . Diisostearyl malate

重量平均分子量：約640 Weight average molecular weight: about 640

．UNIOL D-400，日油股份公司製 . UNIOL D-400, manufactured by Nippon Oil Co., Ltd.

聚丙二醇，重量平均分子量：約400 Polypropylene glycol, weight average molecular weight: about 400

．PEG1500，日油股份公司製 . PEG1500, made by Nippon Oil Co., Ltd.

聚乙二醇，重量平均分子量：約1,500~約1,600 Polyethylene glycol, weight average molecular weight: about 1,500 ~ about 1,600

．NONION S-6，日油股份公司製 . NONION S-6, manufactured by Nippon Oil Co., Ltd.

聚氧化乙烯單硬脂酸酯，約7之重複單位、重量平均分子量：約880 Polyoxyethylene monostearate, about 7 repeat units, weight average molecular weight: about 880

．WILBRIDE s753，日油股份公司製 . WILBRIDE s753, manufactured by Nippon Oil Co., Ltd.

聚氧化乙烯聚氧化丙烯聚氧化丁烯甘油，重量平均分子量：約960 Polyoxyethylene polyoxypropylene polyoxybutylene glycerol, weight average molecular weight: about 960

．UNIOL TG-330，日油股份公司製 . UNIOL TG-330, manufactured by Nippon Oil Co., Ltd.

聚丙二醇的甘油基醚，約6之重複單位，重量平均分子量：約330 Glyceryl ether of polypropylene glycol, repeating unit of about 6, weight average molecular weight: about 330

．UNIOL TG-1000，日油股份公司製 . UNIOL TG-1000, manufactured by Nippon Oil Co., Ltd.

聚丙二醇的甘油基醚，約16之重複單位，重量平均分子量：約1,000 Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 1,000

．UNILUBE DGP-700，日油股份公司製 . UNILUBE DGP-700, manufactured by Nippon Oil Co., Ltd.

聚丙二醇的二甘油基醚，約9之重複單位，重量平均分子量：約700 Diglyceryl ether of polypropylene glycol, repeating unit of about 9, weight average molecular weight: about 700

．UNIOX HC60，日油股份公司製 . UNIOX HC60, manufactured by Nippon Oil Co., Ltd.

聚氧化乙烯硬化蓖麻油，重量平均分子量：約3,570 Polyoxyethylene hardened castor oil, weight average molecular weight: about 3,570

．凡士林，Cognis Japan Ltd.製 . Vaseline, manufactured by Cognis Japan Ltd.

來自石油的烴、半固形 Hydrocarbon, semi-solid from petroleum

上述試料的IOB，熔點及水溶解度如下述表2所示。 The IOB of the above sample, the melting point and the water solubility are shown in Table 2 below.

又，水溶解度依照上述方法測定為於100g之脫鹽水中添加20.0g，24小時後溶解的試料評估為「20g<」、而在100g之脫鹽水中、溶解0.05g但不溶解1.00g的試料評估為0.05~1.00g。 Further, the water solubility was measured by adding 20.0 g to 100 g of demineralized water according to the above method, and the sample dissolved after 24 hours was evaluated as "20 g <", and in 100 g of demineralized water, the sample dissolved in 0.05 g but not dissolved in 1.00 g was evaluated as 0.05~1.00g.

又，關於熔點，「<45」為熔點未達45℃。 Further, regarding the melting point, "<45" has a melting point of less than 45 °C.

將上述生理用衛生棉的頂部薄片的肌膚接觸 面以上述血液改質劑塗佈。將各血液改質劑，血液改質劑在室溫為液體之場合直接、而血液改質劑在室溫為固體之場合加熱至熔點+20℃，接著，使用控制接縫HMA槍，使各血液改質劑微粒化，在頂部薄片的肌膚接觸面的全體，以坪量約成為5g/m2之方式塗佈。 The skin contact surface of the top sheet of the above sanitary napkin is coated with the above blood modifying agent. Each blood modifying agent and blood modifying agent are directly used at room temperature, and the blood modifying agent is heated to a melting point of +20 ° C when the room temperature is solid, and then, using a control seam HMA gun, each The blood modifying agent was micronized, and the entire skin contact surface of the top sheet was applied so as to have a basis weight of about 5 g/m 2 .

圖12為頂部薄片含有三C2L油脂肪酸甘油酯 的生理用衛生棉(No.2-5)中頂部薄片的肌膚接觸面的電子顯微鏡照片。由圖12可明白，三C2L油脂肪酸甘油酯以微粒子狀附著於纖維的表面。 Figure 12 is a top sheet containing three C2L oil fatty acid glycerides An electron micrograph of the skin contact surface of the top sheet in the sanitary napkin (No. 2-5). As can be understood from Fig. 12, the tri-C2L oil fatty acid glyceride adhered to the surface of the fiber in the form of fine particles.

依上述操作手法，測定回滲率與吸收體移動速度。結果如下述表2所示。 According to the above operation method, the rewet rate and the moving speed of the absorber are measured. The results are shown in Table 2 below.

[試驗方法] [experiment method]

在含各血液改質劑之頂部薄片上，放置開孔的丙烯酸板(200mm×100mm，125g，在中央開有40mm×10mm之穴)，由上述穴使37±1℃之馬EDTA血(馬之血液中，為了防止凝結，添加有乙二胺四乙酸(以下、稱「EDTA」)者)3g，使用吸量管滴下(第1次)，1分鐘後，使37±1℃之馬 EDTA血3g從丙烯酸板之穴，以吸量管再度滴下(第2次)。 On the top sheet containing each blood modifying agent, an open acrylic plate (200 mm × 100 mm, 125 g, with a hole of 40 mm × 10 mm in the center) was placed, and the horse was EDTA blood (37 ± 1 ° C) from the above hole. In order to prevent coagulation, 3 g of ethylenediaminetetraacetic acid (hereinafter referred to as "EDTA") was added to the blood, and the mixture was dropped using a pipette (first time). After 1 minute, the horse was 37 ± 1 °C. 3 g of EDTA blood was dropped from the acupuncture point of the acrylic plate and the pipette was again dropped (the second time).

在第2次的血液的滴下後，即刻除去上述丙 烯酸板，於滴下血液的場所，放置濾紙(ADVANTEC東洋股份公司定性濾紙No.2，50mm×35mm)10枚，從其上使壓力成為30g/cm2之方式放置重物。1分鐘後，將上述濾紙取出，用以下的式算出「回滲率」。 Immediately after the dropping of the second blood, the acrylic plate was removed, and 10 pieces of filter paper (ADVANTEC Toyo Co., Ltd. qualitative filter paper No. 2, 50 mm × 35 mm) were placed in the place where the blood was dropped, and the pressure was 30 g/ Place the weight in the way of cm 2 . After 1 minute, the filter paper was taken out, and the "reverse bleed rate" was calculated by the following formula.

回滲率(%)=100×(試驗後之濾紙質量-當初的濾紙質量)/6 Infiltration rate (%) = 100 × (quality of filter paper after test - original filter paper quality) / 6

進而、在回滲率評估外，測定第2次的血液 的滴下後，血液從頂部薄片移動至吸收體的時間亦即「吸收體移動速度」。上述吸收體移動速度係指於吸收體投入血液後至頂部薄片的表面及內部看不見血液的紅色為止的時間。 Furthermore, in addition to the evaluation of the rate of infiltration, the second blood is measured. After the dripping, the time during which the blood moves from the top sheet to the absorber is the "absorbent moving speed". The moving speed of the absorbent body refers to the time from when the absorbent body is put into the blood until the red color of the blood is not visible on the surface of the top sheet and inside.

回滲率與吸收體移動速度的結果如以下的表2所示。 The results of the rewet ratio and the moving speed of the absorbent body are shown in Table 2 below.

接著，吸收體移動速度的試驗後之頂部薄片的肌膚接觸面的潔白度用以下的基準以目視評估。 Next, the whiteness of the skin contact surface of the top sheet after the test of the moving speed of the absorbent body was visually evaluated by the following criteria.

◎：血液之紅色幾乎不殘留，無法區分血液存在的場所與不存在的場所 ◎: The red color of the blood hardly remains, and it is impossible to distinguish between the place where the blood exists and the place where it does not exist.

○：血液之紅色雖有若干殘留，不易區分血液存在的場所與不存在的場所 ○: Although there are some residues in the red color of the blood, it is difficult to distinguish between the place where the blood exists and the place where it does not exist.

△：血液之紅色有若干殘留，可知血液存在的場所 △: There are some residues in the red color of the blood, and the place where the blood exists is known.

×：血液之紅色直接殘留 ×: The red color of the blood directly remains

結果一併如下述表2所示。 The results are shown in Table 2 below.

在不具有血液改質劑的場合，回滲率為 22.7%，而吸收體移動速度雖超過60秒，甘油與脂肪酸之三酯皆回滲率在7.0%以下，而吸收體移動速度在8秒以下，故可知吸收性能被大幅改善。但是，甘油與脂肪酸之三酯中，在熔點超過45℃的NA50，未見到吸收性能大幅改善。 In the case of no blood modifying agent, the rate of reversion is 22.7%, and the absorption speed of the absorbent body exceeds 60 seconds, and the glycerin and fatty acid triesters have a back bleed rate of 7.0% or less, and the absorbent body has a moving speed of 8 seconds or less, so that the absorption performance is greatly improved. However, in the triester of glycerin and fatty acid, at the NA50 having a melting point exceeding 45 ° C, no significant improvement in the absorption performance was observed.

同樣地，可知在具有約0.00~約0.60之IOB 、約45℃以下之熔點、對25℃之水100g為約0.00~約0.05g之水溶解度的血液改質劑，吸收性能大幅被改善。 Similarly, it can be seen that there is an IOB of about 0.00 to about 0.60. A blood modifying agent having a melting point of about 45 ° C or less and a water solubility of about 100 to about 0.05 g for 100 g of water at 25 ° C greatly improves the absorption performance.

[例2] [Example 2]

關於動物之各種血液，依上述操作手法，評估回滲率。實驗中可使用的血液如以下。 Regarding the various blood types of animals, the rate of rewet is evaluated according to the above operation method. The blood that can be used in the experiment is as follows.

[動物種] [Animal species]

(1)人 (1 person

(2)馬 (2) Horse

(3)羊 (3) sheep

[血液種] [blood species]

．脫纖維血：採取血液後，與玻璃珠一起在三角燒瓶內攪拌約5分鐘者 . Defibration: After taking blood, stir it in a conical flask with glass beads for about 5 minutes.

．EDTA血：靜脈血65mL中添加12%EDTA．2K生理食鹽液0.5mL者 . EDTA blood: Add 12% EDTA to venous blood 65mL. 2K physiological saline solution 0.5mL

[分畫] [Division]

血清或血漿：各自使脫纖維血或EDTA血在室溫下以約1900G進行10分鐘離心分離後之上清 Serum or plasma: each defibrinated blood or EDTA blood was centrifuged at room temperature for about 10 minutes at room temperature for 10 minutes.

血球：從血液將血清除去，使殘渣以磷酸緩衝生理食鹽液(PBS)進行2次洗淨，接著加入除去血清分的磷酸緩衝生理食鹽液者 Blood cells: The serum is removed from the blood, and the residue is washed twice with phosphate buffered physiological saline (PBS), followed by phosphate buffered physiological saline solution containing serum.

三C2L油脂肪酸甘油酯以坪量約成為5g/m2之方式塗佈以外，與例2同樣地製造吸收性物品，對上述各種血液，評估回滲率。對各血液進行測定3次，採用其平均值。 An absorbent article was produced in the same manner as in Example 2 except that the amount of the three C2L oil fatty acid glycerides was about 5 g/m 2 , and the rewet ratio was evaluated for each of the above blood. Each blood was measured three times, and the average value was used.

結果如下述表3所示。 The results are shown in Table 3 below.

與在例2得到的馬EDTA血同樣之傾向在人及羊之血液亦可得到。又，脫纖維血及EDTA血中亦觀察到同樣傾向。 The same tendency as the horse EDTA blood obtained in Example 2 was also obtained in the blood of humans and sheep. Also, the same tendency was observed in defibrinated blood and EDTA blood.

[例3] [Example 3]

[血液保留性的評估] [Evaluation of blood retention]

評估含血液改質劑的頂部薄片與不含血液改質劑的頂部薄片中的血液保留性。 The blood retention in the top sheet containing the blood modifying agent and the top sheet containing no blood modifying agent was evaluated.

[試驗方法] [experiment method]

(1)在熱風不織布(聚酯及聚乙烯對苯二甲酸酯所構成的複合纖維、坪量：35g/m2)所形成的頂部薄片的肌膚接 觸面，將三C2L油脂肪酸甘油酯使用控制接縫HMA槍進行微粒化，以坪量成為約5g/m2之方式進行塗佈。又，為了比較，亦準備不塗佈三C2L油脂肪酸甘油酯者。接著，將塗佈有三C2L油脂肪酸甘油酯的頂部薄片與未塗佈的頂部薄片兩者，切為0.2g之大小，正確測定無菌細胞過濾蓋管+頂部薄片的質量(a)。 (1) In the skin contact surface of the top sheet formed by hot air non-woven fabric (composite fiber composed of polyester and polyethylene terephthalate, floor weight: 35 g/m 2 ), three C2L oil fatty acid glyceride was used. The control joint HMA gun was micronized and applied in such a manner that the basis weight became about 5 g/m 2 . Further, for comparison, those who do not apply the tri-C2L oil fatty acid glyceride are also prepared. Next, both the top sheet coated with the tri-C2L oil fatty acid glyceride and the uncoated top sheet were cut to a size of 0.2 g, and the mass (a) of the sterile cell filtration cap tube + top sheet was correctly determined.

(2)使馬EDTA血約2mL由皮膚接觸面側添加 ，靜置1分鐘。 (2) Add about 2 mL of horse EDTA blood from the skin contact side , let stand for 1 minute.

(3)將無菌細胞過濾蓋管設置於離心管，進行低速離心，將多餘的馬EDTA血除去。 (3) The sterile cell filtration cap tube was placed in a centrifuge tube, and subjected to low-speed centrifugation to remove excess horse EDTA blood.

(4)測定含有無菌細胞過濾蓋管+馬EDTA血之頂部薄片的重量(b)。 (4) Determine the weight (b) of the top sheet containing the sterile cell filter cap + horse EDTA blood.

(5)依據下式，算出頂部薄片每1g之當初吸收量(g)。 (5) The initial absorption amount (g) per 1 g of the top sheet was calculated according to the following formula.

當初吸收量=[重量(b)-重量(a)]/0.2 Initial absorption = [weight (b) - weight (a)] / 0.2

(6)將無菌細胞過濾蓋管再設置於離心管，室溫下以約1200G進行1分鐘離心分離。 (6) The sterile cell filtration cap tube was further placed in a centrifuge tube, and centrifuged at about 1200 G for 1 minute at room temperature.

(7)測定含有無菌細胞過濾蓋管+馬EDTA血之頂部薄片的重量(c)。 (7) The weight (c) of the top sheet containing the sterile cell filter cap + horse EDTA blood was measured.

(8)依據下式，算出頂部薄片每1g之試驗後吸收量(g)。 (8) The amount of absorption (g) per 1 g of the top sheet after the test was calculated according to the following formula.

試驗後吸收量=[重量(c)-重量(a)]/0.2 Absorption after test = [weight (c) - weight (a)] / 0.2

(9)依據下式算出血液保留率(%)。 (9) The blood retention rate (%) was calculated according to the following formula.

血液保留率(%)=100×試驗後吸收量/當初吸收量 Blood retention rate (%) = 100 × absorption after test / initial absorption

又，測定進行3次，採用其平均值。 Further, the measurement was carried out three times, and the average value thereof was used.

結果如下述表4所示。 The results are shown in Table 4 below.

暗示含有血液改質劑的頂部薄片血液保留性 低、吸收血液後，可迅速移動至吸收體。 Implied blood retention of the top sheet containing the blood modifying agent Low, after absorbing blood, it can move quickly to the absorber.

[例4] [Example 4]

[含有血液改質劑的血液的黏性] [Voice of blood containing blood modifying agent]

將含有血液改質劑的血液的黏性使用Rheometric Expansion System ARES(Rheometric Scientific，Inc)測定。在馬脫纖維血中添加Panasate810s2質量%，輕輕地攪拌形成試料，於直徑50mm之平行板放置試料，間隙為100μm，在37±0.5℃測定黏度。因為平行板，雖未對試料施加均勻剪斷速度，機器表示的平均剪斷速度為10s-1。 The viscosity of blood containing a blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc). The mass% of Panasate 810s was added to the horse's fiber, and the sample was gently stirred to form a sample. The sample was placed in a parallel plate having a diameter of 50 mm, and the gap was 100 μm, and the viscosity was measured at 37 ± 0.5 °C. Because of the parallel plate, although the uniform shear rate was not applied to the sample, the average shear rate indicated by the machine was 10 s -1 .

含2質量%Panasate810s之馬脫纖維血的黏度 為5.9mPa．s，另一方面、不含血液改質劑的馬脫纖維血的黏度為50.4mPa．s。因此，可知含2質量%Panasate810s之馬脫纖維血，與不含血液改質劑場合比較，下降約90%黏度。 Viscosity of horse defibrinated blood containing 2% by mass of Panasate 810s It is 5.9mPa. s, on the other hand, the viscosity of the horse hair fiber without blood modifying agent is 50.4mPa. s. Therefore, it was found that the horse defibrinated blood containing 2% by mass of Panasete 810s decreased by about 90% in comparison with the case where the blood modifying agent was not contained.

血液已知含有血球等之成分，且具有搖變性之性質， 但認為本發明的血液改質劑在低黏度域可使血液的黏度下降。認為藉由使血液的黏度下降，可使吸收的經血快速由頂部薄片移動至吸收體。 The blood is known to contain components such as blood cells, and has the property of shaking. However, it is considered that the blood modifying agent of the present invention can lower the viscosity of blood in a low viscosity domain. It is believed that by reducing the viscosity of the blood, the absorbed menstrual blood can be quickly moved from the top sheet to the absorber.

[例5] [Example 5]

[含有血液改質劑的血液的顯微鏡照片] [Micrograph of blood containing blood modifying agent]

將健康自願者的經血採集於保鮮膜上，在其一部份，使分散於10倍質量之磷酸緩衝生理食鹽水的Panasate810s以Panasate810s濃度成為1質量%之方式添加。將經血滴至載玻片，並蓋上蓋玻片，以光學顯微鏡觀察紅血球的狀態。不含血液改質劑的經血之顯微鏡照片如圖13(a)，而含Panasate 810s的經血之顯微鏡照片如圖13(b)所示。 The menstrual blood of the healthy volunteers was collected on the wrap film, and Panastate 810s dispersed in 10 times by mass of phosphate buffered physiological saline was added in such a manner that the concentration of Panaseate 810s was 1% by mass. The menstrual blood was dripped onto the slide glass, and the coverslip was covered, and the state of the red blood cells was observed with an optical microscope. The photomicrograph of the menstrual blood containing no blood modifying agent is shown in Fig. 13(a), and the photomicrograph of the menstrual blood containing Panasate 810s is shown in Fig. 13(b).

由圖13可知雖然在不含血液改質劑的經血， 形成紅血球連續排列等之集合塊，但在含Panasate810s之經血，紅血球各自安定地分散。因此，暗示血液改質劑在血液中有使紅血球安定化之作用。 As can be seen from Fig. 13, although in the menstrual blood containing no blood modifying agent, A collection block in which red blood cells are continuously arranged, etc., but in menstrual blood containing Panasate 810s, the red blood cells are stably dispersed. Therefore, it is suggested that the blood modifying agent has a function of calming red blood cells in the blood.

[例6] [Example 6]

[含有血液改質劑的血液的表面張力] [Surface tension of blood containing blood modifying agent]

將含有血液改質劑的血液的表面張力使用協和界面科學公司製接觸角計Drop Master500，以垂滴法進行測定。表面張力係於羊脫纖維血中，添加特定量之血液改質劑，並充分搖動後測定。 The surface tension of the blood containing the blood modifying agent was measured by a drip method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension is applied to the sheep defibrinated blood, and a specific amount of the blood modifying agent is added and measured after shaking sufficiently.

測定雖以機器自動進行，而表面張力γ係藉由以下的式求出(圖14作為參考)。 The measurement was automatically performed by a machine, and the surface tension γ was obtained by the following formula (see FIG. 14 for reference).

γ=g×ρ×(de)2×1/H γ=g×ρ×(de) 2 ×1/H

g：重力常數 g: gravity constant

1/H：由ds/de所求出的修正項 1/H: correction term determined by ds/de

ρ：密度 ρ: density

de：最大直徑 De: maximum diameter

ds：由滴下端僅上升de的位置之直徑 Ds: the diameter of the position where only the de is raised by the drop end

密度ρ係依據J IS K 2249-1995的「密度試驗方法及密度．質量．容量換算表」之5.振動式密度試驗方法，用以下表5所示之溫度進行測定。 The density ρ is measured according to the vibration density test method of "Density Test Method and Density, Mass and Capacity Conversion Table" of JIS K 2249-1995, and is measured at the temperature shown in Table 5 below.

測定係使用京都電子工業股份公司之DA-505。 The measurement was performed using DA-505 of Kyoto Electronics Industry Co., Ltd.

結果如表5所示。 The results are shown in Table 5.

表5可知，血液改質劑具有對25℃之水100g為約0.00~約0.05g之水溶解度亦可明白，雖對水之溶解性非常低但可使血液之表面張力降低。 As can be seen from Table 5, the blood modifying agent has a water solubility of about 0.00 to about 0.05 g per 100 g of water at 25 ° C, and the solubility in water is extremely low, but the surface tension of blood can be lowered.

認為藉由使血液的表面張力下降，吸收的血液不保留於頂部薄片的纖維間，而可快速移動至吸收體。 It is considered that by lowering the surface tension of blood, the absorbed blood does not remain between the fibers of the top sheet, and can be quickly moved to the absorber.

Claims (12)

一種吸收性物品，其係具備液體透過性薄片、液體不透過性薄片、在前述液體透過性薄片及前述液體不透過性薄片間所設置的吸收體，其特徵係前述液體透過性薄片在接受液體的供給之液體被供給領域具備高剛性領域與低剛性領域，前述高剛性領域具有在與前述吸收性物品的長度方向交叉方向延伸設置、略平行並列設置的略直線狀的第1領域，與在與前述第1領域交叉方向延伸設置、略平行並列設置的略直線狀的第2領域，且藉由前述第1領域與前述第2領域之交叉，前述高剛性領域形成為網孔狀，於各網孔內側形成前述低剛性領域，而前述低剛性領域具備可伸展的蛇腹部，前述低剛性領域具有其剛性以比前述高剛性領域的剛性低之方式所形成的液體透過孔。 An absorbent article comprising a liquid permeable sheet, a liquid impermeable sheet, and an absorbent body provided between the liquid permeable sheet and the liquid impermeable sheet, wherein the liquid permeable sheet is in a liquid receiving state The liquid supply region of the supply includes a high-rigidity field and a low-rigidity field, and the high-rigidity field has a first linear field which is slightly linearly arranged in a direction intersecting the longitudinal direction of the absorbent article and arranged in parallel. In the second field which is slightly linear in the direction in which the first field is extended in the direction of the first direction and which is arranged in parallel, and the intersection of the first field and the second field, the high rigidity region is formed in a mesh shape. The inside of the mesh forms the aforementioned low-rigidity field, and the low-rigidity field has an extensible snake abdomen, and the low-rigidity field has a liquid permeation hole formed in such a manner that the rigidity is lower than the rigidity of the high-rigidity field. 如請求項1中記載之吸收性物品，其中，前述第1領域不具有液體透過孔。 The absorbent article according to claim 1, wherein the first field does not have a liquid permeation hole. 如請求項1中記載之吸收性物品，其中，前述第2領域不具有液體透過孔。 The absorbent article according to claim 1, wherein the second field does not have a liquid permeation hole. 如請求項1中記載之吸收性物品，其中，前述蛇腹部在前述吸收性物品的長度方向延伸設置、在前述吸收性物品的寬度方向並列設置，且具有沿著前述寬度方向的斷面為波浪狀之山摺部及谷摺部。 The absorbent article according to claim 1, wherein the snake belly extends in the longitudinal direction of the absorbent article, is arranged side by side in the width direction of the absorbent article, and has a wave section along the width direction. The shape of the mountain folds and valley folds. 如請求項4中記載之吸收性物品，其中，前述液 體透過孔形成於前述山摺部及谷摺部的側面部。 An absorbent article according to claim 4, wherein the liquid is The body through hole is formed in the side surface portion of the mountain fold portion and the valley fold portion. 如請求項4中記載之吸收性物品，其中，前述液體透過孔形成於前述山摺部的最上部或前述谷摺部的最下部。 The absorbent article according to claim 4, wherein the liquid permeation hole is formed at an uppermost portion of the mountain fold portion or a lowermost portion of the valley fold portion. 如請求項1記載之吸收性物品，其中，在前述液體被供給領域的周緣部形成壓縮溝。 The absorbent article according to claim 1, wherein the compression groove is formed in a peripheral portion of the liquid supply region. 如請求項1~7中任1項記載之吸收性物品，其中，前述頂部薄片含有具有0.00~0.60之IOB、45℃以下之熔點、對25℃之水100g為0.00~0.05g之水溶解度之血液改質劑。 The absorbent article according to any one of claims 1 to 7, wherein the top sheet contains an IOB of 0.00 to 0.60, a melting point of 45 ° C or less, and a water solubility of 0.00 to 0.05 g for 100 g of water at 25 ° C. Blood modifier. 如請求項8中記載之吸收性物品，其中，前述血液改質劑為由下述(i)~(iii)：(i)烴；(ii)具有(ii-1)烴部分、與(ii-2)前述烴部分的C-C單鍵間***的羰基(-CO-)及氧基(-O-)所成群中所選出的一個或複數個相同或相異的基之化合物；及(iii)具有(iii-1)烴部分、與(iii-2)於前述烴部分的C-C單鍵間***的羰基(-CO-)及氧基(-O-)所成群中所選出的一個或複數個相同或相異的基、與(iii-3)取代前述烴部分的氫原子的羧基(-COOH)及羥基(-OH)所成群中所選出的一個或複數個相同或相異的基之化合物；以及彼等之任意組合所構成的群中選出，在此，(ii)或(iii)之化合物中，在***2個以上氧基的場合，各氧基不相鄰。 The absorbent article according to claim 8, wherein the blood modifying agent is composed of (i) to (iii): (i) hydrocarbon; (ii) having (ii-1) hydrocarbon portion, and (ii) -2) a compound of one or more of the same or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) interposed between the CC single bonds of the aforementioned hydrocarbon moiety; and (iii) a one selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) interposed between (iii-1) a hydrocarbon moiety and (iii-2) a CC single bond of the aforementioned hydrocarbon moiety a plurality of identical or different groups, one or a plurality of identical or different selected from the group consisting of (iii-3) a carboxyl group (-COOH) and a hydroxyl group (-OH) substituted for a hydrogen atom of the aforementioned hydrocarbon moiety In the compound of (ii) or (iii), when two or more oxy groups are inserted, each oxy group is not adjacent. 如請求項8記載之吸收性物品，其中，前述血液改質劑為由下述(i’)~(iii’)：(i’)烴；(ii’)具有(ii’-1)烴部分、與(ii’-2)於前述烴部分的C-C單鍵間***的羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結的化合物；及(iii’)具有(iii’-1)烴部分、與(iii’-2)於前述烴部分的C-C單鍵間***的羰基鍵結(-CO-)、酯鍵結(-COO-)、碳酸酯鍵結(-OCOO-)、及醚鍵(-O-)所成群中所選出的一個或複數個相同或相異的鍵結、與(iii’-3)取代前述烴部分的氫原子的羧基(-COOH)及羥基(-OH)所成群中所選出的一個或複數個相同或相異的基之化合物；以及彼等之任意組合所構成的群中選出，在此，(ii’)或(iii’)之化合物中，在***2個以上的相同或相異的鍵結場合，各鍵結不相鄰。 The absorbent article according to claim 8, wherein the blood modifying agent is (i') to (iii'): (i') hydrocarbon; (ii') has (ii'-1) hydrocarbon portion And (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond inserted between the CC single bonds of the aforementioned hydrocarbon moiety (-O-) one or more of the same or different bonded compounds selected in the group; and (iii') having (iii'-1) a hydrocarbon moiety, and (iii'-2) in the foregoing a group of carbonyl bond (-CO-), ester bond (-COO-), carbonate bond (-OCOO-), and ether bond (-O-) inserted between CC single bonds of a hydrocarbon moiety One or a plurality of identical or different linkages selected, and one or more selected from the group consisting of (iii'-3) a group of a carboxyl group (-COOH) and a hydroxyl group (-OH) which replace a hydrogen atom of the aforementioned hydrocarbon moiety a compound of the same or different base; and a combination of any combination thereof, wherein, in the compound of (ii') or (iii'), two or more identical or different ones are inserted. In the case of bonding, the bonds are not adjacent. 如請求項8記載之吸收性物品，其中，前述血液改質劑為由下述(A)~(F)：(A)(A1)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的2~4個羥基的化合物與(A2)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的1個羧基的化合物之酯；(B)(B1)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的2~4個羥基的化合物與(B2)具有鏈狀烴部分、 與取代前述鏈狀烴部分的氫原子的1個羥基的化合物之醚；(C)(C1)含有鏈狀烴部分與取代前述鏈狀烴部分的氫原子的2~4個羧基之羧酸、羥基酸、烷氧基酸或側氧酸與(C2)具有鏈狀烴部分、與取代前述鏈狀烴部分的氫原子的1個羥基的化合物之酯；(D)具有鏈狀烴部分、與前述鏈狀烴部分的C-C單鍵間***的醚鍵(-O-)、羰基鍵結(-CO-)、酯鍵結(-COO-)、及碳酸酯鍵結(-OCOO-)所成群中選出的任一個鍵結的化合物；(E)聚氧化C2~6烷二醇、或其烷基酯或者烷基醚；及(F)鏈狀烴；以及彼等之任意組合所成群中所選出。 The absorbent article according to claim 8, wherein the blood modifying agent has a chain hydrocarbon portion and a hydrogen substituted for the chain hydrocarbon portion (A) to (F): (A) (A1) a compound having 2 to 4 hydroxyl groups of an atom and (A2) an ester having a chain hydrocarbon moiety and a compound which substitutes one carboxyl group of a hydrogen atom of the chain hydrocarbon moiety; (B) (B1) has a chain hydrocarbon moiety; a compound having 2 to 4 hydroxyl groups which replaces a hydrogen atom of the aforementioned chain hydrocarbon moiety; and (B2) an ether having a chain hydrocarbon moiety and a hydroxyl group which replaces a hydrogen atom of the aforementioned chain hydrocarbon moiety; (C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a oxo acid having a chain hydrocarbon moiety and a hydrogen atom of 2 to 4 groups which replaces the hydrogen atom of the chain hydrocarbon moiety, and (C2) having a chain hydrocarbon moiety, and An ester of a compound which replaces one hydroxyl group of a hydrogen atom of the aforementioned chain hydrocarbon moiety; (D) an ether bond (-O-) having a chain hydrocarbon moiety interposed between a CC single bond of the aforementioned chain hydrocarbon moiety, a carbonyl bond a compound selected from the group consisting of a knot (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-); (E) a polyoxygenated C 2-6 alkane Alcohol, or its alkyl ester or Alkyl ethers; and (F) a hydrocarbon chain; and any combination of their being in the selected groups. 如請求項8記載之吸收性物品，其中，前述血液改質劑為由(a1)鏈狀烴四醇與至少1個脂肪酸之酯、(a2)鏈狀烴三醇與至少1個脂肪酸之酯、(a3)鏈狀烴二醇與至少1個脂肪酸之酯、(b1)鏈狀烴四醇與至少1個脂肪族1元醇之醚、(b2)鏈狀烴三醇與至少1個脂肪族1元醇之醚、(b3)鏈狀烴二醇與至少1個脂肪族1元醇之醚、(c1)具有4個羧基的鏈狀烴四羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、(c2)具有3個羧基的鏈狀烴三羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇之酯、(c3)具有2個羧基的鏈狀烴二羧酸、羥基酸、烷氧基酸或側氧酸與至少1個脂肪族1元醇 之酯、(d1)脂肪族1元醇與脂肪族1元醇之醚、(d2)二烷基酮、(d3)脂肪酸與脂肪族1元醇之酯、(d4)二烷基碳酸酯、(e1)聚氧化C2~6烷二醇、(e2)聚氧化C2~6烷二醇與至少1個脂肪酸之酯、(e3)聚氧化C2~6烷二醇與至少1個脂肪族1元醇之醚、(e4)聚氧化C2~6烷二醇與鏈狀烴四羧酸、鏈狀烴三羧酸、或鏈狀烴二羧酸之酯、(e5)聚氧化C2~6烷二醇與鏈狀烴四醇、鏈狀烴三醇、或鏈狀烴二醇之醚、及(f1)鏈狀烷烴、以及彼等之任意組合所成群中所選出。 The absorbent article according to claim 8, wherein the blood modifying agent is an ester of (a 1 ) chain hydrocarbon tetraol and at least one fatty acid, (a 2 ) chain hydrocarbon triol, and at least one fatty acid. Ester, (a 3 ) chain hydrocarbon diol and at least one fatty acid ester, (b 1 ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol ether, (b 2 ) chain hydrocarbon triol And an ether of at least one aliphatic monohydric alcohol, (b 3 ) a chain hydrocarbon diol and at least one aliphatic monohydric alcohol, (c 1 ) a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxyl group An acid, alkoxy acid or an acid ester of a side acid with at least one aliphatic monohydric alcohol, (c 2 ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid An ester of at least one aliphatic monohydric alcohol, (c 3 ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or an ester of a side acid and at least one aliphatic monohydric alcohol; (d 1 ) an aliphatic monohydric alcohol and an aliphatic monohydric alcohol ether, (d 2 ) dialkyl ketone, (d 3 ) fatty acid and an aliphatic monohydric alcohol ester, (d 4 ) dialkyl carbonate , (e 1) polyoxy C 2 ~ 6 alkanediols, (e 2) polyoxy C 2 ~ 6 alkylene glycol and at least one fatty acid ester of (e 3) polyoxy C 2 ~ 6 alkylene glycol and at least one of an aliphatic monohydric alcohol ethers, (e 4) polyoxy C 2 ~ 6 alkylene glycol and a chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic An ester of a carboxylic acid or a chain hydrocarbon dicarboxylic acid, (e 5 ) a polyoxy C 2-6 alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or an ether of a chain hydrocarbon diol, and f 1 ) a chain of alkanes, and any combination of them selected in the group.
TW102106979A 2012-02-29 2013-02-27 Absorbent article TWI593396B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012044524 2012-02-29
JP2012044575 2012-02-29
JP2012044439 2012-02-29
JP2012082503A JP5709789B2 (en) 2012-03-30 2012-03-30 Absorbent articles

Publications (2)

Publication Number Publication Date
TW201400098A TW201400098A (en) 2014-01-01
TWI593396B true TWI593396B (en) 2017-08-01

Family

ID=49082522

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102106979A TWI593396B (en) 2012-02-29 2013-02-27 Absorbent article

Country Status (3)

Country Link
AR (1) AR090429A1 (en)
TW (1) TWI593396B (en)
WO (1) WO2013129325A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251512A (en) * 1996-05-31 2000-04-26 普罗克特和甘保尔公司 Web materials exhibiting elastic-like behavior and soft, cloth-like texture
TW200412235A (en) * 2002-12-09 2004-07-16 Uni Charm Corp Liquid permeable top sheet for body excretion absorptive article
TW200534833A (en) * 2004-04-15 2005-11-01 Uni Charm Corp Sanitary napkin
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US20110313385A1 (en) * 2002-12-18 2011-12-22 John Lee Hammons Sanitary napkin for clean body benefit

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2907992B2 (en) * 1990-10-16 1999-06-21 ユニ・チャーム株式会社 Surface sheet for absorbent articles
JP4972500B2 (en) * 2007-09-05 2012-07-11 花王株式会社 Absorbent articles
JP5466489B2 (en) * 2009-11-16 2014-04-09 花王株式会社 Absorbent articles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251512A (en) * 1996-05-31 2000-04-26 普罗克特和甘保尔公司 Web materials exhibiting elastic-like behavior and soft, cloth-like texture
TW200412235A (en) * 2002-12-09 2004-07-16 Uni Charm Corp Liquid permeable top sheet for body excretion absorptive article
US20110313385A1 (en) * 2002-12-18 2011-12-22 John Lee Hammons Sanitary napkin for clean body benefit
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
TW200534833A (en) * 2004-04-15 2005-11-01 Uni Charm Corp Sanitary napkin

Also Published As

Publication number Publication date
AR090429A1 (en) 2014-11-12
WO2013129325A1 (en) 2013-09-06
TW201400098A (en) 2014-01-01

Similar Documents

Publication Publication Date Title
TWI577353B (en) Absorbent items
JP5713951B2 (en) Absorbent articles
JP5925015B2 (en) Absorbent articles
TWI573570B (en) Absorbent items
TWI572343B (en) Absorbent items
TWI629976B (en) Absorbent article
TWI589280B (en) Absorbent article
JP2013078375A (en) Absorbent article
TWI555518B (en) Absorbent items
TWI572344B (en) Absorbent items
TWI581775B (en) Absorbent items
TWI593396B (en) Absorbent article
JP5709789B2 (en) Absorbent articles
JP5713950B2 (en) Absorbent articles
JP5726123B2 (en) Absorbent articles
TWI573573B (en) Absorbent items
JP5762345B2 (en) Absorbent articles

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees